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GLOSSARY OF ACRONYMS 
AIDS     Acquired immune deficiency syndrome 
CFR     Case fatality rate 
DAT     Direct agglutination test 
DDT     Dichlorodiphenyltrichloroethane 
EDCD     Epidemiology and Disease Control Division  
FGT     Formol-gel test 
HIV     Human immunodeficiency virus 
IRS     Indoor residual insecticide spraying 
ITN     Insecticide impregnated nets 
KAtex     Latex agglutination test 
LCA     Latent class analysis 
LLIN     Long-lasting-insecticide-treated-nets 
MOH     Ministry of Health 
NMEP     National Malaria Eradication Programme 
PCR     Polymerase chain reaction 
PHC     Primary health care centre 
PKDL     Post kala-azar dermal leishmaniasis 
Sbv     Pentavalent antimony 
SSG     Sodium stibogluconate 
VL     Visceral leishmaniasis 
WHO     World Health Organization 
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SUMMARY 
Visceral leishmaniasis (VL) is a fatal vector borne disease caused by the protozoon 
Leishmania and transmitted by the bite of a sandfly. More than 50% of the annual 
worldwide cases occur in the poor population living in remote rural regions of the 
Indian subcontinent. In Nepal, a quarter of the country’s population is estimated to 
be at risk of the disease. 
With no vaccine available, the control of this disease has depended on vector control 
and early diagnosis with appropriate treatment of cases. With limited impact of the 
former the latter is presently considered the most effective strategy although there 
are some unresolved issues in its implementation. 
Microscopy for Leishmania donovani bodies, considered the gold standard for 
diagnosis, is not feasible in the peripheral health facilities of these endemic 
countries and recommendations for the serological tests, direct agglutination test 
(DAT) and rK39 strip test, have not been forthcoming due to variations in the 
published estimates of test accuracy. Pentavalent antimony compounds e.g. sodium 
stibogluconate (SSG), the recommended 1st line therapy in most places including 
Nepal, has shown progressive decreasing efficacy in the adjoining state of Bihar, 
India. 
With this background we conducted clinical and epidemiological research to 
generate evidence for more rational recommendations for the case management of 
VL particularly for Nepal. The work describes the burden of VL in Nepal, the 
application of the novel diagnostic tests for early diagnosis of VL and the efficacy of 
the current VL treatment in Nepal. 
The research work was conducted over a period of 6 years at the B.P. Koirala 
Institute of Health Sciences, a university hospital, located in the Terai (lowlands), 
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which has established itself as a specialized VL centre attracting patient from a wide 
area.  
The clinical and epidemiological profile of VL patients admitted from 1999 to 2004 
showed that the VL epidemic in Nepal is well established with no indications 
suggestive of any decline. Moreover there are also signals indicating a possibility of 
extension of the epidemic to newer areas, which needs to be urgently examined, 
along with an increasing trend of cases in the urban regions. We studied the 
economic cost of VL to the affected households in a VL focus and showed how 
catastrophic and devastating an episode of VL could be to these households. A 
significant proportion of the cost was incurred even before starting the specific VL 
treatment. 
The lack of access to early treatment has been related to the unavailability of a test 
that can be easily applied at the level of the peripheral health facility. We 
prospectively evaluated 3 novel tests: DAT, rK39 strip test and, a urine antigen 
detection agglutination test (KAtex) in patients who were clinically suspect of VL. All 
the tests were first studied at a tertiary level hospital and the rK39 and the KAtex 
were further evaluated at a peripheral level hospital. We showed that both the DAT 
and the rK39 had good sensitivity and specificity at the tertiary level hospital though 
the sensitivity of the KAtex was too low to be useful. At the peripheral level hospital 
the rK39 strip test showed good sensitivity, specificity and reproducibility and could 
be recommended as a diagnostic test. 
We showed that the efficacy of SSG was too low, especially in cases coming from 
districts close to the high antimony resistance focus in Bihar, India. Similarly, the 
case fatality rate was also much higher in cases from this region in comparison to 
the others. We also documented an outbreak of cardiotoxicity that occurred on the 
use of a particular brand of generic SSG which emphasizes the need for rigorous 
quality control of these drugs. 
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The VL control program in Nepal does not appear to be able to curtail the present 
epidemic with its current strategy and remedial measures need to be considered. 
The rK39 strip test would allow for accurate diagnosis at a peripheral health facility 
and thus also aid in accessing early treatment. Efficacy of the present 1st line 
therapy, SSG, in Nepal is too low to be acceptable and warrants a revision of the 
present drug policy. This reduced efficacy of SSG may also indicate the spread of 
SSG resistant strains from neighbouring Bihar, India but this needs confirmation by 
drug efficacy monitoring studies. The VL epidemic in Nepal is closely linked to the 
Indian epidemic in Bihar so a close collaboration within the region would be 
essential. The recently launched “Kala-azar elimination programme in South East 
Asia” provides an excellent opportunity to strengthen the control programme and 
also help in building regional collaborations. 
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SAMENVATTING 
Viscerale Leishmaniasis (VL)  is een dodelijke infectieziekte veroorzaakt door een 
protozoön, Leishmania sp., dat wordt overgebracht door de beet van een zandvlieg 
(Phlebotomus sp). Meer dan de helft van het aantal gevallen op wereldschaal treft de 
arme bevolkingsgroepen in afgelegen landelijke gebieden van het Indische 
subcontinent. Men schat dat in Nepal een kwart van de bevolking een potentieel 
risico loopt om deze ziekte te krijgen. 
Aangezien er geen vaccin voorhanden is, bestaat de bestrijding van deze 
infectieziekte voornamelijk uit vroegtijdige diagnose en behandeling van de gevallen 
en vector controle. 
Dat laatste heeft een zeer beperkte impact, en daarom wordt vroegtijdige opsporing 
momenteel als de meest efficiënte strategie beschouwd. Niettemin blijven er nog een 
aantal onopgeloste vragen wat betreft de uitvoering van deze strategie. 
Microscopisch aantonen van Leishmania donovani  wordt als gouden standaard voor 
diagnose beschouwd, maar die technieken zijn niet haalbaar in de perifere 
gezondheidsdiensten van de endemische landen. Officiële aanbevelingen over de 
toepassing van serologische tests, als directe agglutinatie tests (DAT) en rK39 
immunochromatografische dipstick tests, blijven uit wegens variaties in de 
gepubliceerde ramingen van de test nauwkeurigheid. Pentavalente antimoon 
derivaten, b.v. natrium stibogluconaat (SSG), zijn de aanbevolen eerstelijntherapie  
in de meeste landen en dit met inbegrip van Nepal,  maar deze therapie heeft in de 
aangrenzende staat van Bihar, India, geleidelijk zijn doeltreffendheid verloren.  In 
deze context werd er klinisch en epidemiologisch onderzoek verricht, om als basis te 
dienen voor meer rationele aanbevelingen voor het VL beleid, in het bijzonder voor 
Nepal. 
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Dit werk beschrijft de zware druk die VL legt op de getroffen gemeenschappen, de 
evaluatie van nieuwe tests voor vroegtijdige diagnose van VL en de doeltreffendheid 
van de huidige VL behandeling in Nepal. Het onderzoek werd over een periode van 6 
jaar uitgevoerd in het B.P. Koirala Institute of Health Sciences (BPKIHS),  een 
universitair ziekenhuis dat in de Nepalese Terai gelegen is, de vlakte die zich 
uitstrekt aan de voet van de Himalaya. BPKIHS heeft zich tot een gespecialiseerd VL 
centrum ontwikkeld en trekt patiënten van heel de regio aan. 
Het klinisch-epidemiologisch profiel van VL patiënten die van 1999 tot 2004 werden 
opgenomen in BPKIHS, toont aan dat de VL epidemie zich reeds sterk heeft 
doorgezet in Nepal, zonder enige aanwijzing van een eventuele verbetering. 
Bovendien zijn er ook signalen die wijzen op een mogelijke uitbreiding van de 
epidemie naar nieuwe gebieden. Deze eventuele uitbreiding dient dringend te worden 
onderzocht, samen met de stijgende tendens van VL gevallen in stedelijke gebieden. 
We bestudeerden de financiële gevolgen van de ziekte bij getroffen gezinnen in een 
VL transmissiefocus en toonden aan welke verreikende gevolgen VL kan hebben bij 
deze gezinnen. Het gezin spendeert reeds een belangrijk deel van de ziekte-uitgaven 
vóór de aanvang van de eigenlijke VL behandeling.  
Het gebrek aan toegang tot vroegtijdige behandeling is een gevolg van het ontbreken 
van een eenvoudige diagnostische test die op het niveau van de perifere 
gezondheidsdiensten kan worden ingezet. Wij  hebben 3 nieuwe tests geëvalueerd: 
DAT, rK39  en een urine antigeen detectie test (KAtex) bij mensen die klinisch 
verdacht waren van VL. De drie tests werden eerst geëvalueerd in het tertaire 
ziekenhuis, de rK39 en KAtex werden verder geëvalueerd in een perifeer 
districtsziekenhuis. We toonden aan dat zowel DAT als rK39  een goede gevoeligheid 
en specificiteit hebben in het universitair ziekenhuis, terwijl de gevoeligheid van 
KAtex als te laag werd beoordeeld. In het perifere districtsziekenhuis toonde de rK39 
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test goede gevoeligheid, specificiteit en reproduceerbaarheid en zou derhalve als 
diagnose test kunnen worden aanbevolen. 
Verder toonden we aan dat de doeltreffendheid van SSG ontoereikend was, vooral in 
gevallen die uit het grensgebied met Bihar, India, komen, dat een hoge graad van 
SSG resistentie rapporteert. Bovendien was de letaliteit van de ziekte bij deze 
mensen ook veel hoger in vergelijking met die in de andere gebieden. Tijdens de 
onderzoeksperiode werden we geconfronteerd met een probleem van iatrogene 
mortaliteit omwille van de cardiotoxiciteit van een lot van generische SSG van een 
bepaalde producent. In onze rapportering hierover hebben we de noodzaak tot 
strenge kwaliteitscontrole van deze generische medicatie benadrukt. 
Het VL- bestrijdings programma in Nepal krijgt de huidige epidemie duidelijk niet 
onder controle, en daarom moeten er nieuwe maatregelen worden genomen. Het 
invoeren van de  rK39 test op de eerste lijn van de gezondheidsdiensten zou een 
grote verbetering zijn, omdat het de toegang tot vroegtijdige behandeling zou 
verbreden. Volgens onze gegevens is de doeltreffendheid van de huidige 
eerstelijntherapie, SSG,  in Nepal te laag om nog aanvaardbaar te zijn en dit vraagt 
om een herziening van het huidige geneesmiddelenbeleid. De verminderde 
doeltreffendheid van SSG kan wijzen op de verspreiding van SSG resistente 
L.donovani stammen vanuit het naburige Bihar, India , maar dit moet via klinische 
en parasitologische research worden bevestigd. De VL epidemie in Nepal is nauw 
verbonden met de Indische epidemie in Bihar, zodat een nauwe samenwerking 
tussen de gezondheidsautoriteiten van deze landen zich opdringt. Het onlangs door 
de Wereldgezondheidsorganisatie gelanceerde "Kala-Azar eliminatieprogramma in 
Zuidoost-Azië" opent perspectieven om die regionale samenwerking te versterken. 
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CHAPTER 1:
OVERVIEW OF VISCERAL 
LEISHMANIASIS OR KALA-AZAR 
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1.1 Visceral leishmaniasis, the disease 
Etiology and pathogenesis 
Leishmaniasis is a vector-borne parasitic disease, with a spectrum of clinical 
manifestations: visceral, cutaneous and mucocutaneous. The clinical form of the 
disease depends not only on the species of Leishmania, but also on the complex 
interactions resulting from the parasite’s invasiveness, tropism and pathogenicity 
and the host’s genetically determined cell-mediated immune response. Visceral 
leishmaniasis (VL) or kala-azar is caused by Leishmania donovani in the Indian 
subcontinent and east Africa, by L. infantum in the Mediterranean region and west- 
Africa and L. chagasi in Latin-America (Lainson & Shaw JJ 1987). According to some 
authors the latter species is considered identical to L. infantum. These pathogens are 
transmitted exclusively by the bite of a female phlebotomine sandfly. For L.
donovani, man is the only reservoir, whereas for L. infantum and L. chagasi, the 
domestic dog is the main reservoir. The leishmanial parasite exists in two 
morphological forms: the promastigote form (with flagella) extracellularly in the 
sandfly and culture medium and the amastigote form (oval, non-motile cell), 
intracellularly in the vertebrate host.  
The promastigotes, after the inoculation in the skin (dermis) by the sandfly, are 
phagocytosed by the macrophages and get converted to amastigotes that multiply 
inside the acidic parasitophorous vacuoles. They then disseminate through the 
lymphatic and vascular system and infect macrophages throughout the 
reticuloendothelial system. Leishmania use the macrophage like a ‘Trojan horse’ 
(Jeronimo et al. 2005). Increase in the number of infected macrophages in the 
organs (mainly liver and spleen) leads to their hypertrophy. 
The clinical outcome after a leishmanial infection is dependent on the type of 
immune response. Symptomatic VL can be viewed simplistically as a failure of the 
specific cell-mediated immunity leading to lack of activation of the macrophages to 
overcome the infection. These patients have anergy to leishmanial antigens as 
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indicated by a negative delayed hypersensitivity skin test while high titres of 
antileishmanial antibodies are produced that are not protective (Neva 1990). With 
recovery from VL, protective immunity develops and the majority of patients display 
a positive delayed hypersensitivity skin test. 
Immunosuppression including HIV infection and suppressive therapy for organ 
transplantation are associated with increased risk of VL (Fernandez et al. 1987). 
Malnutrition which lowers cell mediated immunity has also been shown to be a risk 
factor (Cerf et al. 1987). 
Transmission cycle of leishmania 
Depending on the transmission characteristics, two types of VL can be 
distinguished: a zoonotic and an anthroponotic form. In the former, there is an 
animal reservoir (dogs, foxes, rodents) where the parasite is maintained and man 
being an occasional host, and in the latter the parasite is exclusively maintained in a 
man-vector-man cycle in the absence of any animal reservoir (Figure 1). 
In the Indian subcontinent, VL is of the anthroponotic type and distribution, 
experimental infection and transmission by bite have proven Phlebotomus 
argentipes, a peridomestic sandfly, to be the vector (Lainson & Shaw JJ 1987). 
Cracks in the mud huts plastered with cow dung in the rural areas of the 
subcontinent provide a good resting place for the sandflies. Density of the sandflies 
is dependent on climatic and environmental conditions. In Nepal, vector density was 
observed to start rising from April, peaking in May and then a decline from 
September to a negligible level in December (Das 1998). Biting is usually nocturnal 
with the highest activity between 21.00 to 01.00 hours (Dinesh et al. 2001). 
The disease is spread when female sandflies ingest amastigotes while taking a blood 
meal from an infected mammal. These transform to promastigotes within the insects’ 
gut, migrate to the proboscis and are deposited in the dermis of the new host when 
the insect next engorges. The mammalian host is infectious to the sandfly as long as 
the parasite persists in the circulating blood or in the macrophages within the 
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dermis. In anthroponotic VL, infectivity to the sandfly may persist even after clinical 
recovery from VL, especially when the patient develops post kala-azar visceral 
leishmaniasis (PKDL). 
Fig.1: Leishmania life cycle
 (Source: CDC’s website, laboratory identification of parasite)
Person to person transmission has been reported through transfusion of 
contaminated blood (Grogl et al. 1993; Shulman 1994), accidental needle stick 
injuries (Evans & Pearson 1988; Herwaldt & Juranek 1993) and sharing of 
contaminated needle syringes in intravenous drug users (Cruz et al. 2002). 
Congenital Leishmania transmission has also been rarely seen (Eltoum et al. 1992; 
Meinecke et al. 1999). 
Clinical features  
Not every infected individual progresses to VL disease, there is a spectrum from 
asymptomatic infection over subclinical disease to the full blown VL syndrome 
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(Pearson & Sousa 1996). Asymptomatic and subclinical forms are frequent as shown 
during epidemiological surveys in various foci e.g. Italy (Pampiglione et al. 1975), 
Brazil (Badaro et al. 1986a; Carvalho et al. 1992; Evans et al. 1992), Kenya 
(Schaefer et al. 1995), Ethiopia (Ali & Ashford 1994) and Sudan (Zijlstra et al. 1994; 
Khalil et al. 2002). The ratio of asymptomatic to clinical cases has varied from 1:2.4 
to 18:1. Subclinical or mild forms were also described in the veterans of Operation 
Desert Storm (Magill et al. 1993). Leishmanial parasites have been cultured from 
healthy blood donors living in a VL endemic area in southern France (Le Fichoux et 
al. 1999). The exact role of these asymptomatic and subclinical cases in the 
transmission of VL is not clear. Some of the subclinical infections may subsequently 
progress to clinical disease when the immune status changes. 
Clinical manifestations of VL or kala-azar are similar throughout the world. The 
incubation period, though difficult to evaluate precisely, is generally 2 to 6 months 
but can range from 10 days to up to 10 years (Dedet JP & Pratlong F 2003). Clinical 
disease may first become symptomatic years after exposure in those who become 
immunocompromised (Badaro et al. 1986b). 
Classical VL usually has a sub-acute or chronic course presenting with an insidious 
onset of fever, weakness, loss of appetite, weight loss, abdominal distension due to 
hepatosplenomegaly and leukopenia. Fever, the commonest symptom, may be 
remittent, intermittent with twice-daily spikes or less commonly continuous. 
Lymphadenopathy is common in Sudan but not in the Indian subcontinent. Hyper 
pigmentation is seen in some patients in the Indian subcontinent – which led to the 
name kala-azar, meaning black fever in Hindi - and this may be related to increase 
in melanocytes (Dedet JP & Pratlong F 2003). A more acute course of the disease is 
described in immunologically naïve populations (Hashim et al. 1994).The symptoms 
usually persist for weeks to months before the person seeks medical attention. In 
advanced disease secondary bacterial infections are common (pneumonia, 
tuberculosis, septicaemia, dysentery or measles) which can be fatal. Other causes of 
death in VL may be due to haemorrhage as a result of thrombocytopenia. The 
differential diagnosis of classical kala-azar includes malaria, relapsing fever, typhoid 
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fever, tuberculosis, AIDS, brucellosis, cirrhosis, lymphomas and leukaemia’s (WHO 
1996). 
VL/HIV co-infection has been reported from 35 countries but most cases have been 
recorded from southwestern Europe. There is evidence of increasing cases from east 
Africa and the Indian subcontinent (Desjeux & Alvar 2003; Hailu & Berhe 2002).VL 
is observed as an opportunistic infection in 3 -7% of persons with HIV infection in 
the Mediterranean basin. Clinical manifestations of VL are usually similar to those 
in HIV negative cases but may develop unusual multi-organ pathology following the 
dissemination of the parasites. Almost all co-infected cases are prone to relapse after 
VL treatment (Russo et al. 2003). 
Post kala-azar dermal leishmaniaisis (PKDL), considered a complication of VL, is 
more commonly seen in inadequately treated VL cases (Zijlstra et al. 2000). In 
Sudan, it occurs in over 50% of VL cases and the lesions appear shortly after the 
symptoms of VL subside (0 to 6 months) (Zijlstra et al. 2003). In the Indian 
subcontinent it is seen in 5-10% of VL cases usually after an interval of 1 to 2 years 
after treatment, though up to 20 years have been reported in exceptional cases 
(Ramesh & Mukherjee 1995). The skin lesions are characterized by a spectrum of 
manifestations ranging from depigmented macules to wart-like nodules over the 
trunk and face, mimicking the lesions of leprosy. In Sudan, most cases cure 
spontaneously but chronic and severe cases require at least 4 months of the 
standard antimonial regimen. PKDL lesions being full up with parasites infectious to 
the sandflies, are considered to play an important role in disease transmission 
between outbreaks (Addy & Nandy 1992; Dye 1992; Dye & Wolpert 1988).  
1.2 Epidemiology and public health importance 
Historical perspective of VL in the Indian subcontinent 
There is no mention of any disease akin to kala-azar in ancient Indian medical 
literature. The earliest reference to this disease was made in the annual report of the 
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inspector general of civil servants for 1872, in which he has quoted Dr French, the 
civil surgeon of Burdwan district in the state of Bengal (Sanyal RK 1985). 
“Dr French is submitting his report, enters into the history of the epidemic from its 
appearance in Mahmadpur in the Jessore district (presently in Bangladesh) in 1824 
when the disease first attracted attention tracing  it into the Nuddea district in 1832 or 
1833 , then to the Hooghly district in 1857 and subsequently in 1862 he considers 
that the epidemic reached Burdwan district………………………….The type of disease 
described is that ordinarily known as ‘malarious intermittent fever’ not infrequently 
the intermittent passes into the remittent, and the latter into the continuous type, and 
either may be followed by dysentery, enlargement of spleen or dangerous local 
derangement and disorganisation”. 
This was apparently the description of the first epidemic in the Indian subcontinent. 
The fever was locally referred to as “Jwar-Vikar’ (febrile disorder) and “Burdwan 
fever”.  
Figure 2: North East India along with Nepal and Bangladesh
China 
(Tibet) 
Bay of Bengal 
UTTAR 
PRADESH
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The epidemic swept through western and central Bengal in eastern India (figure 2) 
leaving a trail of devastation and turning some areas of the Hooghly and Burdwan 
valleys (in Bengal) into ‘a valley of the shadow of death’ with a death toll of 75,000 
lives in 3 years (Sen Gupta PC 1944). After establishing itself in the plains of Bengal, 
kala-azar spread along the lines of the two major rivers, Brahmaputra and the 
Ganges and its tributaries, which were the main lines of communication, to Assam 
in the north-east and Bihar in the west. A full scale epidemic ravaged the valleys of 
Assam from 1890 to 1900 with mortality rates up to 95% (Peters 1981). At a time 
when the population growth was 15-20 % per decade, the epidemic in Nowgong 
district in Assam caused a decrease of over 30% of the population during this 
epidemic. In Purnea district, Bihar, a disease locally called “kala-dukh” meaning the 
“black misery” existed towards the end of the nineteenth century which was 
identified as kala-azar by Ross in 1899 (Sanyal RK 1985). 
Only in  1903 ,  Leishman and Donovan separately described the presence of a 
parasite in cases of kala-azar, which was named Leishmania donovani (LD) by 
Laveran and Mesnil the same year (Wenyon CM 1926).Diagnosis of kala-azar was 
thus established by the demonstration of these LD bodies. The formol-gel or 
aldehyde test was accidentally discovered by Napier in 1921 (Napier LE 1922). He 
observed that the addition of a few drops of formalin to the serum of kala-azar 
patients resulted in “egg white” solidification. This formol-gel test continues to be 
used as a diagnostic test for kala-azar, in many of the peripheral health centres in 
the Indian subcontinent.  
The next kala-azar epidemic, from 1917 to 1929, raged through the eastern part of 
the entire subcontinent and with an intensified situation in Bihar from 1935 to 1937 
(Peters & Prasad LSN 1983). It was during this epidemic, that for the first time in the 
subcontinent, antimony was used on a large scale in the form of tartar emetic which 
was soon replaced by urea stibamine the first pentavalent antimony (Sbv) compound 
introduced by Brahmachari in 1922. This was a remarkable advance in the fight 
against kala-azar, which reduced the mortality from 90 to 95% to less than 5% in 
treated cases. The heavy toll of the disease including the economic impact on the tea 
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plantations in the state of Assam led to the constitution of the “the kala-azar 
commission” which submitted historic reports in 1926 and 1932 outlining the 
dynamics of transmission of the parasite through sandfly vectors (Sanyal RK 1985).  
The number of kala-azar cases started to decline from mid 1950’s to a point of 
almost disappearance within a decade. The causes of disappearance have been 
critically reviewed and identified as: 1. effective treatment of all cases; 2. increase in 
herd immunity and consequent inter-epidemic lull; and 3. impact of 
dichlorodiphenyltrichloroethane (DDT) spraying in the National Malaria Eradication 
Programme (NMEP) (Sanyal RK et al. 1979b). 
A decade after stoppage of the DDT spraying the disease again gained epidemic 
proportions in north Bihar reaching a maximum in 1977 with an estimated 100,000 
cases (Thakur 1984). This resurgence has been linked to a continuing low level of 
transmission along with the persistence of many cases of PKDL. The PKDL cases, 
most of whom were not recognized or not treated, were a potential source of 
infection, and acted as a reservoir (Sanyal RK et al. 1979b; Singh 1968). Since then, 
kala-azar has established itself as an endemic disease in north Bihar and adjoining 
parts of West Bengal in India, with outbreaks like the one in 1991-1992 (Bora 1999). 
Situation in Nepal 
Nepal is ecologically divided from north to south into three regions: mountain, hill 
and the terai (lowlands). The terai has a subtropical climate and is known to 
harbour most tropical diseases. 
There has been no documentation of the kala-azar epidemics of the nineteenth 
century from Nepal. Till 1953 the country was closed to the outside world. Napier in 
1926 reports of a large proportion of VL cases from Calcutta to be Nepalese patients 
(Napier LE 1926). However, it is unclear if these were Nepalese residing in India or 
Nepalese travelling to India for treatment, which was a common practice. The first 
documented evidence of kala-azar in Nepal was made only in 1953 by an Indian 
scientist, NGS Raghavan, who after a survey for vector borne diseases in 1949 
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claimed that kala-azar was endemic in the entire terai (Shrestha & Pant 1994).There 
is also no documentary evidence to show the magnitude of the problem before the 
start of the DDT spraying in the NMEP in 1958. Even there was no mention of kala-
azar in the first report of “Health and health administration in Nepal” published by 
the Directorate of Health Services in 1969 (Shrestha & Pant 1994). The first officially 
recorded case of VL in Nepal was in 1980 from Dhanusha district (Bista 1998). Since 
then there has been a steady increase in the reported cases and presently 12 
districts are identified to be endemic with more than 5.5 million people estimated to 
be at risk of the disease (EDCD 2002b). From 1980 to 1989 the incidence rate per 
100,000 person-years remained below 10. Since then it has been increasing steadily 
and in the last few years it has been reported from 43 to 55 per 100,000 person-
years. The case fatality rate (CFR) for VL has been reported to be around 1% in the 
last few years. However, these surveillance data from Ministry of Health (MOH) are 
considered to be underestimated as it does not include cases treated outside the 
public health facilities (Bista 1998). Little epidemiological research has been 
conducted from Nepal. One small cross- sectional survey in an endemic focus in 
eastern Nepal showed  Leishmania infection rate of 7.5% documented by a 
serological test (Schenkel et al. 2004) and a qualitative survey conducted in 2 
villages in the endemic region revealed poor knowledge about the transmission and 
symptoms of kala-azar (Koirala et al. 1998). 
Control program in Nepal 
A kala-azar control programme under the Epidemiology and Disease Control 
Division (EDCD), MOH is ongoing since 1993. The goal of the programme is to 
reduce kala-azar to less than 1 in 100,000 person-years and PKDL cases to zero by 
the year 2018 (EDCD 2002a).The strategy for control is based on early diagnosis and 
treatment of VL along with indoor residual insecticide spraying (IRS). Case detection 
is done passively in those who present to the public health facilities. The 
recommended diagnostic test is bone marrow microscopy at the level of the district 
 19  
hospitals and above and rK39 striptest (recommended from 2002) at the level of 
primary health care centre (PHC). Sodium stibogluconate (SSG) is the recommended 
1st line therapy that is prescribed at the level of PHC or higher health facility but can 
be continued at the health posts. The 2nd line therapy, amphotericin B, is available 
at the level of district hospitals or higher. In practice as parasitological diagnosis is 
not feasible in the majority of the district hospitals along with the lack of regular 
supply of the rK39 striptest, treatment for VL is started on the basis of the clinical 
features and the formol-gel test (FGT), a non specific test for VL. As a regular system 
of monitoring treatment is lacking, the outcome of VL therapy is not well 
documented. 
Frequency and burden of the disease 
The leishmaniasis constitutes one of the 10 entities of the World Health 
Organization /Tropical Disease Research list of neglected infectious diseases that 
disproportionately affects poor and marginalised populations. Visceral leishmaniasis 
(VL) has been reported from over 60 countries but more than 90% of the estimated 
500,000 annual new cases occur in India, Bangladesh, Nepal, Sudan and Brazil 
(TDR 2005). The Indian subcontinent accounts for 60% of the global burden (in 
terms of disability adjusted life years lost) caused by VL (Murray & Lopez 1996).  
Moreover, as VL has a very focal distribution and preferentially affects the poor 
living in remote areas with difficult access to health care (Guerin et al. 2002), the 
aggregated figures do not reflect the real burden of disease in these affected 
communities. Reported incidence rates of kala-azar in endemic areas vary between 
2/1000 person-years in Kenya (Schaefer et al. 1995), 14/1000 person-years in 
Ethiopia (Ali & Ashford 1994) to 40/1000 person-years in a community survey in 
eastern Sudan (Zijlstra et al. 1994; Khalil et al. 2002). In Bangladesh, an incidence 
of 20/1000 persons-years was recorded in a recently conducted community survey 
(Ahluwalia et al. 2003). The global annual VL mortality is officially estimated at 
59,000, however this is considered severely underestimated (Desjeux 2004).
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Figure 3: Worldwide distribution of VL
VL is a fatal disease and the devastating effects seen in the Indian epidemics before 
the availability of the Sbv compounds is quite illustrative. Even more recently, 
Seaman et al. (1996) described a severe epidemic in Sudan where over the period 
1884 to 1994, an estimated 100,000 VL deaths occurred in a group of 280,000 
people living in Western Upper Nile province affected by civil war and displacement 
of populations. A recent community survey from Bangladesh reported a case fatality 
rate of 19% among adult females with kala-azar (Ahluwalia et al. 2003).  
With most of the VL in the Indian subcontinent affecting the economically active 
population (15 to 45 years), in every member of a family where a VL case occurs, 
many days of productive life are lost due to this severely debilitating disease. 
1.3 Control strategies  
The resurgence of leishmaniasis world-wide has been attributable to the appearance 
of new risk factors in addition to an increase in the previously identified ones 
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(Desjeux 2001). The major risk factors for VL include: 1. low socio-economic level 
and cultural practices; 2. environmental factors e.g. moist soil, organic debris near 
household etc.; 3. changing ecology e.g. new settlements especially in urban areas, 
civil war; 4. migration of population e.g. cross border migration between India and 
Nepal; 5. emergence of VL/HIV co-infections, and 5. ineffectiveness of control 
programmes. At the community level, the proximity to a previous kala-azar patient 
was an increased risk (Bern et al. 2005).  
The intervention strategies for prevention or control depend on the specific eco-
epidemiological situation with control strategies tailored to the two main 
epidemiological entities: anthroponotic and zoonotic.  
Historical examples of effective VL control are available though limited. VL was a 
major parasitic disease in north-east China with 530,000 cases reported in 1951 
(Guan & Shen 1991). From 1950-1958 a strenuous control campaign including 
treatment of cases and spraying of insecticides was launched. The disease was 
largely brought under control in the plains region where anthroponotic form had 
reigned but was not quite successful in the mountainous and hilly regions having 
zoonotic VL.  
In one district in Bihar, India there was a 65% decrease in the number of VL cases 2 
years after an intensive integrated control campaign (Saxena et al. 1996). The 
intervention consisted of active surveillance for case detection and treatment 
combined with residual insecticidal spraying in the households along with 
information, education and communication activities. 
The several theoretically possible control interventions include: 1. vector control and 
personal protection; 2. reservoir control; 3. immunoprophylaxis; and 4. early 
diagnosis and treatment. An overview of each is given below. 
Vector control and personal protection
As detection of the sandfly breeding sites is generally difficult, control measures 
against immature forms are not feasible (Alexander & Maroli 2003). Indoor residual 
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insecticide spraying (IRS) of households is the most widely used intervention for 
controlling sandflies that are endophilic (rest mostly indoors after feeding), and have 
yielded good results in India (Joshi & Rai 1994; Kaul et al. 1994). However cost of 
the insecticides, suitable public health infrastructure (spraying equipment trained 
personnel), the low acceptance by the community (Gupta PC 1975) compromise the 
longer-term effectiveness and sustainability of this intervention.The extensive DDT 
spraying during the NMEP in the 1960’s in the Indian subcontinent along with 
malaria also decreased the cases of VL to negligible levels but the cessation of 
spraying was followed by major epidemics of VL.  
Insecticide impregnated nets (ITN) were shown over the past two decades as one of 
the most effective methods of reducing man-vector contact in intra- and peri-
domiciliary transmission of vector-borne diseases. ITN is considered an effective, 
cheap and sustainable method in the control of malaria. 
A case control study, investigating factors associated with VL, found a 70% less 
probability of getting VL in those who used untreated nets compared to people who 
did not use any nets. (Bern et al. 2000). Treatment of the wide mesh nets with 
insecticides enhances the effect and has shown to decrease sandfly bites by 64 to 
100% (Davies et al. 2003). Field studies in Syria, Iran and Afghanistan have shown 
the ITN to be effective in cutaneous leishmaniasis, but no such studies have been 
undertaken for VL so far. 
Control of reservoir 
Control of leishmaniasis by controlling the reservoir hosts has been recommended 
for zoonotic cutaneous as well as visceral leishmaniasis (WHO 1990). In zoonotic VL 
annual surveys for canine infection along with culling of the dogs has been a part of 
the control programme in Brazil. But as this has failed to reduce the number of 
notified cases it has let to scepticism of the effectiveness of this programme (Ashford 
et al. 1998). Other strategies for reservoir control have been the application of topical 
insecticides (dipping the dog in insecticide or application of insecticidal lotions) 
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(Reithinger et al. 2001) which can substantially reduce the number of sandfly bites 
in the dogs. A novel experimental approach using pyrethenoids treated collars not 
only reduced the risk of infection to the dogs but also to the children living in the 
same village (Gavgani et al. 2002). In anthroponotic VL, where humans are the only 
reservoir, active case detection and treatment of VL and PKDL is recommended.  
Vaccines 
At present there is no vaccine available for any type of leishmaniasis. Leishmaniasis 
is considered a unique parasitic disease as a single vaccine would have the potential 
to protect against more than one species and be successful for both treating and 
preventing disease. Pioneering work on 1st generation leishmanial vaccines, using 
whole organism preparations, demonstrated limited potential against both 
cutaneous and visceral leishmaniasis (Khalil et al. 2000; Modabber 1995). Over the 
past 2 decades several antigens have been identified and characterized that could be 
potential vaccine candidates. Animal studies have demonstrated effective 
prophylactic and therapeutic protection against multiple forms of leishmaniasis. The 
1st defined vaccine for leishmaniasis in human clinical trials, Leish 111f , has 
completed phase 1 safety testing in normal human subjects and is currently 
undergoing therapeutic trials in cutaneous and mucocutaneous leishmaniasis in 
Latin America (Coler & Reed 2005). However, for VL the situation is less promising. 
Human trials of vaccines against VL are likely to follow only from successful 
outcomes of those against cutaneous leishmaniasis (Davies et al. 2003). 
Early diagnosis and control 
In the background of limited efficacy of vector control and in the absence of a 
vaccine, early case detection and treatment is considered the basic intervention to 
limit morbidity and mortality in anthroponotic VL. Active surveillance, though 
difficult to organise and implement, was observed to be more efficient compared to 
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insecticide spraying during the epidemic of 1976-1978 in Bihar state, India (Sanyal 
RK et al. 1979a). Moreover, special attention should also be given to detection and 
treatment of PKDL cases, an important source for transmission but has remained a 
neglected part of the control programme (Thakur & Kumar 1992). 
The diagnosis and treatment of VL is dealt with in the following section. 
1.4 Management of visceral leishmaniasis 
Diagnosis  
Microscopic demonstration of the amastigotes of L.donovani from tissue aspirates 
continues to be the recommended method of diagnosis ever since the discovery of 
the parasite by Leishman and Donovan over a century ago. Executed by a trained 
microscopist this technique is 100% specific but the sensitivity varies with the type 
of aspirate : spleen tissue being the most sensitive, over 95% (Bryceson 1996; 
Thakur 1997; Zijlstra et al. 1992). In addition to being an invasive and complex 
procedure (WHO 1996), a small risk of fatal haemorrhage remains (Chulay & 
Bryceson 1983). Lymph node and bone marrow aspirations are safer procedures but 
their sensitivity has been shown to be only 58 to 64 % and 70 to 86 % respectively 
(WHO 1984; Zijlstra et al. 1992). A major limitation in establishing parasitological 
diagnosis in VL endemic countries is the lack of expertise (physician to perform the 
procedures and the laboratory technician to stain and read the slides) outside 
reference tertiary hospitals or specialized treatment centres. 
In the pursuit for alternatives to parasitology, several serological tests have been 
developed and evaluated in the field over the last 2 decades. Their main advantage is 
non-invasiveness but they do not discriminate between clinical, subclinical or past 
infection and also cross-reaction with other pathogens is possible (Hommel et al.
1997). The Direct Agglutination Test (DAT) developed by El Harith et al. (1986; 1988) 
proved to be very accurate under laboratory conditions (el Safi & Evans 1989; Joshi 
et al. 1999; Singla et al. 1993). In field conditions, low specificity values were 
reported in series of clinical suspect patients with a range depending on the 
 25  
reference test used, between 58 % (Boelaert et al. 1999a) and 72 % (Zijlstra et al. 
1991). The effectiveness of DAT proved satisfactory in a large multi-centre study 
(Boelaert et al. 1999b). Another problem of DAT has been its low reproducibility 
(Boelaert et al. 1999c) which is due to the fragility of the antigens. The antigens 
which are produced in a few laboratories in Europe have a risk of losing potency, 
due to heat and shaking, during transport to the endemic countries. This problem 
has been overcome by the development of the freeze dried version (Meredith et al.
1995; Zijlstra et al. 1997). 
More recently a test based on 39- amino acid repeat recombinant leishmanial 
antigen from Leishmania chagasi (rK39) has been introduced in an ELISA (Badaro et 
al. 1996; Zijlstra et al. 1998), and later in a lateral flow dipstick format (Sundar et al.
1998a). The latter is very easy to use in the field and an initial study showed 100% 
sensitivity and 98% specificity. However, the performance of this strip test in 
subsequent studies was not consistent, showing low sensitivity (Jelinek et al. 1999; 
Zijlstra et al. 2001) and specificity (Veeken et al. 2003). 
Recently, a urinary leishmanial antigen, a low molecular weight heat stable 
carbohydrate, detected in the urine of visceral leishmaniasis patients has been 
described (Sarkari et al. 2002). A latex agglutination test for the detection of this 
urinary antigen (KAtex) evaluated in laboratory trials, showed a specificity of 100% 
and sensitivity between 64 to 100% (Attar et al. 2001). An antigen detection test 
could be promising for both diagnosis and prognosis. 
The application of molecular biology techniques like polymerase chain reaction (PCR) 
for diagnosis of VL have been validated using tissue aspirates as well as blood 
samples (Adhya et al. 1995; Andresen et al. 1997; Osman et al. 1997). The 
sensitivity has been shown to be very high, being able to detect the equivalent of 
even less than one parasite per sample (Salotra et al. 2001). It has been shown to be 
successful in the diagnosis of immuno-competent VL children in Italy (Cascio et al.
2002) and for monitoring of relapses in HIV co-infected patients (Pizzuto et al. 
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2001).The major limitation of the conventional PCR for field use is the sophisticated 
technique and the high cost. 
In the VL endemic countries, confirmation of clinical diagnosis remains a problem. 
In addition, the patients delay in seeking medical attention. In a study from India, 
the mean time from onset of symptoms to definitive diagnosis was 7.7 months 
(Sundar S et al. 1991). 
Treatment  
Visceral leishmaniasis, a fatal disease, has a limited number of drug options 
available and almost all of them are far from satisfactory. This disease has recently 
gained attention as one of the “most neglected diseases” along with Chagas’ disease 
and sleeping sickness due to the lack of effective, affordable or easy to use drug 
treatments (Trouiller et al. 2002; Yamey & Torreele 2002). 
The drugs currently available for the treatment of VL include the pentavalent 
antimonials, sodium stibogluconate (SSG) (Pentostam®, GlaxoSmithKline) and 
meglumine antimoniate (Glucantime®, Aventis), pentamidine, amphotericin B and 
its lipid formulation AmBisome® (Gilead), miltefosine (Impavido®, Zentaris) and 
paromomycin. 
Pentavalent antimonials (Sbv) in use since the 1940’s and despite its prolonged 
parenteral therapy remains the 1st line therapy in most regions due to the time 
tested efficacy and affordability (Berman 1997; Murray 2001).Recent evaluations 
comparing the branded Sbv with the cheaper generic SSG in Sudan showed the 
latter to be equally effective but costing only one-fourteenth of the generic brand 
(Moore et al. 2001; Murray 2004; Veeken et al. 2000).The major problems with SSG 
have been its increasing failure rate and toxicity. The decrease in cure rates in the 
state of Bihar, India was first noted in the early 1980’s and this was overcome by 
increasing the dose and duration of therapy of SSG (WHO 1984; 1990). However in 
the early 1990’s, in spite of the use of the maximum recommended and tolerated 
doses (20mg/kg/day for 30 to 40 days) there was a steady decline in the cure rates 
to reach as low as 35%, thus its use has been abandoned in this region (Jha TK et
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al. 1992; Sundar et al. 2000). In Nepal, little information is available except for one 
study conducted in 1996 which showed a cure rate of 93% in a cohort of 27 VL 
patients treated with SSG 20mg/kg/day for 30 days (Karki et al. 1998) 
With the maximum tolerated doses the common toxicities include chemical 
pancreatitis, symptomatic pancreatitis and musculoskeletal pain in one-third to 
two-third of cases (Gasser, Jr. et al. 1994). Though significant cardiotoxicity is not 
common in patients receiving single courses (Berman 1997; Herwaldt & Berman 
1992; Murray 2001), serious cardiotoxicity including deaths was observed with bad 
batches of some generic preparations (Sundar et al. 1998b). 
The increase in treatment failure of SSG, has been linked to the use of inadequate 
doses (Sundar et al. 1994) and emergence of resistance strains of L.donovani (Lira et 
al. 1999). Inadequate and incomplete treatment being the major factor for the 
development of the latter (Bryceson et al. 1985).  
Pentamidine, a diamidine, was used as a 2nd line drug especially in SSG refractory 
cases. However, its usefulness has been limited due to decline in its efficacy and 
serious toxicity (both hypo- and hyperglycaemia) (Jha et al. 1991; Thakur et al.
1991). 
Amphotericin B desoxycholate, a polyene antibiotic, has proved to be highly effective 
with over 95% cure (Thakur et al. 1999) for the treatment of antimony resistant VL 
and is the recommended 2nd line therapy except in Bihar where it has become the 1st
line regimen. However, its major drawbacks includes prolonged hospitalization as it 
needs to be given by infusion lasting at least 4 hours, toxic adverse effects requiring 
close laboratory monitoring and comparatively higher overall cost of treatment 
(Berman 1997; Murray 2001). Among the lipid formulations of amphotericin B 
(AmBisome®, unilamellar liposomes; Abelcet, lipid complex; Amphocil, colloidal 
dispersion) liposomal amphotericin or AmBisome® is by far the best available drug 
with respect to the efficacy and side effects (Berman et al. 1998). This has also 
significantly decreased the use of pentavalent antimonials in Europe (Murray 2004). 
Cure rates similar to amphotericin B was obtained at low dosages (2mg/kg/day for 5 
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days) in India (Sundar et al. 2004). However, even with these doses the cost of the 
drug is way beyond the reach of most VL patients. 
Miltefosine, an alkylphosphocholine, originally developed as an anti cancer drug, is 
the first and presently the only oral drug available for VL. Clinical trials in India 
have shown a high cure rate (Jha et al. 1999; Sundar et al. 2002) and it remains to 
be seen if it has similar efficacy in other VL regions e.g. east Africa and South 
America. Gastrointestinal side effects though common (60%) are mild and transient. 
However, the major drawback is that it must be used with great caution in women of 
child bearing age as it is teratogenic in animals (Croft & Coombs 2003). 
Paromomycin, an aminoglycoside antibiotic, in early clinical trials conducted in 
India has shown high level efficacy and low rates of adverse events (Thakur et al.
2000). If these are confirmed in further trials paromomycin has the potential to 
replace amphotericin B in Bihar, India and Sbv in the other regions as a 1st line 
therapy.  
A major consideration of the choice of the drug in the treatment of VL other than 
efficacy and adverse events has been its cost, which is quite varied. The estimated 
cost of the different drugs for treating a 25 kg patient in India is: generic SSG = US$ 
22; amphotericin B= US$ 60; AmBisome® (2mg/kg/day for 5 days)= US$ 800; 
miltefosine = US$ 100 (Murray 2001; Murray 2004). Additional cost would include 
the cost of hospitalisation, monitoring of therapy and the re-treatment of failures 
and would vary in the different regions. 
Immuno-chemotherapy and new chemotherapy have been experimented (e.g.
interferon γ, and granulocyte –macrophage colony stimulating factor), but it would 
be a difficult and long process for these to reach the stage of clinical application for 
this neglected disease (Murray 2004).  
Recently, a consensus emerged that drug resistance in VL should be avoided by 
combination therapy combining the currently available drugs (Guerin et al. 2002). 
This will not only overcome the problems related to drug resistance and treatment 
failure but may also mitigate the toxicity with shorter regimens. 
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2.1 Rationale of the research:
Lack of adequate epidemiological information has been implicated as a major hindrance 
for VL control efforts (Bista 1998). In Nepal in particular, little is known on the disease 
trend and even less on the true extent of this purported epidemic nor on the economic 
impact of this chronic fatal disease on the affected communities that come from the 
lowest socio- economic strata of the society. This information was urgently needed. 
Besides, the options for control, especially for the anthroponotic form of VL i.e. that 
without animal reservoir, are limited. With no vaccine foreseen in the near future, the 
present strategies include vector control and early case detection with appropriate 
treatment. As the former has so far shown limited impact there is a wide consensus 
that the latter is the single most important strategy presently available (Boelaert et al.
2000; Guerin et al. 2002). However, there remain several unresolved issues for 
appropriate implementation of the early detection and treatment strategy. 
To build an effective and efficient test and treatment strategy first of all sensitive, 
specific, reproducible, feasible and cheap diagnostic tests are needed (de Raadt 1977). 
Since the discovery of Leishmania, microscopic demonstration of Leishmania donovani
(LD) bodies from spleen or bone marrow aspirate continues to be the recommended 
mode for confirmation of the diagnosis (WHO 1996). However -in addition to being an 
invasive test- microscopy is not feasible in the endemic countries where most peripheral 
hospitals lack laboratory facilities and/or trained personnel. Over the last 2 decades 
alternative serological tests for diagnosis of VL in the field, the direct agglutination test 
(DAT) (El Harith et al. 1986) and the immunochromatographic rK 39 test (based on 39- 
amino acid repeat recombinant leishmanial antigen from Leishmania chagasi) (Sundar 
et al. 1998) have been developed, but published estimates of their accuracy have varied.  
The development of any new diagnostic test undergoes different phases of evaluation. 
As proposed by Zhou et al. (2002) in phase I, the exploratory phase, the objective is to 
assess whether the new test has any diagnostic value and comparison is made between 
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confirmed cases and healthy volunteers. Subsequently in phase II, challenge phase, the 
test’s accuracy is challenged in potentially different subgroups of patients with and 
without the disease. As the study sample in phase II does not reflect the relative 
prevalence of the subpopulations from the target population it is usually not possible to 
measure the test’s operational accuracy in this phase. This is overcome in phase III, the 
clinical phase, where the test is evaluated on a representative sample of patients from a 
well defined clinical population. A recent consensus statement on evaluation of 
diagnostics underlined the crucial need for properly conducted phase III trials (Whiting 
et al. 2004). 
The DAT showed good performance in laboratory trials (Phase I and II) using banked 
sera (El Harith et al. 1986; el Safi et al. 1995; Singla et al. 1993; Sinha & Sehgal 1994), 
however its performance in the clinical setting (phase III) showed contradictory results 
with low specificity in some reports (el Masum et al. 1995; Zijlstra et al. 1991). Similarly 
the performance of rK 39 strip test showed variable results depending on the phase of 
study, location of the study and the brand of the dip-stick (Delgado et al. 2001; Schallig 
et al. 2002; Sundar et al. 1998; Veeken et al. 2003; Zijlstra et al. 2001). As few studies 
evaluated these tests on patients’ representative for the clinical setting (phase III), there 
remained a need to more thoroughly evaluate these “easy to use rapid tests” before 
practice guidelines and policy recommendations could be formulated. 
Finally, the arsenal available for treatment for VL is limited and the available drugs are 
either associated with significant toxicity (sodium stibogluconate, amphotericin B 
deoxycholate, pentamidine) or unaffordable (liposomal amphotericin B). Sodium 
stibogluconate (SSG), a pentavalent antimonial, which has been in use for over 6 
decades, remains the 1st line therapy in most regions. Decreasing cure rates with SSG 
in the early 1980’s were overcome by increasing the dose and duration of therapy. 
However, since the early 1990’s reports from the adjoining Bihar state in India showed 
progressive decrease of cure rates even with the maximum recommended doses, 
reaching levels as low as 35% (Sundar et al. 2000) along with high case fatality rates 
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and cardiotoxicity (5 to 10%) (Singh et al. 1989; Sundar et al. 1997). There was and is 
little information available on the efficacy or toxicity of SSG in Nepal, though it 
continues to be recommended as a 1st line regimen in the national control programme. 
Hence, it was important to assess these parameters in Nepal in order to provide 
evidence for a rational drug policy for the control programme. 
All the above led us to formulate the following objectives for the clinical and 
epidemiological research on VL which we launched in 1999. 
2.2 Objectives 
General objective: 
Provide evidence for more rational VL control and case management of kala-azar in the 
Indian subcontinent in general and in Nepal in particular. 
Specific objectives: 
1. Describe the clinical and epidemiological pattern and the burden of disease due to 
kala-azar in Nepal 
2. Evaluate the possible contribution to diagnosis of the recently developed diagnostic 
tests  
3. Explore the efficacy and safety of currently used anti-kala-azar drugs. 
2.3 Presentation of the published work 
2.3.1 Clinical and epidemiological pattern and burden of disease due to kala-
azar 
The objective of the paper in chapter 3.1 (“Visceral leishmaniasis in Nepal: spreading 
endemicity and emerging antimony resistance”) was to describe the extent and trend of 
visceral leishmaniasis in Nepal. A longitudinal description of 926 VL cases over a period 
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of 5.5 years (1999 to 2004) is given from the perspective of a referral hospital in an 
endemic region. It presents the demographic and clinical profile of patients presenting 
from the different districts of the country along with the duration of the illness and the 
outcome of the current treatment regimens. We show a trend of increasing number of 
cases from some non-endemic districts, which hitherto has not been picked up in the 
surveillance reports of the Ministry of Health. Also, in 2004 in comparison to 2003 there 
is a more than 2 fold increase in cases from Sunsari district and an over 10 fold 
increase from Dharan town, suggesting an emerging outbreak. Our findings also signal 
the possibility of further extension of the VL endemic to the previously not affected hilly 
districts.  
In anthroponotic VL, where humans are the only reservoir, post kala-azar dermal 
leishmaniasis (PKDL) has been implicated for initiating (Addy & Nandy 1992) and 
sustaining epidemics. Such cases have been neglected by the control programmes 
(Thakur & Kumar 1992). PKDL is commonly seen in the clinical practice at BPKIHS 
(Garg et al. 2001). In the paper in chapter 3.2 (“Post-kala-azar dermal leishmaniasis 
with visceral leishmaniasis: a rare presentation”) we document an unusual presentation 
of a case of PKDL combined with VL in a previously under-treated case of VL. This 
particular combination is estimated to occur in 1:700 PKDL cases (Sen Gupta PC 1968), 
and may reflect an important burden of PKDL in the community.  
It has been known that VL patients in the Indian subcontinent come from the poorest 
socio-economic class (Thakur 2000), but the economic impact of the disease on the 
affected community has not been clearly elucidated. During a survey in a rural region, 
Charigua hamlet was identified as being amongst the most affected with VL. 
Information on all direct and indirect costs incurred in the households with VL, over the 
last 3 years, was collected. The results are reported in the paper “The economic burden 
of visceral leishmaniasis for households in Nepal” (chapter 3.3). In this hamlet, where 
almost 15% of the individuals had suffered from kala-azar during the past three years, 
the cost of the disease was enormous. Household expenditure incurred for a case of VL 
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was above the median annual per capita income and over 75 % of the direct costs 
related to treatment occurred even before VL treatment was actually obtained (for free). 
The ill equipped peripheral health care centres which lack tools to diagnose or treat VL 
prompted patients to first seek treatment with local faith healers or private 
practitioners, which contributed substantially to the incurred cost. 
2.3.2. Evaluation of novel diagnostic tests 
Recently serological tests, DAT and rK39 immunochromatographic test have been 
proposed as field tests but their performance was not always consistent. We thus 
conducted a prospective study presented in chapter 4.1 (“Prospective evaluation and 
comparison of the direct agglutination test and an rK 39 antigen-based strip test for the 
diagnosis of suspected kala-azar in Nepal”) to validate these two tests using microscopy 
for LD bodies (bone marrow and/or spleen aspirate) as the reference test. The study 
was conducted at B.P. Koirala Institute of Health Sciences (BPKIHS), a university 
hospital in Dharan, eastern Nepal, on a cohort of 184 clinical VL suspect cases. 
Although the sensitivity of rK39 strip test was 97%, its specificity was evaluated at only 
71%. For DAT the sensitivity was 99% with lowest cut off titer (1:400) and specificity did 
not exceed 82% even with a high cut off titer (1: 512,000). With these results these tests 
could only be recommended as a screening test. However, the specificity of the tests 
may have been underestimated due to the use of an imperfect reference test. Although 
microscopy for VL is very specific the sensitivity is below 90%, except in spleen aspirate, 
which was not possible to perform in all the cases due to contraindications. It has been 
shown that a flawed reference test can substantially affect validity estimates of new 
tests under scrutiny (Staquet et al. 1981). Hadgu and Qu (1998) suggested that latent 
class analysis (LCA), a mathematical modeling technique, which models associations 
between observed variables that imperfectly measure a non observable (latent) variable, 
could be a potential solution to overcome the gold standard problem. In the paper in 
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chapter 4.2 (“A comparative study of the effectiveness of diagnostic tests for visceral 
leishmaniasis”), we compared the validity of 4 serological tests, rK39 strip test, DAT, 
formol-gel test (FGT) and the indirect fluorescence antibody test along with 
pancytopenia as diagnostic criteria for visceral leishmaniasis on another cohort of 310 
clinical suspect VL cases at BPKIHS. The sensitivity and specificity of all the tests were 
determined with parasitology as the reference test and also by applying LCA. For both 
the rK 39 strip test and DAT, the sensitivity estimates obtained by LCA were similar to 
the estimates with parasitology as reference test, but specificity estimates were 
substantially higher with LCA (DAT = 93.7% versus 77.8%; rK39 strip test = 93% versus 
77%). In addition to confirming the doubts with regards to parasitology as a gold 
standard, the study provided evidence that the serological tests, DAT or the rK39 strip 
test, can replace parasitology as a diagnostic test for VL in the Indian subcontinent. The 
choice between the two would depend on other factors like the ease of use, cost and the 
availability. 
The disadvantage of these serological tests is their inability to discriminate between 
clinical, subclinical or past VL infections. A urine leishmanin antigen detection 
agglutination test (KAtex) had been recently developed and evaluated in laboratory trials 
with encouraging results (Attar et al. 2001). As this could potentially overcome the 
disadvantage of the serological tests we decided to evaluate this test in the field which is 
presented in chapter 4.3 (“Evaluation of a urinary antigen-based latex agglutination test 
in the diagnosis of kala-azar in eastern Nepal”). The validity and reproducibility of KAtex 
was determined on 232 clinical suspects of VL using parasitology combined with DAT 
as the reference standard. It showed excellent specificity (98.7%) but the sensitivity was 
quite low (47.7%). The reproducibility, between the laboratories in Nepal and Antwerp, 
Belgium, was only moderate. Although this antigen detection test could become a real 
breakthrough in VL diagnosis there is a need to further improve its performance to 
become useful. 
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Even in the endemic countries the performance of any test in a peripheral level hospital 
may be quite different from that in a referral hospital due to various reasons. Firstly, 
patients in the district level may present with less advanced disease which may 
influence the sensitivity or specificity. Also the prevalence of VL in clinical suspects 
would be different from that of a referral level, thus influencing the predictive values of 
a test. Finally, the limited training of staff could affect the execution and/or 
interpretation of the tests. As most of the VL patients present in peripheral hospitals it 
was essential to know the usefulness of the VL tests at this level of care. Between the 
rK39 strip test and DAT, the former test is considered a simpler test to perform and 
interpret. We thus assessed the accuracy, reproducibility and feasibility of the rK39 
strip test along with the FGT and the KAtex on 142 clinical suspect VL recruited at 
Rangeli district hospital, a peripheral level hospital, which is presented in chapter 4.4 
(“Field validity and feasibility of diagnostic tests for visceral leishmaniasis in rural 
Nepal”). The reference test was based on a combination of parasitology along with DAT, 
the latter being performed at BPKIHS. The sensitivity of the rK39 strip test was 89% 
and significantly higher than FGT (52%) and KAtex (57%), though the specificity was 
over 90% in all three. The reproducibility of rK39 strip test was also found to be high 
and above the others. The study thus provided evidence for the feasibility of integration 
of the rK39 strip test as a diagnostic test in the peripheral level health services.  
2.3.3 Efficacy and safety of current drug treatment 
Pentavalent antimonials e.g. SSG, continues to be used, as a 1st line therapy, in most of 
the regions including Nepal. With reports of increasing failure rates to the drug from the 
adjoining Bihar focus in India, we decided to document the response of this drug in 
Nepal which is presented in chapter 5.1 (“Treatment of visceral leishmaniasis in south-
eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to 
limit further decline”). One hundred and twenty new cases of VL were treated with the 
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full dose and duration of SSG (20 mg/kg/day for 30 days) and were followed up for 
another 6 months to asses the definite cure rate. Patients who failed their follow up 
appointments were traced in the villages. The overall definite cure rates, in those who 
completed the full therapy and follow up, was 90% but it was only 76% in patients who 
came from a district bordering the high resistance Bihar focus. These results provide 
evidence that the decreasing cure rate with SSG seen in Bihar, India, has extended to 
Nepal, which could be related to the spread of resistant strains. 
In addition to the efficacy of SSG, its safety has also been a concern. Besides inherent 
toxicity of SSG, higher toxicity and deaths have also been related to the quality of the 
drug. In the paper “Sodium stibogluconate cardiotoxicity and safety of generics” 
(chapter 5.2), we report an outbreak of cardiotoxicity and deaths related to the use of a 
particular brand of generic SSG in Nepal in April/May 2000. In the 23 patients treated 
with this particular generic brand, there were 8 (35%) deaths which is in contrast to 
3.2% deaths in the 252 patients treated, from August 1999 to December 2001, with the 
regular generic brand. Almost all the deaths were due to cardiotoxicity. Although 
generic versions of SSG have been shown to be equivalent to branded SSG (Moore et al. 
2001; Ritmeijer et al. 2001; Veeken et al. 2000) it is important to ensure their safety 
and efficacy by applying rigorous quality control. 
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Abstract: Visceral leishmaniasis (VL) is endemic in south eastern Nepal in spite of the 
control efforts. We document the epidemiological trend and treatment outcome of cases 
admitted from 1999 – 2004 to a teaching hospital situated in the endemic area. Over the 
whole period 926 VL cases were admitted from 13 districts, 4 of which are non-endemic 
for VL. In 2004 the cases, both from the rural and urban regions, increased by over 2 
folds compared to 2003. In 1st time treated patients, cure rates (initial and definite) with 
the recommended 1st line drug, sodium stibogluconate (SSG), were significantly lower in 
cases from districts close to Bihar, the Indian high resistance focus (76.6% and 59.9% 
respectively) than in cases from other districts (92.5% and 86.1% respectively). Our study 
signals silent epidemics alongside extension of the VL endemicity in Nepal and evidences 
the spread of SSG resistance from Bihar.  
Key words: visceral leishmaniasis; kala-azar; epidemiology; treatment; sodium 
stibogluconate; treatment failure; drug resistance; Nepal 
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Introduction 
Visceral leishmaniasis (VL) is the most severe, systemic, form of leishmaniasis, and is 
almost always fatal if untreated (1). Although VL is reported from 61 countries, more than 
90 % of the estimated annual 500,000 new cases occur in India, Bangladesh, Nepal, 
Sudan and Brazil  (2). In the Indian subcontinent and Sudan VL is caused by 
anthroponotical transmission of Leishmania donovani and it typically affects the poorest 
people from the rural communities.  
In Nepal, the first officially reported case of VL or kala-azar was observed in 1980. Since 
1992, the VL incidence rate has been increasing rapidly, reaching up to 55/100,000 
person-years in the past few years (3). More than 5.5 million people are estimated to be at 
risk of the disease and presently 12 districts in the southern plains or Terai (Nepal 
lowlands) region, bordering the state of Bihar, India, are endemic with a few more 
districts showing sporadic cases (4). The 1980 VL case was observed in Dhanusha 
district. Before that date, there is no historic record of VL in Nepal, but an Indian 
scientist who surveyed the region for vector borne diseases in 1949 claimed that Kala- 
azar was endemic in the entire Terai (5).  
In India, there are records of major epidemics of VL in the eastern part since the first 
quarter of the nineteenth century, extracting a heavy toll on human lives (6). In the 
1950’s and 1960’s there was a dramatic drop in the number of cases due to the effect of 
extensive DDT spraying in the malaria eradication programme. The last 2 epidemics in 
India had their origin in north Bihar, adjoining the Terai districts of eastern and central 
regions of Nepal. The most recent epidemic in Bihar, which started in 1991/1992, is 
estimated to have caused 200,000 to 250,000 cases (7). Most likely, the current epidemic 
in Nepal is a cross-border extension of this Bihar focus, as exemplified by the 
homogeneity of the L.donovani population (personal communication G.Schoenian). 
The Ministry of Health (MOH) of Nepal launched, in 1992, a national programme for the 
integrated control of vector borne diseases, targeting malaria, kala-azar and visceral 
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leishmaniasis. This includes provision of free anti-VL drugs to district hospitals along 
with selective indoor residual insecticide spraying in VL endemic areas. Nevertheless, the 
VL case numbers continue to rise. In 1993 Nepal reported 1368 VL cases, but the more 
recent epidemiological surveillance figures show 2020, 2389 and 1921 new cases in  
2001, 2002, and 2003 respectively (MOH, unpublished). It is believed that the reported 
VL figures are a gross underestimate of the true VL incidence, as many patients consult 
in the informal or private sector, and their records never end up in the surveillance data 
(4). 
One of the major limitations for control of VL in Nepal has been the lack of adequate 
epidemiological data (4) apart from figures from 2 small studies. In 1996-1997, Koirala et 
al. (8) conducted a cross-sectional sero-survey in 2 villages in the eastern region, and 
showed a seropositivity of 6.09 % (n=1083) for Leishmania infection using the direct 
agglutination test. A case control study looking at risk factors for VL that included 84 
cases and 105 controls from 3 districts from the central region concluded that sleeping 
on a bed or cot and sleeping under a bed net were protective against VL (9).  
This paper provides the first longitudinal data from Nepal, over a period of 5 years (1999 
to 2004), and reports the epidemiological and clinical profile of patients and on trends of 
VL as seen from a teaching hospital located in the heart of the endemic region.  
Patients and Methods: 
Context 
Nepal is ecologically divided into 3 distinct regions: mountain in the north, hilly region in 
between, and the plains (Terai) in the south, bordering India. In the latter, a sub-tropical 
climate prevails, and it is affected by several tropical diseases. B.P. Koirala Institute of 
Health Sciences (BPKIHS) is a health sciences university, situated in Dharan, Sunsari 
district, in the Terai region (Figure 1). Its 640-bed teaching hospital serves as a referral 
hospital for the eastern region of Nepal, and the tropical disease unit is known to the 
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inhabitants of Terai as a specialized kala-azar centre providing free treatment to kala-azar 
patients. It also attracts a major part of the VL patients from the neighboring districts. 
Patients usually tend to seek care at BPKIHS after traditional healers or private 
practitioners have failed to cure their symptoms. Several others consult directly without 
going to the first line public health facilities. 
Patients
The observations are based on a database of all patients diagnosed with VL who were 
admitted at BPKIHS from August 1999 to the end of 2004. The diagnosis of VL was 
suspected in all persons presenting with a history of fever of 2 weeks or more with a 
palpable spleen. The diagnosis of “confirmed VL” was made by demonstration of 
Leishmania donovani amastigotes in bone-marrow or spleen aspirate smears stained with 
Giemsa stain. Clinical suspects who were parasitologically negative but serology positive 
(rK39 immunochromatographic test or direct agglutination test titer, >1:3200 titer) and in 
whom other diseases were ruled out were considered as “probable VL”. Age, sex, 
occupation, place of residence (district and village development corporation/town), 
duration of symptoms, clinical characteristics, haematological profile, treatment received 
and outcome were routinely recorded. 
Treatment and follow up: 
As per the national guidelines, confirmed and probable VL cases were treated with a 
pentavalent antimony (sodium stibogluconate (SSG), 20/mg/kg of body weight, 
intramuscular, for 30 days) as a first line therapy, except for one series of patients that 
accepted to be enrolled in a Phase IV study of Miltefosine between September 2003 and 
March 2004. Amphotericin B, 0.5-1mg/kg/day, infusion for 14 days was given as the 
second line therapy in cases of treatment failure. The patients received the full course of 
treatment either in the hospital or ambulatory. The latter applied only for the 1st line 
therapy in those who were unable to stay in the hospital for the full course. These 
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patients were supplied the full dose at the time of discharge, to be taken at the nearest 
health facility, with recording of the doses on a treatment card. All patients were followed 
up for clinical and parasitological evaluation at the end of treatment and at 6 months 
after treatment. 
Outcome of treatment was defined as: initial cure, i.e. resolution of clinical features along 
with a negative parasitology at the end of treatment; definite cure, i.e. initial cure who did 
not show signs of relapse (recurrence of fever, increase in spleen size) during 6 months 
follow up; non-response, i.e. a person who remained parasitologically positive at the end 
of treatment; relapse, those with initial cure but recurrence of symptoms along with 
positive parasitology during a 6 months follow up period. Treatment failure was defined 
as either non-response or relapse. All patients were encouraged to present for a follow-up 
visit at 6 months. Reimbursement of transport cost and compensation for daily wage lost 
for this follow-up visit was available throughout most of the study period. The patients for 
whom no information was available after starting treatment, due to loss to follow up, were 
excluded from the analysis of outcome of treatment.  
The data were analysed with EpiInfo 2002 (Centers for Disease Control and Prevention, 
Atlanta, GA) and SPSS v. 11 (SPSS, Chicago, IL). 
Results:
A total of 926 VL cases were admitted between August 1999 and December 2004 at 
BPKIHS. The cases were admitted throughout the year with a higher proportion between 
March to July and the lowest in December and January. This pattern was similar every 
year.
Patients came from 13 districts (9 known endemic and 4 non-endemic ones), (Table 1) 
with the majority of the cases (87 %) from the 3 closest districts, namely, Morang, 
Sunsari and Saptari (Figure 1, No 2,3 &4 respectively). Interestingly, 23 patients (2.5 %) 
were admitted from the non-endemic districts Bhojpur (No 12), Dhankuta (No 11), Ilam (No
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10) and Bardia (No 13), the former 3 being hilly and the latter  a lowland district in far 
western Nepal.  
In 2004 there was a dramatic increase in the number of cases when compared to the 
preceding years, both from non endemic and endemic districts (Table 2). There were in 
particular 9 cases from Bhojpur (No 12). In Sunsari district, where BPKIHS is located, the 
number of admissions from the rural areas (village development corporations) almost 
tripled in the last year. In Dharan town there was a dramatic, almost 10-fold, increase in 
the number of cases in 2004. 
Ninety percent of the total cases were confirmed VL and 10% probable VL, 56% were 
males and age-wise 29.5 %, 60.9% and 9.6% were less than 15 years, 15 to 45 years and 
over 45 years respectively. The duration of history of fever prior to admission ranged from 
2 to 104 weeks with a median of 8 weeks (Inter quartile range 4-12).In cases from the 
non-endemic districts the proportion of males and the duration of fever prior to 
admission was higher than in cases from the endemic districts, and none of them had 
received past treatment for VL (Table 1).  
Overall, 125 out of the 926 patients (13.5%) had history of treatment of VL in the past. 
Majority of these had received SSG (76.8%) and 80% had given history of receiving the 
full course (although there was no documents available with most of them). While 80% 
had received the treatment in a public health facility only 20 % received it at 1st line 
health services. The incidence of co-infection with HIV was nil from 1999 to 2002, and 
0.8 % and 0.75 % in 2003 and 2004 respectively. All HIV positive cases were from the 
urban regions. 
On admission at BPKIHS, 823 patients were treated with the 1st line therapy - 700 with 
sodium stibogluconate (Albert David, Calcutta, India) and 123 with miltefosine (Zentaris, 
Frankfurt, Germany) - and 92 with 2nd line therapy Ampotericin B. Six patients defaulted 
and 5 died before the specific treatment could be started. In those who were treated the 
follow up visit at end of treatment and at 6 months was achieved in 92 % and 60% 
respectively. Outcome of treatment in 1st time SSG treated patients is shown in table 3. 
Both the initial and definite cure rate was significantly lower, by 15.8 % and 26.5% 
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respectively, in cases coming from the districts bordering the Bihar high resistance zone 
(figure 1: district no 4 to 9). Also the death rate and toxicity to SSG was higher in cases 
from these districts. The highest death rate was noted in the year 2000, when it was 13.5 
% in patients from districts bordering the Bihar high resistance zone and 6.9% in the 
other patients. 
Discussion: 
As our data show, VL has become well established in the Nepal plains as a major endemic 
tropical disease. Although the majority of the patients are still from the lowland districts, 
there is an alarming trend in the number of cases from the non endemic hilly districts. 
Curiously, there have been no records of cases from these districts in the surveillance 
reports of MOH from 1999 to 2003. The increase we observed at BPKIHS signals, in our 
view, the appearance of new foci in Bhojpur, Ilam and Dhankuta districts, as there was 
no history of recent travel to known endemic regions in the cases originating there.  
Moreover, as the national VL control programme does not cover these districts, it is likely 
that several cases of VL are not diagnosed or treated in the local hospitals, and the 
number of cases seen in this cohort may well represent only a fraction of the total cases 
occurring in the hilly areas. The longer duration of fever, which is an approximation of 
the duration of the disease, in these cases reflects the problems of access to our center. 
The higher proportion of males is also related to the difficulty, especially for women, to 
come to BPKIHS, which requires a few days of travel. The single case from Bardia district 
(No 13) in far western Nepal traveled over 600 kms, as he could not obtain the anti VL 
drugs locally. He gave a history of travel to north India before the start of the illness. 
Migration to other countries, including India, for work has generally increased recently 
due to the ongoing violent conflict and increasing poverty, and may be an important risk 
factor for the occurrence of the disease in the non endemic regions. 
A limitation of this study is that our data are hospital based, and we cannot absolutely 
exclude that the increasing trend we observed might be due to higher attraction of cases 
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to the hospital in comparison to the previous years. The doubling of cases in 2004, 
compared to 2003, could be for instance related to the spreading news of an oral drug, 
Miltefosine, becoming available at our centre.(10). However, this cannot be a factor of 
meaningful importance for patients from Sunsari district, where BPKIHS is located. Those 
patients traditionally seek treatment at BPKIHS, which is easily accessible for them and 
has been providing free treatment to VL patients during the whole study period. 
Therefore, the dramatic increase of the number of cases from Sunsari district in 2004, 
suggests in our view an increasing transmission of the disease. The figures for Dharan 
and Itahari, both urban areas within Sunsari district, seem even to indicate an evolving 
outbreak. Almost all the cases in these towns occurred in recent suburban settlements, 
which are unorganized with poor environmental conditions. Migration from rural to urban 
areas has also in Brazil led to quick urbanization of VL (11).  The urbanization of VL in 
this region of the world carries the threat of rapid increase of VL and HIV co-infection, 
which at present appears to be still quite low. However, towns like Dharan are known to 
have a high prevalence of intravenous drug users and recent reports found a high 
prevalence of HIV infection (45 to 60%) in these groups (12). 
The case fatality rate (CFR) in patients treated with SSG in our study is higher than what 
has been reported by the epidemiological surveillance system of MOH (around 1%), but 
we feel ours is probably a more realistic rate. Indeed, in the public health facilities follow 
up information after completion of treatment is available in only a few patients. Though it 
has been felt that SSG at the present recommended doses is considered safe (13), this 
mainly refers to patients treated for cutaneous or mucocutaneous leishmaniasis. Reports 
of higher CFR in visceral leishmaniasis treated with SSG have been noted elsewhere 5.9% 
in India (14)and 8.4% in Sudan (15). In addition to the failure to respond, cardiotoxicity 
due to SSG is known to increase the mortality and this is related to the quality of the 
SSG. A high rate of cardiotoxicity and deaths occurred in our hospital in the year 2000 
linked to the use of one batch of SSG produced by a particular generic manufacturer (16). 
Similar incidents have also been reported from India (17). 
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Although the pentavalent antimonials have been in use for more than 50 years, they 
continue to remain the first line therapy in most countries, including Nepal. This is 
mainly attributable to it’s time tested efficacy and affordability. However, over the last 
decade there have been consistent reports of progressive decrease of the cure rates with 
SSG in Bihar, India (18). Estimated cure rates as low as 35 % have led to abandoning 
their use as a first line agent (14;19;20).The present study documents, for patients 
treated for the first time with SSG, significantly lower cure rates in those cases coming 
from the districts bordering the high resistance Bihar focus. This confirms an earlier 
observation where cases from Saptari district (No 4) had a definite cure rate of only 76% 
when compared to the overall cure rate of 90% in a cohort of novel patients from Morang, 
Sunsari and Saptari treated with SSG (21). Important reasons for treatment failure have 
included rampant use of sub therapeutic doses and incomplete duration of treatment 
which are likely to be the main determinants of the emergence of resistant strains of 
Leishmania donovani to SSG, which have been isolated from relapsed patients in Bihar 
(22). In our study the majority of our patients that have been treated in the past had 
received complete courses, which is in contrast to studies from Bihar where only 26% of 
cases presenting with refractory disease had received treatment as per the WHO 
guidelines (23;24).The close proximity of Bihar, along with the intense cross border 
movement, in addition to increased transmission, could easily explain the spread of drug 
resistance from Bihar to Nepal. 
In spite of the control measures implemented by the national programme, which has been 
operational for over 10 years, we provide evidence of intensified transmission of VL in 
Nepal and of the emergence of new foci. The surveillance system and the national 
programme need to be strengthened and extended to these “non endemic districts” where 
cases are appearing. Epidemiological and entomological surveys should be conducted to 
better document the emergence of new epidemic foci. Recommendations for the use of 
SSG as a first line therapy in the national programme needs to be revised urgently, 
particularly in those districts bordering the high resistance Bihar focus. The 
epidemiological trends in Nepal, including the spread of resistance to drugs, are being 
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heavily influenced by the Indian epidemic and a close cross border collaboration between 
the control programs of the two countries is essential. The recently launched kala-azar 
elimination programme for the region would be a good platform to build this collaboration 
(25) 
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Table 2: Yearly number of VL cases admitted at BPKIHS, Nepal  by endemicity of  
districts of origin and by rural or urban regions from Sunsari District, 2000 to 
2004
 2000 2001 2002 2003 2004 
All districts      
Endemic 155 148 143 122 271 
       Non endemic 2 2 5 2 12 
Total 157 150 148 124 283 
     
Sunsari district      
     Rural regions      
            Amahibelaha 1 2 0 2 13 
            Aurabani 1 0 2 0 17 
            Barahachetra 6 6 8 1 2 
            Bokraha 0 2 0 5 17 
            Others 37 23 27 21 32 
            Sub total 45 33 37 29 81 
     Urban regions      
             Dharan 6 9 7 3 44 
             Inaruwa 2 2 3 8 1 
             Itahari 2 0 10 9 4 
            Sub total 10 11 20 20 49 
Total (Sunsari) 55 44 57 49 130 
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Case Report
 
A 48-year-old man presented with multiple papules, nodules
and verrucous plaques on the face, trunk and extremities of
1-year duration. Two years ago he had prolonged fever and
splenomegaly and was diagnosed with kala-azar, for which
he received inadequate treatment from the local health center.
A year later he developed erythematous papules in the peri-
oral region and these lesions gradually increased in size and
number. Simultaneously he also developed multiple nodules
in the extremities along with hypopigmented macules on the
trunk. A diagnosis of lepromatous leprosy was made at the local
health center and he was started on World Health Organization-
multi bacillary multi drug therapy (WHO-MBMDT). He
discontinued the medication after 6 months when there was
no improvement in his lesions.
There was no history of hypoaesthesia over the lesions,
neuritis, epistaxis, pedal edema, eye complaints, orchitis, fever,
loss of weight or loss of appetite.
On cutaneous examination he was found to have multiple
hypopigmented macules, erythematous papules, nodules and
plaques of various sizes on the face, trunk and extremities
(Fig. 1). The plaques on the dorsum of the legs were large and
verrucous with maceration of the skin (Fig. 2). Papules and
nodules were also present on the dorsum of the tongue (Fig. 3),
the hard palate and the scrotum. All the lesions were asymp-
tomatic. No nerves were thickened or enlarged. He had mul-
tiple bilateral cervical and inguinal lymphadenopathy. The
lymph nodes were 3–4 cm in size, discrete, nontender, mobile
and firm. The skin over the nodes was normal. On systemic
examination the spleen was found to be enlarged to 3 cm below
left costal margin, and there was no hepatomegaly.
The results of investigations were as follows: Hemoglobin
was 9.2 g/dl and erythrocyte sedimentation rate (ESR) was
48 mm in 1 h. Urine microscopy, liver function tests, renal
function tests, chest X-ray and electrocardiogram (ECG) were
all within normal limits. The Mantoux test and human
immunodeficiency virus (HIV) test were negative. Peripheral
blood examination did not reveal the malaria parasite. Skin
slit smears from the nodules, macules and plaques on the face,
trunk, foot, leg and ear lobes for Mycobacteriuum leprae
were negative. However, many Leishmania donovani bodies
(LDB) were seen in these lesions stained with Giemsa. Fine
needle aspiration cytology from the lesions and lymph nodes
showed epitheloid cell granulomas with LDB. Skin biopsy
from the skin lesions showed epitheloid cell granulomas with
dense inflammatory infiltrate of plasma cells, histocytes
Figure 1 Nodules on the lips, nose, forehead and cheeks
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and lymphocytes. A few LDB were also seen (Fig. 4). Bone
marrow aspirate stained with Giemsa also showed many
LDB and the rK39 dipstick test was found to be positive. The
patient was diagnosed as a case of post-kala-azar dermal
leishmaniasis with visceral leishmaniasis and was referred
to the nearest primary health center with a prescription
to start injections of sodium stibogluconate 20 mg/kg/day
intramuscularly until all the lesions resolved.
Discussion
Post-kala-azar dermal leishmaniasis (PKDL) is a known
squaelae to visceral leishmaniasis (VL) or kala-azar (KA) that
develops in 10–20% patients in the Indian subcontinent. It usu-
ally manifests several months to a few years after “cure” of
KA. However, in Sudan, it develops in nearly 56% of cured
KA patients within weeks to a few months after treatment.
 
1
 
The rash of PKDL may be macular, maculopapular, nodular
or plaque-like. The lesions may become verrucous, papillo-
matous, annular or fibroid.
 
2
 
 Ulceration is uncommon.
 
3
 
 The
lesions initially appear in the peri-oral region and then spread to
the face, trunk and upper/ lower extremities. Papules or nodules
may be present on the scrotum. Mucosal lesions on the tongue
are also uncommon.
 
4
 
 Dissemination of the lesions all over the
body may mimic lepromatous leprosy.
 
3
 
 Lymph nodes may be
enlarged but most PKDL patients do not have demonstrable
parasites in lymph node or bone marrow aspiration.
 
1
 
Our patient presented with large verrucous plaques, which
is a rare presentation in PKDL, along with nodules on the
tongue, face and upper limbs. The patient was misdiagnosed
as having leprosy and received treatment for 6 months. Dif-
ferentiation from leprosy is difficult in places where both dis-
eases are endemic. However, diagnosis of PKDL can be made
clinically provided that the appearance, distribution and tem-
poral relationship with kala-azar are taken into account.
 
5
 
Diagnosis can be supported by slit skin smear examination
for LDB. Therefore, it is important that physicians be aware
of the differential diagnosis of PKDL.
The exact pathogenesis of PKDL is not known. However,
there is evidence that immune responses have a major role. A
high concentration of interleukin-10 (IL-10) in the peripheral
blood of KA patients predicts the development of PKDL.
After treatment of KA, peripheral blood mononuclear cells
(PBMC) start producing IL-10, which plays an important role
in the regulation of the immune system.
 
2
 
 The immune system
shifts from a T helper type 2 (Th2) to T helper type 1 (Th1) or to
a mixed Th2/Th1 response. The Th1 cells migrate to the skin,
and their subsequent attack on the parasites may be an important
factor in the pathogenesis of PKDL.
 
3
 
 The production of IL-10
by PBMC also coincides with the appearance of PKDL lesions.
 
2
 
Immunity after cure of KA has been known to be almost
Figure 2 Verrucous plaques on the dorsum of both feet
Figure 3 Nodular lesions on the tongue
Figure 4 Microphotograph showing epitheloid cell granulomas 
with dense inflammatory infiltrates of plasma cells, histiocytes 
and lymphocytes in the dermis. A few LDB were also present and 
are marked by arrows (hematoxylin and eosin, ×40)
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lifelong, provided there is no immunosuppression.
 
5
 
 The struc-
tural and functional component(s) of the visceral immunity may
protect the host from recurrence of KA by preventing infection
from freshly infected sandfly bites, or by blocking re-invasions
of the parasites from the skin in the case of PKDL or by pre-
venting reactivation of the latent parasites in the viscera.
 
5
 
However, a few cases of PKDL associated with KA have been
reported in the literature.
 
5–12
 
 One study from India estimated
this to occur in one in every 700 patients with PKDL. A degree
of immunosuppression induced by intercurrent diseases such
as measles, malaria, tuberculosis and HIV infections favors
reinvasion of the parasites from the skin to the viscera.
 
10
 
The development of partial immunity after incomplete treat-
ment leads to clinical improvement, but persistence of para-
sites seems likely. Failure to develop complete immunity may
result in re-establishment of VL from the skin or from other
organs. Renewed multiplication of the latent parasites in the
viscera might be the cause of relapsed VL in our patient, as he
received inadequate treatment for VL. However, re-infection
as a cause of relapse of VL could not be ruled out because the
patient was from an endemic area and the long interval between
VL and PKDL leaves room for speculation about re-infection.
We report this case because of its uncommon features and its
rare association, and to point out that patients with long-
standing unrecognized PKDL may play a role in transmission
as they may act as a reservoir, particularly in India and Nepal
where the transmission of KA is anthroponotic.
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SUMMARY
Visceral Leishmaniasis (VL) affects persons from the lowest socio-economic strata of 
the community, but its economic impact is not precisely known. An exploratory 
survey to document the economic costs of VL to households was conducted in an 
endemic focus in eastern Nepal and data was collected from the 20 households of this 
cluster. Cases of VL over the last 3 years were elicited and information on direct and 
indirect cost incurred due to the disease and income of the households over the last 
year was estimated. 15 % (16/107) of the residents had suffered from VL and almost 
all the patients had preferred, at the first instance, to visit the private services or local 
faith healers instead of visiting the local public health facility.  Average total cost 
incurred per episode of VL was above the median annual per capita income and 6 of 
the 7 affected households had to either sell part of their livestock or take loan to cover 
the costs. Direct costs consisted of 53% of the total cost with 75 % of this cost 
incurred before the patients actually received any treatment for VL. 
This study demonstrates how VL can lead to catastrophic expenditure for the affected 
households.
Keywords economic burden, visceral leishmaniasis, Nepal, poverty, health care 
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INTRODUCTION 
Visceral leishmaniasis (VL), a vector-borne disease that is fatal if untreated, has 
recently earned public attention as one of the “most-neglected diseases” (Trouiller et
al. 2002). The World Health Organization estimates that there are about 500,000 new 
VL cases per year, of which more than 90 % occur in India, Bangladesh, Nepal and 
Sudan, and 59,000 deaths (UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases 1997). However, the reported figures may 
be grossly underestimated. In Bihar, the epicenter of the Indian epidemic, door to door 
surveys revealed that the real prevalence was 5 times higher than the officially 
reported one (Desjeux 1991). Similarly, the Ministry of Health (MOH) of Nepal 
acknowledges that only those cases who attend the government health facilities are 
represented in the reported figures (Bista 1998). Moreover, as VL has a very focal 
distribution, the aggregated figures do not reflect the real burden of disease in affected 
communities. In prospective cohort studies reported incidence rates of VL vary 
between 2/1000 over 14/1000 person-years in Ethiopia (Ali and Ashford 1994), to 
40/1000 person-year in Sudan (Zijlstra et al. 1994). Incidentally, these rates are 
comparable to or higher than the incidence rates of tuberculosis at community level. 
VL is a poverty-related disease that affects the poorest of the poor (Desjeux 1996; 
Boelaert et al. 2000) . In Bihar, 75% of VL patients had a daily income < US$ 1 and 
77% were living in mud or grass covered houses (Thakur 2000) .The vector, 
Phlebotomous argentipes, breeds in cracks of mud-plastered houses and moist soils. 
In Nepal almost all VL patients live in remote rural communities.  
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The impact of VL on economic development is still not fully recognized. Without 
quantifying it, Wijeyaratne et al. (1994) have drawn attention to the tremendous 
barrier the disease poses to the development of the affected communities. There is 
also little known on the possibly catastrophic economic consequences of VL on the 
affected households. Adhikari and Maskay (2003) in a letter to the editor made 
reference to the total medical cost incurred (US$ 210) per episode of VL care in 
Nepal and a qualitative survey on the perception of VL at community level in 
Bangladesh reported in passing how gathering the US$ 85 to 500 necessary for 
diagnosis and treatment left the household destitute (Ahluwalia et al. 2003). 
Moreover, in every family where a VL case occurs, many days of productive life may 
be lost directly or indirectly but this has never been quantified. We therefore 
conducted an exploratory study to better document the economic costs of VL to 
households.
METHODS  
During a survey conducted in eastern Nepal to estimate the incidence of leishmanial 
infection and disease, Charigua, a hamlet in Dulari village, was identified to be 
amongst the most affected locality (unpublished data). VL being a focal disease with 
cases occurring in clusters, we selected this hamlet which would be representative of 
other VL foci within the region. Charigua hamlet consisted of 20 huts, between the 
village road and the paddy fields and half a kilometre away from the national 
highway. All the huts in Charigua are mud plastered with thatched roofs. A few 
families rear animals on their backyard, close to their huts. The nearest health facility, 
a sub-health post, was 2 kms away. This is the lowest level in the Nepalese public 
health system and supervised by an auxiliary health worker with 1 year training. A 
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district hospital run by 2 medical doctors and catering to a population of about 
700,000 is located 20 kms away. A tertiary care university hospital, B.P. Koirala 
Institute of Health Sciences (BPKIHS) is situated 25 kms away, and is easily 
accessible by bus or taxi via the above mentioned highway. BPKIHS has been 
providing free VL care (VL drugs, diagnostic tests and hospitalisation fees) to patients 
over the last 5 years.  
From April to June 2004 every household in Charigua was visited by a trained 
interviewer. Data was collected from the head of the household and the patients 
and/or their caretakers in case of children on a pre-tested questionnaire. First, VL 
episodes (which was defined as fever treated with VL drugs) occurring in the 
household in the last 3 years were elicited, and these data were later cross-checked 
and validated against the hospital admission records at BPKIHS. For all episodes 
health seeking behavior was recalled including local faith healers, private services 
(pharmacies and private practitioners) and public health services. Information 
collected on costs included direct health care cost (diagnostic tests, all drugs, fees paid 
to providers) and other associated cost (transportation and food) and indirect costs 
(earnings lost/foregone due to the illness by patients or caretakers). Costs incurred at 
the level of 1st line care (faith healers, private services and peripheral public health 
service) and at the level of referral level (BPKIHS) were separated. For all households 
we estimated the total yearly income from wages, agricultural activities and other 
sources in the past year. As the yearly inflation rate was low (around 5%), no 
adjustment for inflation was made. All costs were recorded in Nepalese rupees and 
have been transformed to US$ at the 2004 exchange rate (1US$= NRs 74). 
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RESULTS 
The Charigua hamlet had a total population of 107, living in 20 households. The sex 
ratio was around 1:1 for both adults and children. Eighty percent was less than 45 
years of age and children < 15 years comprised 42%. None of the households owned 
any farming land, and all the male adults were daily wage laborers, either farm 
laborers or rickshaw drivers. Some of the female household members and older 
children also worked occasionally, as laborers, mainly during the paddy plantation 
and harvest season. Livestock raised (and/or backyard gardening) was strictly for self 
consumption except during times of crises when they sold part of their livestock. The 
median annual per capita household income (PCI) was US$ 81.07 (Q1 69.44; Q3 
113.47).
Over the past 3 years, 15 % (16/107) of the residents of Charigua had been diagnosed 
with VL. The cases were concentrated in 7 out of the 20 households. Six patients had 
first visited local faith healers, 9 private health services, and only one person had first 
consulted the public first-line health post. Fifteen patients eventually attended 
BPKIHS for VL treatment after a median delay of 8 weeks (Q1 4; Q3 12) and one 
received treatment in a private clinic. The median age of the patients was 23.5 years 
(Q1 11.25; Q3 30.75), of which 5 were < 15 years of age. All the patients were treated 
with sodium stibogluconate (20mg/kg/day for 28 days), the recommended first line 
therapy.  
Notwithstanding the free provision of VL care at BPKIHS, the total cost incurred by 
patients was on average US$ 113.65 (median US $ 84.41 (Q1 50.09; Q3 139.50)) per 
episode (Table 1) which was above the median annual PCI of US$ 81.07. The median 
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cost of treatment for VL in those households which had more than one case (4 
households) was US$ 425 ( Q1 250; Q3 506) which is more than the  median annual 
household  income of US$ 405 (Q1 324; Q3 486) for the affected households. 
 Direct costs on average consisted of only 53% of the total costs. The indirect costs 
were due to loss of earnings for days lost due to illness or caretaker which was on 
average 57 days (median 37 days (Q1 13; Q3 75)). Of the total cost incurred at the 1st
line care, 88.5% occurred in the private health services and only 11.5 % during visits 
to the local faith healers. 
The direct costs incurred in the 1st line or referral level care were comparable, but in 
the former it mainly consisted of health care cost (89%) and in the latter, other 
associated costs (66%) which were essentially for transport and food for the patient 
and their caretakers. Seventy five percent of the mean total direct health care cost 
occurred at the 1st line care before the patient had actually received any VL treatment.  
 All 7 affected households used their savings and also borrowed money from their 
friends and neighbors to cover the cost of treatment. Additionally, three households 
had to take a loan from money lenders at very high interest rates (6% per month), and 
3 other households had to sell part of their livestock assets. 
DISCUSSION 
This exploratory study quantifies for the first time the different components 
contributing to economic cost incurred due to VL and shows how VL can lead to 
enormous health expenditure at the household level. The 3 year recall used in our 
study is quite long for obtaining an accurate estimate of the expenses made, but as 
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these expenses had been quite substantial to these households and with little variation 
over this period, we feel our data are a good approximation of the costs incurred.  
It is of note that, almost all patients first sought care from the local faith healers or 
private services although a public health post was within walking distance (2 km). 
Communities lack confidence in the health post which is equipped with limited 
facilities and drug supply. Surprisingly, most of the health care cost for VL care was 
incurred during the first line of care, which in this case was mainly in the private 
sector. In Nepal the private services in the rural areas, mainly consist of over-the 
counter sales of drugs in the medicine shops or poorly trained private practitioners 
with very irrational prescribing practices. There is no system of monitoring or 
regulation of this private sector. As with other neglected tropical diseases, VL can 
lead to “iatrogenic poverty” (Van Damme et al. 2004;Meessen et al. 2003).  
The MOH in Nepal is committed to the control of kala-azar. The kala-azar control 
programme launched in 1992 has been providing free VL drugs to the public hospitals 
in the endemic region. However, as the diagnosis of kala-azar is only possible at the 
level of the district hospitals it appears that many VL patients are not able to get 
access to this “free care”. The cost of travel and the loss of earnings deter most 
patients, who are daily wage laborers, to travel to these public hospitals at the first 
instance. Only 10.2 % of the population in rural Nepal lives within one hour travel to 
a public district hospital (Hotchkiss et al. 1998).
A survey conducted in India on the mean household expenditure related to an episode 
of kala-azar, observed a significant difference between the state of Bihar (US $ 401.6) 
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and West Bengal (US$ 59.8) (V Annigeri, unpublished report). These differences 
could be related to care seeking behavior of the community and the accessibility to the 
health system, the latter being much better developed in West Bengal compared to 
Bihar.  
Our study indicates that quality VL treatment in Nepal is too centralized in 
specialized care centers situated in the larger towns and cities. The MOH should 
stimulate decentralization by introducing simple case-management strategies and by 
making reliable and feasible diagnostic tools eg. rK 39 dipstick test (Sundar 1998; 
Boelaert 2004), and drugs available in the peripheral levels of the health system. In 
addition to the provision of free VL care, activities to increase awareness within the 
community needs to be intensified. Koirala et al. (1998) observed poor knowledge of 
VL in the community, in a survey conducted in an endemic area in Eastern Nepal. 
Most importantly, policy makers should recognize how neglected diseases such as VL 
can maintain the vicious circle of poverty, and should combat them more intensively 
including the strengthening of first-line health systems. 
Conflicts of interest: The authors have no conflicts of interest concerning the work 
reported in this paper.
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CHAPTER 4:
EVALUATION OF NOVEL
DIAGNOSTIC TESTS
Prospective evaluation and comparison of the direct
agglutination test and an rK39-antigen-based dipstick test
for the diagnosis of suspected kala-azar in Nepal
F. Chappuis1, S. Rijal2, R. Singh2, P. Acharya2, B. M. S. Karki2, M. L. Das2, P. A. Bovier1, P. Desjeux3, D. Le Ray4,
S. Koirala2 and L. Loutan2
1 Geneva University Hospital, Geneva, Switzerland
2 B.P. Koirala Institute of Health Sciences, Dharan, Nepal
3 Communicable Disease Surveillance and Response, World Health Organization, Geneva, Switzerland
4 Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
Summary The diagnosis of visceral leishmaniasis (kala-azar) remains difﬁcult in rural endemic areas and practical
and reliable tests are badly needed. Two serological tests, the Direct Agglutination Test (DAT) and an
rK39-antigen-based dipstick test, were compared to parasitological diagnosis in a group of 184 patients
presenting at a tertiary care centre in south-eastern Nepal with a history of fever ‡14 days and
splenomegaly; 139 patients had a parasitologically proven kala-azar and 45 patients had a negative
parasitological work-up. The rK39 dipstick showed a sensitivity of 97% and a speciﬁcity of 71%. The
DAT was up to 99% sensitive with a low cut-off titre (1:400) but its speciﬁcity did not exceed 82%
even with a high cut-off titre (1:51 200). Both tests could be used for screening suspect patients in
endemic areas. However, their use as conﬁrmatory tests should be restricted to situations where the
proportion of kala-azar among clinical suspect patients is high. The rK39 dipstick is cheaper and easier
to use than the DAT and could be used widely provided that both its performance and production
remain stable.
keywords visceral leishmaniasis, kala-azar, diagnosis, direct agglutination test, k39 antigen, dipstick,
Nepal
Introduction
An estimated 500 000 persons are affected by visceral
leishmaniasis (VL, also known as kala-azar) every year
worldwide. The vast majority of these cases (90%) occurs
in poor rural areas of Sudan, India, Bangladesh, Nepal and
Brazil (Desjeux 1996). Kala-azar is usually fatal if left
untreated but the use of sodium stibogluconate, the most
frequently prescribed ﬁrst-line therapy generally considered
to be relatively safe, can have severe side-effects (Sundar
et al. 2000). It is, therefore, of prime importance to have
accurate and practical diagnostic methods available in
endemic areas. In most countries, diagnosis relies on
microscopic examination of lymph nodes, bone marrow or
spleen aspirates. Lymph node and bone marrow aspira-
tions are safe procedures but their sensitivity for diagnosing
kala-azar is only 58–64% and 70–86%, respectively
(WHO 1984; Zijlstra et al. 1992). Spleen aspiration is
generally considered as the gold standard for kala-azar
diagnosis (Ho et al. 1948; Zijlstra et al. 1992) because of
its high sensitivity and speciﬁcity (both close to 100%).
However, it is contra-indicated in quite a number of kala-
azar suspect patients, although it is a safer procedure than
thought by many physicians. When performed properly,
the death rate due to severe bleeding is 0.1% as reviewed
by Kager & Rees (1983). One of the major drawbacks of
parasitological diagnosis is the expertise required from
both the physician to perform the procedures and the
laboratory technician to stain and read the slides accu-
rately. This expertise is very difﬁcult to obtain in practice
outside reference tertiary hospitals or specialized treatment
or research centres.
Research has focused on the development of cheap,
simple and reliable serological tests for kala-azar, which
could replace parasitological diagnosis in the ﬁeld. The
Direct Agglutination Test (DAT) was ﬁrst described by
Allain & Kagan (1975) and the method was then adapted
by El Harith et al. (1986, 1988). The DAT proved to be a
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very valuable tool for ﬁeld workers especially when high
numbers of patients present to health facilities, as during
the disastrous epidemics raging in Sudan for the last
15 years. The DAT is very accurate under laboratory
conditions (El Saﬁ & Evans 1989; Singla et al. 1993; Joshi
et al. 1999) with high speciﬁcity when control groups were
composed of healthy persons from endemic areas (Schaefer
et al. 1995; Boelaert et al. 1999a). In ﬁeld conditions, the
DAT is very sensitive, but low speciﬁcity values were
reported in series of clinical suspect patients, with a range
depending on the reference test used, between 58%
(Boelaert et al. 1999b) and 72% (Zijlstra et al 1991). Use
of the DAT has been encouraged by WHO for surveillance
and control programmes of VL (DAT workshop, Antwerp,
25–27 March 1998).
More recently, serological testing against a recombinant
antigen derived from a 39-amino acid repeat in Leishmania
chagasi (rK39) was developed. It is very accurate when
used in an ELISA format (Singh et al. 1995; Badaro et al.
1996; Zijlstra et al. 1998). It was later developed as a
dipstick format that showed to be 100% sensitive and 98%
speciﬁc in India (Sundar et al. 1998). As Zijlstra et al.
(2001) found a sensitivity of only 67% in Sudan these
results require further conﬁrmation.
Within this context of new diagnostic development, this
study aimed at evaluating and comparing the validity of the
DAT and an rK39-antigen-based dipstick for the diagnosis
of VL among clinically suspect patients in Nepal.
Materials and methods
Study site
This study took place at the B.P. Koirala Institute of Health
Sciences (BPKIHS), a 650-bed University Hospital located
2 km away from the town of Dharan, Sunsari District,
Eastern Region of Nepal. The BPKIHS serves as a reference
tertiary hospital for the eastern region, which includes
several kala-azar endemic districts. Recruitment of patients
took place in the Outpatient Department (OPD) and the
Emergency Room of BPKIHS from July 1999 to August
2000. The research protocol was approved by the Ethical
Committee of BPKIHS on May 1999.
Inclusion and exclusion criteria
All patients coming to BPKIHS with a history of fever for
14 days or more and clinical splenomegaly were eligible for
the study and were included after informed consent was
given by the patient or his/her closest relative (for
unconscious or paediatric patients). Only clinically suspect
patients were thus included in the study. Indeed, as
emphasized by Sackett et al. (1991), we considered it
essential to validate both diagnostic tests on a patient
group representative for those persons on whom physicians
will use the tests in the future. Patients with prior treatment
for kala-azar were excluded from the study. Serological
diagnosis is known to be unreliable in such patients
because of the long persistence of antibodies against
Leishmania donovani after treatment.
Diagnostic procedures
All patients included were admitted to the medical ward
for the initial diagnostic work-up and treatment. On day 0
(admission day), blood was drawn for complete blood
count, chemistry, coagulation proﬁle, thick and thin smear,
blood cultures and HIV testing after pre-test counselling
(Vironostica and Recombigen ELISA tests). Chest
X-ray, abdominal ultrasound and other tests were
performed at the physician’s discretion.
rK39 dipstick test
The rK39-antigen-based dipstick test (InSure Rapid Test
for Visceral Leishmaniasis from InBios International,
Seattle, USA) was performed using patient serum on day 0
or 1 by the same house ofﬁcer throughout the study and the
results were kept blinded to the physician in charge of the
patient. The procedure was as follows: after allowing the
serum specimen and the dipstick to reach room tempera-
ture, 20 ll of serum were added on the dipstick, which was
then placed vertically in a test tube. Two drops of the chase
buffer solution provided with the dipstick kit were added
in the test tube. The results were read after 5 min and, if
still negative, after 10 min. Even a weak band in the test
region was considered as a positive result. The test was
repeated if the control line remained negative after 10 min.
Direct agglutination test
Patients sera were kept frozen at )70 C and the DAT was
performed at BPKIHS every 3–6 months by a laboratory
technician (M.L.D.) previously trained on-site by the chief
laboratory technician of the Protozoology Unit of the
Prince Leopold Institute of Tropical Medicine in Antwerp
(ITMA). Results of the DAT were thus not used for clinical
decisions. Crosschecking of the DAT was performed at
ITMA from blood impregnated on ﬁlter papers on day 0
and stored in sealed plastic bags. The DAT antigen was
prepared at ITMA using a modiﬁcation of the method of El
Harith et al. (1986) and described by Boelaert et al.
(1999c). The liquid antigen was kept at 4 C during
transport and storage at BPKIHS. The test was carried out
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in microtitre plates (V-shaped wells) with the necessary
positive and negative controls. The test was read visually
against a white background and the end-point titre was
taken as the last well where agglutination was seen. A ﬁrst
serum dilution was tested at 1:400; when positive, full
titration was performed (1:400 to 1:204 800).
Parasitological diagnosis
All patients underwent bone marrow aspiration on day 0
or 1. Careful microscopic search for the amastigote form of
L. donovani (LD bodies) was carried out independently at
both the Department of Microbiology and the Department
of Pathology of BPKIHS by two examiners. When results
were discordant, both examiners met in order to reach a
consensus. Moreover, slides from discordant results were
reviewed at the Parasitology Laboratory of the University
Medical Centre of Montpellier (Dr J. Dereure). If bone
marrow aspiration was negative for LD bodies, spleen
aspiration was performed unless one or more of the
following condition was present: coagulation disorder or
platelet count £50 000 mm)3, refusal of the patient or
her/his physician, alternative diagnosis ascertained by
initial work-up with a clear clinical response to speciﬁc
therapy or spleen size £3 cm under the left costal margin.
Case deﬁnitions
A conﬁrmed case of kala-azar was deﬁned as a patient with
positive parasitology on either bone marrow or spleen
aspiration smear. A controlwas deﬁned as an eligible patient
in whomkala-azarwas excluded by a negative bonemarrow
aspiration and by a subsequent negative spleen aspiration.
Also, we considered as a control a patient with a negative
bone marrow smear in whom a ﬁrm alternative diagnosis
was reached. In addition, all control patients were carefully
followed-up for 6 months. Patients showing any clinical or
parasitological evidence of kala-azar during this 6-month
follow-up have been excluded from our control group.
Case management
All patients were hospitalized until clinical improvement.
Kala-azar patients with no prior history of complete anti-
leishmanial treatment were treated with generic sodium
stibogluconate (SAG from Albert David Ltd – Calcutta)
20 mg/kg/day for 30 days.
Statistical analysis
Data were entered at BPKIHS in an Excel data sheet and
electronically sent on a weekly basis to the principal
investigator. Kala-azar and control patients were
compared on socio-demographic, clinical and laboratory
characteristics, using cross-tabulations and chi-square tests
for categorical variables and comparison of means and
t-test for continuous variables. Sensitivity, speciﬁcity,
positive and negative predictive values were calculated for
the rK39-antigen-based dipstick test and for each dilution
of the DAT, as well as their 95% conﬁdence intervals. The
performance of the two DATs (BPKIHS and ITMA) was
analysed by comparing the area under the curve (AUC) of
the corresponding receiver-operating characteristics curves
with a statistical software (Statistical Package for Social
Sciences, v. 10.1.0). All statistical tests were two-tailed,
with a signiﬁcance level of 0.05.
Results
A total of 227 clinically suspect patients were admitted to
BPKIHS during the 14-month study period. Of these, 195
patients were included in the study after exclusion of three
patients because of early defaulting and 29 patients
(25 kala-azar cases, four controls) because of previous
treatment for kala-azar. Seven patients were later excluded
from analysis because their physician treated them for
kala-azar despite the absence of parasitological evidence
and four patients were excluded from the control group
because kala-azar was diagnosed during follow-up.
The analysis of the validity of the rK39 dipstick and the
DAT was performed in the remaining 184 patients: 108
males and 76 females with a mean age of 23 years. There
were 139 kala-azar patients and 45 controls. The propor-
tion of kala-azar among clinical suspects was 76%. The
diagnosis of the 139 kala-azar patients was made by a
positive bone marrow (131 patients) or spleen (eight
patients) aspiration.
All 45 controls had a negative bone marrow aspiration
but spleen aspiration was performed for only six patients.
The main reasons for not performing spleen aspiration
were a clear initial response to treatment of an alternative
diagnosis (17 patients), a refusal of the patient or his
physician (13 patients), a spleen too small to be punctured
(eight patients) and a coagulation disorder (one patient).
The discharge diagnosis of the 45 controls was malaria (20
patients), disseminated tuberculosis (ﬁve patients), enteric
fever (four patients), leukaemia (three patients), other
haematological disorders (three patients), infectious
endocarditis (two patients), sepsis (two patients), solid
malignancy (one patient) and other infections (ﬁve
patients). Follow-up was completed at 1, 3 and 6 months
for 29 of 45 controls (64%).
The presence of weight loss, skin darkening and the
absence of cervical lymph nodes were signiﬁcantly more
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frequent in kala-azar patients and the mean platelet count
was signiﬁcantly lower in kala-azar patients (data not
shown). HIV testing was negative for all 184 patients.
The InSure dipstick was performed on the 184
patients. The result was positive in 148 patients and
negative in 36 patients. The sensitivity of the InSure
dipstick is 97% (95% CI: 92–99%) and the speciﬁcity is
71% (95% CI: 56–81%). The positive and negative
predictive values of the dipstick test are 91% (95% CI: 85–
95%) and 89% (95% CI: 73–95%), respectively. The
diagnosis of kala-azar would have been missed in four
patients. Three out of the four patients had also a low DAT
titre (£1:800) but one patient had a DAT titre of 1:25 600.
The dipstick was positive in 13 controls. Final diagnosis of
these patients was malaria (10 patients), enteric fever (two
patients) and disseminated TB (one patient). These patients
were treated according to their clinical diagnosis and had a
good initial response. Nine out of the 13 patients were
followed-up at 6 months and were all considered as
deﬁnitely cured.
The DAT was performed on 183 patients. One serum
tube from a kala-azar patient was lost. The performance
of the DAT depends on the cut-off titre chosen
(Table 1). When compared with the DAT performed at
BPKIHS, the DAT performed at ITMA shows similar
sensitivity values but a trend towards higher speciﬁcity
(data not shown). The AUC of the DAT performed at
BPKIHS is 0.858, as compared to 0.890 for the DAT
performed at ITMA (Figure 1). This difference is not
signiﬁcant (P ¼ 0.25).
The predictive values calculated for both the rK39
dipstick and the DAT would vary greatly according to
the proportion of kala-azar in clinical suspect patients
(Figure 2). For a prevalence of 50%, for example, the
InSure dipstick would have a positive predictive value
(PPV) of 77% and a negative predictive value (NPV) of
96%, the DAT 1:400 a PPV of 60% and a NPV of 96%,
the DAT 1:6400 a PPV of 74% and a NPV of 88% and the
DAT 1:51 200 a PPV of 82% and a NPV of 81%.
The four patients initially classiﬁed as controls but later
excluded because they developed kala-azar during follow-
up interestingly had all a positive dipstick and, for three of
them, a DAT > 1:6400 between 3 and 6 months before
kala-azar was diagnosed.
Table 1 Sensitivity, speciﬁcity and predictive values of the DAT performed at BPKIHS*
DAT cut-off
titre
Kala-azar,
no. of cases
Controls,
no. of cases Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
<1:400 2 16
1:400 4 7 99 (94–99) 36 (22–49) 82 (76–87) 89 (64–96)
1:800 1 4 96 (90–98) 51 (36–64) 86 (79–90) 79 (60–89)
1:1600 1 3 95 (89–97) 60 (44–72) 88 (81–92) 79 (62–89)
1:3200 5 1 94 (89–97) 67 (51–78) 90 (83–93) 79 (62–88)
1:6400 4 3 91 (84–94) 69 (53–80) 90 (83–94) 70 (55–81)
1:12 800 4 1 88 (81–92) 76 (60–85) 92 (85–95) 67 (52–77)
1:25 600 5 2 85 (77–90) 78 (63–87) 92 (86–95) 63 (49–73)
1:51 200 3 0 81 (73–87) 82 (67–90) 93 (87–96) 59 (46–69)
1:102 400 109 8 79 (71–85) 82 (67–90) 93 (87–96) 56 (43–67)
* Values in parentheses are 95% conﬁdence limits.
 One serum sample was lost.
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Figure 1 Receiver-operating characteristics curves of the DAT
performed at ITMA and BPKIHS.
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Discussion
This validation study, conducted in a tertiary hospital of
South-East Nepal where kala-azar is endemic, evaluated
and compared the performance of the DAT and the rK39-
based InSure dipstick test for the diagnosis of VL among
a group of 184 clinical suspect patients.
When interpreted with a cut-off titre of 1:6400, corres-
ponding to the titre of 1:3200 found in the original report
of El Harith et al. (1986), the DAT was 91% sensitive and
69% speciﬁc. When setting a higher cut-off titre
(1:51 200), DAT speciﬁcity would increase only moder-
ately to 82% but at the cost of lower sensitivity (81%).
There was a non-signiﬁcant trend towards a better specif-
icity when the test was performed in the reference
laboratory. The relative lack of reproducibility of the DAT,
previously described by Boelaert et al. (1999c), did not
signiﬁcantly alter the results in our study considering the
good conditions of transport and storage of the liquid
antigen and the speciﬁc training received on site by the
laboratory technicians.
The sensitivity of the DAT is invariably recorded above
90% in the literature when low or intermediate cut-off titres
are used. However, its speciﬁcity varies greatly and depends
to a large extent on the choice of the control group. DAT
speciﬁcity is reported well above 90% when control groups
are composed of non-symptomatic people or patients with
known other diseases (except African trypanosomiasis),
coming either from kala-azar endemic or non-endemic areas
(El Harith et al. 1987; Sinha & Sehgal 1994; Schaefer et al.
1995; Boelaert et al. 1999a). When only clinically suspect
patients are studied, a much more realistic situation for a
physician, the reported DAT speciﬁcity falls to 58%
(Boelaert et al. 1999b) and 72% (Zijlstra et al. 1991). Our
ﬁndings of a speciﬁcity of 69% for a cut-off titre set at
1:6400 are consistent with these previous reports.
DAT 1:6400
100
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rK39 dipstick
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Figure 2 Positive (PPV) and negative (NPV) predictive values of the rK39 dipstick and the DAT with cut-off titres of 1:400, 1:6400 and
1:51 200 depending on the prevalence of kala-azar among clinical suspect patients.
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The DAT is a well-validated test for the diagnosis of
kala-azar and has been widely used for more than 15 years.
Because of the quantitative results obtained by gradual
dilution, the cut-off titres to use can be (and should be)
tailored for each epidemiological situation. The main
limitation of the DAT is its relatively sophisticated proce-
dure, which impairs its wide application in peripheral
health structures and the fragile nature of the antigen in its
liquid form, which is a source of logistic problem for
transport and the likely cause of lack of reproducibility.
The latter problems could be solved in the future by the use
of freeze-dried antigen (Meredith et al. 1995; Zijlstra et al.
1997; Oskam et al. 1999). The relative high price of the
DAT liquid antigen (4.5 US$ per test) is also a constraint
but Boelaert et al. (1999d) showed that currently the cost
of test-treatment strategies depend mainly on the cost of
hospitalization and treatment.
The rK39-antigen-based InSure dipstick showed a
sensitivity of 97% and a speciﬁcity of 71% in our study. It
proved to be very easy to perform with minimal training.
Reproducibility of the dipstick was not assessed here but is
clearly an issue to be considered in future studies. Indeed,
the test line can be sometimes very faint and the distinction
from the white background of the dipstick can be difﬁcult.
It is difﬁcult to compare these results with those obtained
from previous studies assessing the value of serology
against rK39 antigen. The initial studies showed excellent
sensitivity and speciﬁcity but used an ELISA format that is
not practical to use in most health facilities in kala-azar
endemic areas (Badaro et al. 1996; Zijlstra et al. 1998).
A well-designed study from Sundar et al. (1998) showed
excellent results (sensitivity: 100%; speciﬁcity: 98%) of an
rK39-antigen-based test on a dipstick format in India but
these results were challenged by a low sensitivity (67%)
found by Zijlstra et al. (2001) in Sudan. The manufacturer
of the dipstick tested in the two latter studies has now
abandoned its production. A second generation of InSure
dipstick is currently produced and commercialized and is
designed to be more speciﬁc than the ﬁrst-generation
dipstick tested in our study. A preliminary retrospective
study in Nepal showed a sensitivity and speciﬁcity of 100%
of this second-generation dipstick but only 14 VL patients
were included and the control group was composed of
non-symptomatic villagers with no personal or household
history of VL (Bern et al. 2000).
The transition of rK39-antigen-based serological test
from its very accurate ELISA format to a very practical to
use dipstick format is not without difﬁculties. With the
current format expressing only a qualitative result (positive
or negative), it will be difﬁcult for manufacturers to
produce a dipstick with both high sensitivity and speciﬁcity
applicable in all kala-azar endemic areas. An alternative
approach would be to produce a dipstick with two test
lines (or two separate dipsticks): one detecting low
antibody titre for screening and one detecting high
antibody titre for potentially conﬁrming the diagnosis. The
dipstick tested in this study has a high potential for use as a
screening test for kala-azar in peripheral health structures
where parasitological diagnosis and the DAT cannot be
used for technical reasons. This will apply to the currently
produced second-generation InSure dipstick only if its
sensitivity remains unchanged. Another constraint for the
InSure dipstick is the sustainability of production by a
private company of a diagnostic test for kala-azar, a
neglected disease with low proﬁt potential.
The speciﬁcity of the InSure dipstick and the DAT
might have been underestimated in our study because of
the imperfection of our gold standard. Indeed, only six of
the 49 patients with an initial negative bone marrow
underwent spleen aspiration. Because of the limited sensi-
tivity of bone marrow aspiration, some diagnosis of kala-
azar might have been missed. We believe that the number
of missed cases is small considering that only four of the
49 (8.2%) initial controls were diagnosed with kala-azar
during follow-up and that 6-month follow-up was com-
pleted in two-thirds of the patients. Boelaert et al. (1999b)
showed in a group of 149 clinical suspect patients that
speciﬁcity of the DAT raised from 68% to 85% when a
mathematical model (Latent Class Analysis) was applied to
correct for the imperfection of the parasitological gold
standard (which did not include spleen aspiration). Fur-
thermore, the conﬁdence intervals of the speciﬁcity values
are relatively wide in our study because of the limited
number of patients included in the control group.
The speciﬁcity of serological tests for VL is anyway
affected by the long persistence of antibodies after
L. donovani infections, which are most frequently
sub-clinical. Hailu (1990) showed in Ethiopia that the
DAT remained positive in most kala-azar patients up to
7 years after treatment. Antibodies targeted against the
more speciﬁc rK39 antigen have been shown to be
detected by a strip test signiﬁcantly less frequently than
antibodies detected by the DAT 12 months after
completion of treatment of kala-azar patients in Sudan
(Zijlstra et al. 2001). However, the strip test used in
this study was lacking sensitivity and IgG directed
against rK39 have been detected up to 24 months post-
treatment in Sudan by the more sensitive ELISA
technique (Zijlstra et al. 1998). Because of this long
persistence of antibodies, clinical suspect patients with a
positive rK39 dipstick or an elevated DAT titre who
have a prior history of kala-azar should have a
conﬁrmatory bone marrow or spleen aspiration
performed.
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Despite the relative lack of speciﬁcity of both the
InSure dipstick and the DAT, both tests can be used as
fairly reliable conﬁrmatory tests at BPKIHS with positive
predictive values of, respectively, 91% and 90% (cut-off
titre: 1:6400). This would not apply in areas where the
proportion of kala-azar among clinically suspect patients
is lower. In these areas, spleen puncture could be used for
conﬁrmation of the diagnosis or decision analysis
strategies aiming at increasing the pre-test probability of
kala-azar before initiating treatment could be evaluated
and applied.
Both the InSure dipstick and the DAT with a very low
cut-off titre (1:400) have a negative predictive value of
89% and can be used at BPKIHS as fairly reliable screening
tests. The proportion of kala-azar among clinical suspects
is high at BPKIHS (76%) because of its status as a reference
tertiary hospital and its situation in a low endemic area for
malaria, a usual alternative diagnosis. Both tests are very
sensitive and would perform much better as screening tests
in areas where the proportion of kala-azar within patients
tested is 50% or lower, a situation found in East Africa, for
example, where malaria is much more frequent. For a
proportion of 50%, for example, the negative predictive
value of the dipstick and the DAT (cut-off titre 1:400)
would be 96%.
None of the 184 patients included in this study were
infected with HIV. The sensitivity of several serological
tests being decreased in HIV–kala-azar co-infected patients
(Rosenthal et al. 1995; Medrano et al. 1998), the per-
formance of the DAT and the Insure dipstick shown
here should not be extrapolated to settings where HIV–
kala-azar co-infection rate is high.
In summary, our results show that in Nepal, the
potential of the ﬁrst-generation Insure dipstick test to be
used as a screening test for VL in peripheral health
structures is excellent. Patients with a positive dipstick
could then be referred to secondary or tertiary hospitals for
diagnosis conﬁrmation (by bone marrow or spleen aspir-
ation or by the DAT with a high cut-off titre) and for
speciﬁc treatment.
Before deﬁnite guidelines of utilization of these tests in
Nepal can be drawn, the performance of the currently
produced second-generation Insure dipstick needs to be
prospectively assessed in clinical suspect patients. Such
evaluation has just been completed in Nepal and results
should be published soon. Moreover, the feasibility,
reproducibility and predictive values of these tests, when
performed in more peripheral health structures, are
being assessed in a district hospital based study in the same
region.
The ongoing ﬁght led by numerous medical organiza-
tions for a better access in developing countries to essential
drugs for diseases like AIDS, multidrug resistant tuber-
culosis, African trypanosomiasis or leishmaniasis should
include the support of development and production of
standardized, affordable, practical and reliable diagnostic
tests. Both the lack of diagnosis of kala-azar, a deadly
disease if left untreated, and the overdiagnosis of this
condition, exposing patients to relatively toxic drugs, can
have fatal consequences for the patients.
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Abstract. We compared the validity of pancytopenia, the formol-gel test (FGT), the indirect fluorescence antibody
test (IFAT), the direct agglutination test (DAT), and the rK39 dipstick test as diagnostic criteria for visceral leishma-
niasis (VL) in Nepal. Between September 2000 and January 2002, 310 clinical suspects had a bone marrow aspirate, and
if negative, a spleen aspirate smear examined for Leishmania donovani. Sensitivity and specificity of all tests were
determined compared with parasitology and by latent class analysis (LCA). Compared with parasitology, the sensitivities
of the other tests were as follows: pancytopenia 16.3% (95% confidence interval [CI] 11.3−22.5%), FGT 39.9%
(95% CI  32.7−47.4%), IFAT  28.4% (95% CI  22.0−35.5%), DAT  95.1% (95% CI  90.8−97.7%), and the
rK39 dipstick test 87.4% (95% CI 81.7−91.9%). Sensitivity estimates obtained by LCA were similar, but specificity
estimates were substantially higher (DAT 93.7% versus 77.8%; rK39 dipstick test 93.1% versus 77.0%). The DAT
or the rK39 dipstick test can replace parasitology as the basis of a decision to treat VL in Nepalese peripheral health
services.
INTRODUCTION
Visceral leishmaniasis (VL) or kala-azar is considered as
one of the most neglected tropical diseases.1 Communities
affected by kala-azar often live in remote areas and have poor
access to health services. The need for innovation in VL che-
motherapy and diagnosis was recently highlighted.2 Treating
patients on clinical presumption is inadequate because of the
potentially serious side effects of current chemotherapy. Di-
rect microscopic examination and/or culture of spleen tissue
aspirate is the reference test for diagnostic confirmation, but
this technique is hardly recommendable in the first-line health
services in endemic areas. Alternatively, bone marrow and
lymph node aspirates are used, but these methods are sub-
stantially less sensitive.3 Past research aimed at developing a
cheap and reliable serologic test that could replace parasitol-
ogy. El Harith and others developed a direct agglutination
test (DAT) in the 1980s and proposed it as a test for field use.4
However, some investigators disagreed because of a presum-
ably low specificity in the clinical setting.5 The effectiveness of
the DAT proved satisfactory in a large multi-center study.6
More recently, high validity was reported for the rK39 dip-
stick test,7 but this was contested soon after the initial re-
port.8,9 Moreover, commercial production of the dipstick test
was interrupted several times.9
Diagnostic research in VL has been hampered by the lack
of a gold standard. As Staquet and others10 showed, a flawed
reference test can substantially affect validity estimates of
new tests under scrutiny. Thus, the published sensitivity and
specificity estimates of serologic tests might be biased to some
extent, depending on the controls and reference test used.
Parasitology for VL is very specific, but unless spleen aspi-
rates can be taken, its sensitivity is less than 90%.3 The alleg-
edly low specificity of serologic tests for VL, along with prob-
lems of regular supply, have so far prevented their introduc-
tion into routine health service practice. For example, in rural
Nepal, most VL patients in peripheral health facilities are still
treated on the basis of clinical suspicion and/or the result of a
formol-gel test (FGT).11
To avoid biased estimates and needless discussions, a better
and more standardized validation methodology is needed.
Hadgu and Qu12 suggested latent class analysis (LCA) could
be a potential solution to the gold standard problem. This
method of analysis is a mathematical technique that models
associations between observed variables that imperfectly
measure a non-observable (latent) variable.13,14 When a di-
agnostic test is validated in a group of people, their true dis-
ease status can be considered as a latent variable with two
mutually exclusive and exhaustive classes or categories: dis-
eased and non-diseased. The LCA model estimates disease
prevalence and sensitivity and specificity of all the diagnostic
tests. So far, LCA has been used extensively in psychiatric
research and in the social sciences, but experience in biomedi-
cal research is still limited. To clarify the current options in
VL diagnostics in endemic areas, we validated three existing
(FGT, DAT and an indirect fluorescence antibody test
[IFAT]) and one novel serologic test (rK39), as well as a
hematologic sign (pancytopenia) in a clinical care setting. We
used classic contingency table analysis as well as LCA to cor-
roborate the findings.
METHODS
Patients. The data were collected at the B.P. Koirala Insti-
tute of Health Sciences (BPKIHS) in Dharan in the Morang
District of Nepal. This is a 648-bed tertiary care center serving
the eastern region of Nepal, which includes VL-endemic ar-
eas. Patient recruitment aimed at enrolling at least 100 true
cases of VL and at least 100 true non-cases to achieve ad-
equate precision for the sensitivity and specificity estimates of
the tests. Therefore, the total sample size to enroll was fixed
at 300 clinical suspects given the expected prior probability of
70% VL cases in a group of presenting clinical VL suspects.9
Patients were enrolled consecutively until the required
sample size was achieved.
Am. J. Trop. Med. Hyg., 70(1), 2004, pp. 72–77
Copyright © 2004 by The American Society of Tropical Medicine and Hygiene
72
95
Clinical suspicion for VL was defined as a history of fever
of 14 days or more and splenomegaly. Children of very young
age were excluded. All clinically suspected adult and pediatric
patients who presented to the Out-Patient Department and
Emergency rooms between September 2000 and January 2002
were enrolled on the condition that they (or their guardian)
gave informed consent.
A questionnaire with clinical and epidemiologic data was
filled out for each patient at enrollment and diagnostic pro-
cedures were performed: bone marrow aspiration and the
leishmanin skin test. Also, a venous blood sample and a urine
sample was taken. If the bone marrow aspirate was negative,
and malaria had been ruled out, a spleen aspirate was pro-
posed. All VL patients were offered free treatment in accor-
dance with current policy at BPKIHS and World Health Or-
ganization guidelines. The Institutional Review Board of the
BPKIHS and of the Prince Leopold Institute of Medicine in
Antwerp (ITMA) gave ethical clearance for the study.
Diagnostic criteria and tests. Pancytopenia. Pancytopenia
was defined as a hemoglobin level < 11 g/dL, a white blood
cell count < 4 × 109/L, and a platelet count < 100 × 109/L.
Formol-gel test. Twenty microliters of 40% formaldehyde
(Glaxo India, Ltd., Bombay, India) was added to 200 L of
serum in a glass tube, and after 20 minutes the gelification
reaction was visually assessed as positive or negative.
Indirect fluorescence antibody test. The IFAT was carried
out at the Unidade de Leishmanioses of the Institute of Hy-
giene and Tropical Medicine in Lisbon, Portugal according to
the procedure of Lanotte15 using cultured promastigotes of
Leishmania (Leishmania) infantum MON-1 as antigen.
Washed promastigotes were dispensed on immunofluorescent
microscope slides, air-dried and kept at -70°C until use. Total
anti-human immunoglobulins conjugated with fluorescein
isothiocyanate and diluted 1:100 (BioMérieux, Lyon, France)
was used. A cut-off value  1:32 was used to establish a
positive IFAT result for a child < 15 years old and a value 
1:128 was used for adults.
Direct agglutination test. The DAT was performed at
BPKIHS on 1 L of serum according to standard proce-
dures.4,6 The antigen was produced at ITMA as follows. Pro-
mastigotes of the reference batch L. (L.) donovani 1-S were
cultivated in a temperature-controlled cell shaker in glucose
lactalbumin serum hemoglobin.16 Log phase promastigotes
were harvested and treated with 0.4% trypsin, fixed with 4%
formaldehyde, stained with 0.025% Coomassie blue, and
stored at 4°C until use. This DAT antigen was mixed in V-
shaped well microtiter plates (Greiner-Bio One GmbH,
Frickenhausen, Germany) with patient serum dilutions be-
tween 1:200 and 1:204,800, and after 12 hours the agglutina-
tion reaction was visually assessed against a white back-
ground. The end titer was read as the dilution immediately
before the well with a clear sharp-edged blue spot identical in
size to the negative control. For the analysis, a DAT titer >
1:3,200 was considered positive.
rK39 dipstick test. The rK39 dipstick test (lot numbers
AF1008 and BF1019, InSure Rapid Test for Visceral Leish-
maniasis®; InBios International, Seattle, WA) was performed
at BPKIHS.17 At room temperature, 30 L of serum was
added to the dipstick, which was then placed vertically in a
test tube. Two drops of the chase buffer solution provided
with the dipstick kit were added to the test tube. The results
were read after five minutes and, if still negative, after 10
minutes. Even a weak band in the test region was considered
a positive result. The test was repeated if the control line
remained negative after 10 minutes.
Parasitology. Two independent readers at BPKIHS per-
formed direct semi-quantified microscopic examination of
methanol-fixed (10 minutes), Jenner-stained (five minutes),
Giemsa-stained (15 minutes) smears of bone marrow or
spleen aspirate. Two independent readers at ITMA per-
formed quality control on 10% of the slides.
Statistical analysis. The data were processed with SPSS for
Windows version 10.0.5 (SPSS, Inc., Chicago, IL), as well as
with Latent Gold® version 2.0.18 (Statistical Innovations,
Inc., Belmont, MA). Sensitivity and specificity were estimated
by the classic validation method as well as by LCA modeling.
We used parasitology as the reference test in the 2 × 2 con-
tingency table: a patient with a positive bone marrow aspirate
and/or spleen aspirate was considered a kala-azar case. In
LCA, we started by fitting the basic two latent class model.
Given a group of individuals with unknown disease status, for
whom results from several diagnostic tests are available, LCA
will model the probability of each combination of test results
conditional on latent class, i.e., disease status. In basic latent
class models, tests are taken to be conditionally independent
(conditional on latent class), i.e., there are no associations
between test errors within each category of the latent variable
(diseased/not-diseased). Subsequently, more advanced mod-
els were fitted in which this condition was relaxed.12,18 Model
fit was assessed on the basis of the Bayes information crite-
rion.19 We report sensitivity and specificity of tests with an
approximate 95% confidence interval (1.96 × SE) as esti-
mated by the best model.
RESULTS
Between September 6, 2000 and December 23, 2001, 310
patients with febrile splenomegaly syndrome were enrolled in
the study. Bone marrow aspirates were negative for 132.
However, spleen aspirates could not be obtained in 101
(76.5%) because of contraindications or patient refusal. A
diagnosis of kala-azar was reached by parasitologic confirma-
tion in 184 (59.4%) of the 310: 178 by positive bone marrow
and six by spleen aspirate.
Three confirmed VL syndromes were re-admissions of re-
lapse cases. The 181 confirmed new kala-azar patients had a
median age of 25 years (25th percentile  13 years, 75th
percentile  36 years). The male:female ratio was 1.7:1. The
median duration of fever at first admission was eight weeks
(25th percentile  3.5 weeks, 75th percentile  11 weeks)
and mean ± SD spleen size was 6.1 ± 3.7 cm below the costal
margin. Anemia was present in 166 (91.7%) of 181, leukope-
nia in 104 (57.5%), and thrombocytopenia in 41 (22.7%). Pan-
cytopenia was present in 29 (16%) of the 181 patients.
There were 126 febrile splenomegaly syndromes with a
negative parasitology. For 13 (10.3%) of them, the clinicians
indicated that kala-azar was the most probable diagnosis on
the basis of the overall case history and clinical picture. In 91
(72.2%), an anatomopathologically or microbiologically con-
firmed alternative diagnosis was reached. For 20 (15.9%) pa-
tients, such an alternative diagnosis was deemed most likely
on clinical grounds. Two patients left against medical advice
before a final clinical diagnosis was reached.
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The validity of pancytopenia and serologic tests as diagnos-
tic markers for VL in the 310 febrile splenomegaly syndromes
is shown in Table 1. When compared with the results of para-
sitology as the reference test, pancytopenia, the FGT, and the
IFAT had low sensitivity, but very high specificity. The DAT
and rK39 dipstick test had high sensitivity, but moderate
specificity. The quality control done on the parasitology
smears showed perfect concordance for grade 2+ or higher,
but for smears with scanty parasites (grade 1), there was con-
siderable discrepancy.
The validity of pancytopenia and diagnostic tests (including
parasitology) as estimated by the best LCA model is shown in
Table 1. This best model was reached in a modeling strategy
comparing nine models (Table 2). A basic two latent class
model did not fit the data very well because there was con-
siderable residual correlation between the FGT and IFAT,
between the IFAT and pancytopenia, and between the FGT
and parasitology. Therefore, we fitted several other two latent
class models including direct effects between pairs of tests.18
Model 5, which included a direct effect between the FGT and
IFAT, gave the best fit. The expected frequencies of diagnos-
tic test patterns, as well as the probability of belonging to
latent class VL predicted by this model, are shown in Table 3.
The LCA estimates for sensitivity of pancytopenia, the
FGT, and IFAT, as estimated by the best-fitting LCA model,
were low, whereas the DAT showed high sensitivity and the
rK39 dipstick test and parasitology showed good sensitivity
(Table 1). Almost exactly the same sensitivity estimates were
obtained by both validation methods. The specificity of DAT
and the rK39 dipstick test was good and substantially higher
in LCA than when estimated by classic validation. The dis-
criminatory power of each test based on LCA results is shown
in Figure 1. The estimated prevalence of VL in this group of
patients was 65.4% (n 309) in LCA versus 59.2% (n 310)
according to parasitologic results only and 64.0% (n  308)
according to the clinicians’ final diagnosis.
DISCUSSION
The main finding in our study was that the sensitivity and
specificity of the DAT and rK39 dipstick test compared fa-
vorably in the diagnosis of VL with that of parasitologic ex-
amination of bone marrow combined with spleen aspirates.
Moreover, our study illustrates the problems related to parasi-
tology as a reference test for the validation of VL diagnostics.
To our knowledge, no study so far has addressed the per-
formance of VL diagnostics by a comparative assessment on
the same patients from an endemic area. Although our pa-
tients were certainly representative for the clinical suspects
presenting to referral hospitals in eastern Nepal, this does not
necessarily imply that frequency and stage of VL would be
the same in patients presenting to first-line health services.
Serologic test performance is known to be dependent on stage
of the disease, so one must be careful in extrapolating results.
The rK39 dipstick test format evaluated in this study was a
prototype version distributed in 2000 by the company for re-
search purposes only. Although similar to the currently com-
mercialized version (Raychaudhury S, 2003, personal commu-
nication), discrepancies between our findings and those of
other investigators9 might be explained by the fact that they
evaluated earlier prototypes.
Validation studies of VL diagnostics are usually based on
parasitologic examination as a reference test. This should not
be too problematic if spleen aspirates can be used for case
ascertainment in all subjects, but this is rarely the case. In this
tertiary care setting, it was not possible to obtain spleen as-
pirates for all patients with a negative bone marrow because
of contraindications or patient refusal. When a reference test
with sub-optimal sensitivity for case ascertainment is used,
true VL cases are missed and therefore included in the group
of controls. They will generate a positive result in any new test
one wishes to evaluate (assuming this new test is 100% sen-
sitive). For those cases, the new test is actually right while the
reference test is wrong, and the specificity of the new test will
thus be systematically underestimated. To prevent this kind
of bias, our study included a multivariate analysis of the data
by LCA, a technique based on loglinear modeling. LCA con-
firmed that parasitology, even though optimized by the com-
bined use of bone marrow and spleen aspirates, had a lack of
sensitivity as a reference test in this setting. As anticipated,
the specificity estimates of the DAT and rK39 dipstick test
were considerably higher in LCA than in classic validation.
The specificity estimates of the IFAT and FGT were less
affected because these tests were also less sensitive. Remark-
ably, LCA did not estimate the specificity of parasitology as
100% as one would expect on theoretical grounds. The read-
ing of smears for L. donovani bodies is not easy. Our quality
control showed discrepancies in the low-graded smears (grade
1), and some smears might actually have been wrongly taken
as positive. This demonstrates again that parasitology cannot
TABLE 1
Validity of pancytopenia and diagnostic tests compared to parasitology, and as estimated by the best model in latent class analysis (CA)*
Compared to parasitology† LCA‡ (n  309)§
Sensitivity %
(n  183)§
Specificity %
(n  126) Sensitivity % Specificity %
Pancytopenia 16.3 (11.3–22.5)¶ 96.8 (92.1–99.1) 16.0 (10.9–21.1) 98.4 (95.8–100.0)
FGT 39.9 (32.7–47.4) 95.2 (89.9–98.2) 33.7 (26.5–40.9) 98.5 (95.8–100.0)
IFAT 28.4 (22.0–35.5) 94.4 (88.9–97.7) 30.0 (22.9–37.0) 98.3 (92.0–100.0)
DAT 95.1 (90.9–97.7) 77.8 (69.5–84.7) 96.9 (94.1–99.8) 93.7 (88.0–99.4)
RK39 dipstick test 87.4 (81.7–91.9) 77.0 (68.6–84.0) 90.1 (85.7–94.6) 93.1 (87.5–98.6)
Parasitology Reference Reference 88.1 (83.2–92.9) 94.8 (89.9–99.7)
* FGT  formol-gel test; IFAT  indirect fluorescence antibody test; DAT  direct agglutination test.
† Estimate with 95% exact binomial confidence interval.
‡ Estimate with approximate 95% confidence interval (1.96 × SE).
§ One serum sample was missing in the group with positive parasitology.
¶ n  184.
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claim the gold standard role, and the usefulness of comple-
mentary approaches such as LCA for validation.
Which of the five diagnostic markers we evaluated could
then play a role in the first-line health services in this region
of Nepal? Clinicians in tertiary hospitals rely on pancytopenia
as a sign for VL when present in a case of febrile splenomeg-
aly. Our data showed its specificity was extremely high, but
unfortunately, its sensitivity was not. Furthermore, since labo-
ratory infrastructure for hematology is limited in peripheral
health services, this criterion might not be very helpful in the
field. Interestingly, the specificity of the FGT was high in this
study, but its sensitivity was low. The FGT is known to show
positive results quite late in the disease process, and requires
at least three months evolution, which may explain part of the
low sensitivity in this study.
The performance of a MON-1/L.infantum-based IFAT us-
ing the same diagnostic cut-off titer as the reference values of
the Portuguese laboratory showed low sensitivity in this area
endemic for L. donovani, an observation that was already
made in Sudan.20 However, a receiver-operator characteristic
analysis of the IFAT at several age-independent cut-off val-
ues showed good discrimination. An age-independent IFAT
cut-off value for positivity  1:16 had a sensitivity of 87.4%
(95% confidence interval [CI] 81.7−91.9%) and a specific-
ity of 77.0% (95% CI  68.6−84.0%). Other investigators
have reported comparable sensitivity but higher specificity of
TABLE 3
Observed and expected frequencies of tests patterns and probability of visceral leishmaniasis (VL) as estimated by latent class analysis model 5*
Pancytopenia FGT IFAT DAT
Rk39
dipstick Parasitology
Observed
frequency
Estimated
frequency
Probability of VL as
estimated by model 5
− − − − − − 88 85.9766 0.0004
− − − − − + 4 4.9455 0.0479
− − − − + − 6 6.7107 0.0436
− − − − + + 2 2.5157 0.8602
− − − + − − 6 6.8152 0.1477
− − − + − + 13 7.7639 0.959
− − − + + − 14 9.628 0.9549
− − − + + + 63 68.0188 0.9997
− − + − + − 1 0.0974 0.5228
− − + + − − 1 0.2173 0.8064
− − + + + + 12 11.8322 1
− + − − − − 1 0.921 0.0125
− + − + − + 2 2.6889 0.9987
− + − + + − 2 3.3207 0.9986
− + − + + + 30 24.5246 1
− + + − − + 1 0.0919 0.9763
− + + − + − 1 0.1138 0.9739
− + + + + − 2 3.4831 0.9999
− + + + + + 26 25.7573 1
+ − − − − − 1 1.3781 0.0044
+ − − − − + 1 0.1204 0.3759
+ − − − + + 1 0.4191 0.9866
+ − − + − + 1 1.4278 0.9964
+ − − + + − 1 1.7637 0.9961
+ − − + + + 10 12.9926 1
+ − + + + − 2 0.3058 0.9998
+ − + + + + 3 2.2608 1
+ + − + + + 4 4.686 1
+ + + + − + 1 0.5389 1
+ + + + + + 9 4.9216 1
* For definitions of other abbreviations, see Table 1.
TABLE 2
List of models fitted to the data*
Models
Number of
latent classes† LL BIC df
Model
P
1 A, B, C, D, E, F 1 607.918 281.118 57 3.60 × 10−93
2 X, A|X, B|X, CX, D|X, E|X, F|X 2 85.675 −200.992 50 0.0013
3 X3, A|X3, B|X3, C|X3, D|X3, E|X3, F|X3 3 44.6516 −201.882 43 0.4
4 X4, A|X4, B|X4, C|X4, D|X4, E|X4, F|X4 4 30.6552 −175.745 36 0.72
5 X, A|X, BC|X, D|X, E|X, F|X 2 55.6076 −225.326 49 0.24
6 X, AC|X, BC|X, D|X, E|X, F|X 2 50.3012 −224.899 48 0.38
7 X, AC|X, BC|X, BF|X, D|X, E|X 2 46.0745 −223.393 47 0.51
8 X, AC|X, BC|X, BF|X, CE|X, D|X 2 39.7886 −223.945 46 0.73
9 X, AC|X, BC|X, BE|X, BF|X, CE|X, D|X 2 37.3878 −220.613 45 0.78
* LL  loglikelihood; BIC  Bayes information criterion; df  degrees of freedom; A  pancytopenia; B  FGT; C  IFAT; D  DAT; E  rk39 dipstick test; F  parasitology; X 
latent variable (disease status); A|X probability of test result A depends on disease status; BC|X probability of test results B and C depends on disease status but also on direct effect between
B and C. For definitions of other abbreviations, see Table 1.
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the IFAT when used in areas endemic for L. infantum.21,22
Because the IFAT cannot be regarded as an option for pe-
ripheral health services in Nepal because of technologic con-
straints, we did not explore this further.
This study corroborated the known high sensitivity and the
more than acceptable specificity of the DAT.6 The features of
the rK39 dipstick test format and of parasitology were found
comparable to DAT in this study. In peripheral health ser-
vices, the DAT or rK39 dipstick test could replace parasitol-
ogy as the basis of a decision to treat, if one looks only at the
validity criteria, while simplicity of use favors the dipstick
format. However, deciding which test to include in diagnostic
algorithms for VL should include other criteria, such as dis-
ease prevalence and health service context, as well as test
reproducibility, cost, and sustainability.
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Evaluation of a urinary antigen-based latex agglutination test
in the diagnosis of kala-azar in eastern Nepal
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Summary background We evaluated the diagnostic accuracy as well as the reproducibility of the urine latex
agglutination test ‘KAtex’ in the diagnosis of kala-azar in patients recruited at a tertiary care centre in
Dharan, Nepal, between November 2000 and January 2002.
methods All patients presenting with fever of 2 weeks or more and splenomegaly were consecutively
enrolled. Bone marrow and – if negative – spleen aspirates were examined for Leishmania donovani.
Serum and urine samples were taken in duplicate for the Direct Agglutination Test (DAT) and KAtex.
The reference laboratory determined sensitivity and speciﬁcity of KAtex. Reproducibility between both
laboratories was assessed.
results KAtex was performed on urine from 155 parasitologically conﬁrmed kala-azar and 77
non-kala-azar cases (parasitology and DAT-negative). KAtex showed a sensitivity of 47.7% (74/155,
95% CI: 39.7–55.9) and a speciﬁcity of 98.7% (76/77, 95% CI: 93.0–100.0). Reproducibility of
KAtex showed a kappa of 0.684 (P < 0.001, n ¼ 232).
conclusion KAtex evaluation showed high speciﬁcity, low sensitivity and moderate reproducibility.
A urine test for kala-azar could become a real breakthrough in kala-azar management if its
reproducibility and sensitivity could be further improved.
keywords visceral leishmaniasis, sensitivity and speciﬁcity, diagnostic accuracy, urine antigen
detection test, Nepal
Introduction
Visceral leishmaniasis (VL) or kala-azar is considered a
major public health problem in Nepal where it is endemic in
the south-eastern Terai region, with an estimated 5.5 million
people at risk of acquiring the disease (HMGN 2001/2002).
The recommended method for diagnosis of VL is the
microscopic demonstration of amastigotes of Leishmania
donovani (LD bodies) from spleen or bone marrow
aspiration, although the sensitivity of the latter technique
has been shown to be only 70–86% (WHO 1984; Zijlstra
et al. 1992). Moreover, these techniques require expertise
both from the physician and the laboratory technician and
in Nepal LDmicroscopy is limited to reference hospitals. As
the disease affects the poorest of the poor in remote rural
regions, most patients lack access to these reference centres.
The diagnosis of VL in those areas is thus usually based on
non-speciﬁc clinical features (cachexia, anaemia, prolonged
fever and hepato-splenomegaly) along with a positive
formol-gel test.
Serological tests for the detection of antibodies have
been developed in the pursuit of an alternative to parasit-
ology. Their main advantage is non-invasiveness but they
do not discriminate between clinical, subclinical or past
infection, and cross-reaction with other pathogens is
possible. The Direct Agglutination Test (DAT) developed
by El Harith et al. (1986, 1988) has excellent diagnostic
accuracy (Boelaert et al. 2004), but its use in Nepal has so
far also been limited due to the expertise required for its
execution. The indirect immunoﬂuorescence antibody test
(IFAT) requires an immunoﬂuorescence microscope and is
thus neither appropriate nor affordable for decentralized
diagnosis. A test based on 39-amino acid repeat recom-
binant leishmanial antigen from L. chagasi (rK39) has been
introduced in an enzyme-linked immunosorbent assay
(ELISA) (Badaro et al. 1996; Zijlstra et al. 1998) and,
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later, in a lateral ﬂow dipstick format (Sundar et al. 1998).
The latter is very easy to use in the ﬁeld and the initial
study showed 100% sensitivity and 98% speciﬁcity
(Sundar et al. 1998). However, an evaluation in Sudan
showed only 67% sensitivity (Zijlstra et al. 2001). More-
over, this particular format of the dipstick is no longer
available. Another version tested in India proved to be a
good diagnostic guide in kala-azar suspect cases (Sundar
et al. 2002). Sarker et al. (2003) found in Bangladesh high
sensitivity in conﬁrmed kala-azar patients and high spe-
ciﬁcity in healthy endemic controls and patients suffering
from other conditions. In Nepal, an early version of this
dipstick showed a speciﬁcity of only 71% in controls who
presented as clinical suspect cases of kala-azar (Chappuis
et al. 2003); however, more encouraging results were
obtained with later generations of this dipstick (Bern et al.
2000; Boelaert et al. 2004).
Recently, Sarkari et al. (2002) described a urinary
leishmanial antigen. This is a low-molecular weight, heat
stable carbohydrate detected in the urine of VL patients but
not in the urine of patients suffering from malaria,
schistosomiasis, or non-parasitic diseases including typhoid
and brucellosis. An agglutination test for the detection of
this urinary antigen has been evaluated in laboratory trials,
using urine collected from well-deﬁned cases and endemic
and non-endemic controls. The test had 100% (95%
CI: 98.8–100.0) speciﬁcity and sensitivity between 64
(95% CI: 42.5–82.0) and 100% (95% CI: 47.8–100.0)
(Attar et al. 2001). In a ﬁeld trial in Sudan the test was
positive in all 15 microscopy-positive kala-azar cases
[sensitivity 100% (95% CI: 78.2–95.2)] and was negative
in 41 of 45 bone marrow and/or lymph node smear
negative clinical suspect cases of kala-azar [speciﬁcity
87.2% (95% CI: 78.8–97.5)]*.
We evaluated the diagnostic accuracy and the repro-
ducibility of the KAtex, a urinary leishmanial antigen-based
latex agglutination test, in clinically suspect patients in an
endemic kala-azar area in Nepal.
Materials and methods
Study population
The study was conducted at the B.P. Koirala Institute of
Health Sciences (BPKIHS), a 648 bed University Hospital
located in Dharan, in the south-eastern region of Nepal.
BPKIHS serves as a reference tertiary level hospital for the
eastern region, which includes several kala-azar endemic
districts. The research protocol was approved by the
ethical committee of BPKIHS in August 2000. Ethical
clearance was also obtained from the institutional review
board of the Institute of Tropical Medicine in Antwerp
(ITMA), Belgium. The patients were prospectively recrui-
ted from the outpatient department and the emergency
department of BPKIHS between November 2000 and
January 2002. Every patient presenting with a history of
fever for 2 weeks or more and clinical splenomegaly was
considered as a clinical suspect case and was enrolled if
he/she gave written informed consent. For paediatric
patients, informed consent was sought from the guardian.
Reference standard
Splenic aspiration is considered close to gold standard for
VL diagnosis, but as it is an invasive procedure, bone
marrow-negative patients often reject it at BPKIHS.
Therefore, we used a combination of parasitology and
serology as the reference standard for the evaluation of the
KAtex. We considered those with positive microscopy in
bone marrow or spleen as conﬁrmed kala-azar cases. A
non-kala-azar case was somebody with negative parasit-
ology and negative serology (i.e. DAT titre £ 3200).
Diagnostic procedures
All patients enrolled were admitted to the medical wards
for the diagnostic work up and treatment. On day 0
(admission day), blood was drawn for complete blood
count, chemistry, coagulation proﬁle, thick and thin smear
for malaria parasite, blood cultures and HIV testing after
pre-test counselling. Chest X-ray, abdominal ultrasound
and other tests were performed at the physician’s discre-
tion. Serum was collected for DAT. A urine specimen was
collected in duplicate at day 0 and stored at )70 C until
analysis.
Parasitological diagnosis
All patients had a bone marrow aspiration performed at
day 0 or 1 and a microscopic search for the amastigote
form of L. donovani (LD bodies) was carried out by the
Department of Microbiology of BPKIHS. Giemsa-stained
smears were designated as positive if LD bodies were seen
or negative if no LD bodies were seen in 1000 oil
immersion ﬁelds. If bone marrow aspiration was negative
for LD bodies, spleen aspiration was performed except in
those with prolonged prothrombin time, decreased plate-
lets below 50 000/mm3 or spleen <2 cm palpable below the
costal margins. A parasite density score was determined
microscopically at magniﬁcation objective 100 · eye piece
10 in the Giemsa-stained smear by use of a scale ranging
* Conﬁdence intervals were computed by authors on the basis
of published ﬁgures.
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from 0 (no parasites per 1000 oil immersion ﬁelds) to +6
(>100 parasites per ﬁeld) using the method originally
developed for splenic biopsies (WHO 1990) but which has
been successfully applied to the quantiﬁcation of bone
marrow smears both in BPKIHS and ITMA.
Two independent readers at BPKIHS read the slides,
and, in case of discrepancy, the reading of a third more
senior reader was decisive. For quality control, 10% of the
positive and 10% of the negative slides were cross-checked
in the same way at the Protozoology Unit, ITMA.
Direct Agglutination Test
The DAT was performed by a laboratory technician at
BPKIHS who had been previously trained by the chief
laboratory technician of the Protozoology Unit of ITMA.
The DAT antigen was prepared at ITMA using a modiﬁ-
cation of the method of El Harith et al. (1986) and
described by Boelaert et al. (1999). The liquid antigen was
kept at 4 C during transport and storage at BPKIHS. The
test was carried out on microtitre plates (V-shaped wells)
with the necessary positive and negative controls. The test
was read visually against a white background and the end
titre was read as the dilution immediately before the well
with a clear sharp-edged blue spot identical in size to the
negative control. For the analysis, a DAT titre >1:3200 was
taken as positive.
Urine latex agglutination test
Urine samples were taken on the day of admission and kept
frozen until analysis. The KAtex urine latex agglutination
test (Kalon Biological Ltd, Aldershot, UK) was performed
by one technician at both BPKIHS and ITMA. Both
technicians were blinded to the patient’s diagnosis. The
KAtex kit consists of test latex, a positive and a negative
control and a reusable glass test slide with a black
background.
As pretreatment, 1 ml of urine was transferred into the
sample tube and placed on a boiling water bath for 5 min.
This was to inactivate heat labile material capable of
causing a false positive reaction. Meanwhile, all test
reagents were brought to the ambient temperature. Fifty
microlitres of the treated urine sample was placed to a
reaction zone in the glass slide and a drop of test latex was
added to it. The liquids were stirred to a completely
homogenous mixture and rotated continuously for 2 min.
For every assay, a negative control in the reaction zone
next to the test sample was run. Any agglutination
discerned when compared with the negative control was
considered as positive. When no agglutination was seen,
KAtex was considered negative.
Data analysis
Numerical variables were summarized by mean and SD if
normally distributed and if they were not, by median and
quartiles. Mean values were compared with Student’s t-test
and medians with the Mann–Whitney U-test, at a critical
a-level of 0.05. All P-values were two-sided. The results of
KAtex obtained in ITMA were used to assess diagnostic
accuracy of the KAtex. Sensitivity of KAtex was assessed in
conﬁrmed kala-azar patients, i.e. those who were para-
sitologically positive. The speciﬁcity of KAtex was assessed
in the group of patients with negative parasitology and a
negative DAT (i.e. DAT titre £1:3200). We excluded
patients who could not be categorized according to this
reference standard from the data analysis. Exact 95%
binomial conﬁdence intervals were computed for the
sensitivity and speciﬁcity. The association of KAtex posi-
tivity in kala-azar patients with size of spleen, duration of
fever and the parasite intensity was assessed by Pearson’s
chi-square for linear trend. Reproducibility between the
KAtex performance at ITMA and BPKIHS was assessed by
Cohen’s kappa. The data were analysed with SPSS for
Windows version 10.0.5 (SPSS Inc., Chicago, IL, USA).
Results
A total of 269 kala-azar suspect cases were enrolled between
November 2000 and January 2002. Eight cases had to be
excluded, as the KAtex could not be performed in Antwerp
because urine samples were lost during transport. Of the
remaining 261 cases, there were 155 conﬁrmed kala-azar
cases (with positive microscopy) and 77 non-kala-azar cases
(negativemicroscopy andnegativeDAT). Twenty-nine cases
were excluded from the analysis, 28 because they could
not be classiﬁed by our reference standard (negative micro-
scopy but positive DAT) and one because he left the hospital
early, against medical advice. The diagnosis of kala-azar in
the 155 patients was reached by a positive bone marrow
(n ¼ 152) or positive spleen aspirate (n ¼ 3). The quality
control done on the parasitology smears showed perfect
concordance for grade 2+ or above, but for smears
with scanty parasites (grade 1), there was considerable
discrepancy.
Table 1 shows the characteristics of the kala-azar and
non-kala-azar cases. There were signiﬁcant differences
between the two groups with respect to the duration of
fever, spleen size, haemoglobin percentage, platelet count
and the white cell count.
The most frequent discharge diagnosis in the non-
kala-azar group was malaria (42 patients, 54.5%). The
other diagnoses were haematological malignancy (n ¼ 8),
tuberculosis (n ¼ 6), haemolytic anaemia (n ¼ 4), portal
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hypertension (n ¼ 3), enteric fever (n ¼ 3), septicaemia
(n ¼ 3), HIV (n ¼ 3), systemic lupus erythematosus
(n ¼ 1) and other infections (n ¼ 4).
The KAtex performed at ITMA was positive in 74 of the
155 kala-azar patients, sensitivity 47.7% (95% CI: 39.7–
55.9) and negative in 76 of the 77 non-kala-azar patients,
speciﬁcity 98.7% (95% CI: 93–100). The association of the
intensity of parasite, size of spleen and duration of fever
with KAtex sensitivity in the 155 conﬁrmed kala-azar
patients was assessed. As shown in Table 2, the sensitivity
of KAtex increased signiﬁcantly with increasing parasite
intensity, spleen size and duration of fever.
In Nepal all urine samples were tested within 3 months
of collection. In Antwerp, storage time varied, but all
samples were analysed within 26 months. We found no
signiﬁcant difference in the sensitivity of samples stored
longer or shorter than 10 months.
In comparing the reproducibility of the tests performed
at BPKIHS and ITMA, the test was negative at BPKIHS in
16 patients of the 75 that were positive at ITMA. There
were also 16 negatives in ITMA from the 75 that were
positive at BPKIHS. The kappa score was 0.685 (95%
CI: 0.586–0.784).
Discussion
In this study, the sensitivity of KAtex was found to be low
in conﬁrmed VL cases although the speciﬁcity was excel-
lent amongst a control group of patients with similar
symptoms in whom kala-azar was ruled out. The study
design purposefully included this spectrum of patients, as
they would represent the persons on whom physicians
would use the test for diagnosis in future.
We observed a signiﬁcant increase in the KAtex sensi-
tivity with the duration of fever, spleen size and the
parasite intensity in the tissue aspirate; the ﬁrst two
probably reﬂect the duration of the illness. Parasite
intensity is probably well-correlated with antigen load in
urine. The low overall sensitivity is in contrast to earlier
results by Attar et al. (2001) and unpublished data from
Muzzafarpur, India and Sudan. However, Attar et al.
(2001) reported data from Brazil where only 16 of 25
conﬁrmed kala-azar showed a positive KAtex (64%, 95%
CI: 42.5–82).
Low sensitivity in our study could possibly be explained
by shorter duration of the disease in the patients present-
ing. Also, our series of kala-azar patients contained a high
number with low parasite intensity, 46.5% had grade 1+ or
2+. On the contrary, smaller sample sizes in the earlier
studies lead to wider conﬁdence intervals around those
Table 1 Clinical and haematological
characteristics of conﬁrmed kala-azar and
non-kala-azar patients in Dharan, Nepal
Conﬁrmed kala-azar
(n ¼ 155)
Non-kala-azar
(n ¼ 77) P-value
Age (years) 23 (13; 26) 20 (10; 30) 0.084
Fever duration (weeks) 8 (4; 12) 4 (3; 8) 0.001
Spleen size (cm) 5 (3; 8) 3 (1; 5) <0.001
Haemoglobin (gm%)* 8.4 (2.0) 9.5 (2.7) <0.001
Median WCC (mm3) 3800 (3100; 4400) 6050 (4550; 10 150) <0.001
Platelets (mm3)* 140 143 (67 632) 237 947 (131 727) <0.001
* Mean (SD).
 Mean values were compared with Student’s t-test, medians with a Mann–Whitney
non-parametric test.
 Median (quartile 1, quartile 3).
Table 2 KAtex sensitivity according to duration of fever, spleen
size and parasite grading in 155 conﬁrmed kala-azar patients in
Dharan, Nepal, 2001–2002
N
Number of
KAtex-
positive
KAtex
sensitivity P-value
Duration of fever (weeks) 0.024*
<9 96 39 0.406
‡9 59 35 0.593
Spleen size (cm) 0.005**
<4.0 44 13 0.295
4.0–5.9 36 20 0.556
6.0–7.9 28 11 0.393
‡8.0 47 30 0.638
Parasite grading <0.001**
1 29 6 0.207
2 43 11 0.256
3 41 24 0.585
4 36 28 0.778
5 6 5 0.833
* Pearson v2 test; ** v2 for linear trend.
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sensitivity estimates. Deterioration of antigen due to
freezing and storage of the urine samples is unlikely to be a
major contributor to this low sensitivity, as the detection of
antigen was shown to be stable, although at a reduced
score, over an 8 year storage period at )20 C. Also, we
observed similar low sensitivity of KAtex in a recent study
comparing fresh and frozen urine samples collected from a
group of kala-azar patients from Nepal (unpublished data).
The reproducibility of KAtex results was good. The main
difﬁculty in reading the test is the discrimination of a 1+
test result (the test is normally graded from 1+ to 3+) from
a negative result; any tendency to interpret the KAtex test
result conservatively will decrease the sensitivity of the test.
Sensitivity is one of the crucial parameters in the choice
of a diagnostic test for VL. Although not ideal as a
diagnostic test in its present format, there are ﬁeld settings
with minimal laboratory infrastructure where the test
could be of use. Given its high speciﬁcity, the positive
predictive value of a positive KAtex result is likely to be
high, in this study it was 0.987 (95% CI: 0.928–1.0). One
might consider treating a clinical suspect patient with a
positive KAtex without the need for a parasitological
diagnosis. However, a negative KAtex result is of little
value, and such a patient should be referred for further
investigation.
A latex agglutination test detecting a heat stable
leishmanial antigen from the urine from kala-azar patients
presents an interesting technology. It is simple to use,
results are immediately available, it does not require any
electric appliances and is thus feasible in the rural health
centres. Testing the urine is acceptable to the patients
especially when compared with the alternative of the
invasive bone marrow aspirations. Testing of an antigen
has moreover a potential for monitoring response to
treatment where the antibody-based tests are of no help.
Therefore, the test merits further development and evalu-
ation. However, future assessment of KAtex should care-
fully document the stage of disease, parasite intensity as
well as handling of samples (fresh/stored).
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Field validity, reproducibility and feasibility of diagnostic tests
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Summary objectives To assess the ﬁeld accuracy, reproducibility and feasibility of the formol gel test (FGT), the
urine latex agglutination test (KAtex) and a rK39 antigen-based dipstick for the diagnosis of visceral
leishmaniasis (VL) in rural Nepal.
method Patients with clinical suspicion of VL were recruited at Rangeli District Hospital (DH), a
15-bed government hospital located in south-eastern Nepal. FGT, KAtex and rK39 dipstick tests were
performed on site and later repeated at a reference kala-azar diagnostic laboratory to assess reproduc-
ibility. Diagnosis of VL was conﬁrmed by either a positive bone marrow aspirate examination or a
positive direct agglutination test (DAT titre ‡1:3200) in patients who later responded to anti-leishmanial
therapy.
results Of 155 patients initially recruited, 142 (85 with VL and 57 with another diagnosis) were
included in the study. The sensitivity of the rK39 dipstick [89%; 95% conﬁdence interval (CI): 81–94]
was signiﬁcantly higher than that of the KAtex (57%; 95% CI: 46–67) and the FGT (52%; 95% CI: 41–
62). All three tests had a speciﬁcity of at least 90%. Agreement was higher for the rK39 dipstick
(j ¼ 0.87) than for the FGT (0.68) and the KAtex (0.43). All tests required £20 min of actual work and
£40 min to obtain the results.
conclusion The rK39 dipstick was easy to do, more accurate and reproducible than other rapid
diagnostic tests for VL in a DH of rural Nepal. It should be integrated into the ﬁeld diagnostic algorithm
of VL in this region and mechanisms to secure its availability should be found.
keywords kala-azar, visceral leishmaniasis, diagnosis, serology, antigen detection, Nepal
Introduction
Visceral leishmaniasis (VL) or kala-azar affects an estima-
ted 500 000 persons yearly, predominantly in the poor
rural areas of India, Bangladesh, Nepal, Sudan and Brazil
(Desjeux 1996). Most patients present with prolonged
fever, weight loss and an enlarged spleen. This clinical
picture is shared by several other endemic diseases such as
malaria, disseminated tuberculosis or enteric fever, which
are also commonly seen in the same focus. Laboratory
testing is therefore necessary to conﬁrm the diagnosis of
VL. A highly sensitive and speciﬁc diagnostic approach is
needed, because of the fatal evolution of the disease
without speciﬁc treatment and the serious toxicity of the
most widely used ﬁrst-line drug, sodium stibogluconate
(Sundar et al. 2000). Most communities affected by VL are
poor and located in remote rural areas with limited access
to referral hospitals. Therefore, laboratory tests for VL
diagnosis need to be cheap, easy to perform and available
in peripheral health centres to insure that most patients
have an adequate access to diagnosis. The development of
diagnostic tests for improved case-management of VL has
been rated as one of the most needed among other
infectious diseases prevalent in the developing world
(Mabey et al. 2004).
Direct microscopic examination of spleen aspiration is
considered the gold standard for VL diagnosis but the
expertise required for the procedure makes it unsuitable for
generalized ﬁeld use. Alternatively, lymph node or bone
marrow aspirates are often used but these are substantially
less sensitive (Zijlstra et al. 1992). Serological tests have
been developed to replace parasitological diagnosis in the
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ﬁeld. The direct agglutination test (DAT), developed in the
1980s (Harith et al. 1986, 1987), has been validated in
several endemic areas (Boelaert et al. 1999a, b, c, 2004). Its
use has been encouraged by the World Health Organiza-
tion (WHO) for surveillance and control programs of VL
(DAT workshop, Antwerp, 25–27 March 1998). Unfortu-
nately, the relative sophistication of the DAT procedure
(e.g. need for micropipettes and microtitration plates)
restricts its use to referral hospitals or well-supported
health centres.
Simpler tests designed for ﬁeld use exist. Recently,
serological testing based on the detection of antibodies
against a recombinant antigen derived from a 39-amino
acid repeats in Leishmania chagasi (rK39) was developed
into a dipstick format. Validation studies have shown
variable results depending on the location of the study site,
the brand of the dipstick and the study method (Sundar
et al. 1998; Delgado et al. 2001; Zijlstra et al. 2001;
Chappuis et al. 2003; Schallig et al. 2002; Carvalho et al.
2003; Veeken et al. 2003; Boelaert et al. 2004). The
formol gel test (FGT) is a cheap, easy to perform but poorly
sensitive test that is at present the only diagnostic test
available for VL in many peripheral health centres in the
Indian sub-continent and in East Africa (Chowdhury et al.
1992). A urinary antigen-based latex agglutination test
(KAtex) has been recently developed and evaluated. The
speciﬁcity of KAtex was found to be excellent but its
sensitivity varied from 48% to 100% (Attar et al. 2001;
Rijal et al. 2004).
In Nepal, where VL is endemic in 12 south-eastern
districts located in the Terai region, the DAT, rK39
dipstick, FGT and KAtex have been prospectively evalu-
ated in groups of clinical suspect patients recruited in
referral tertiary hospitals (Chappuis et al. 2003; Boelaert
et al. 2004; Rijal et al. 2004). However, the performance
of the tests might be different in a ‘real life’ setting of
district hospitals (DHs), where most of the VL patients
attend, for several reasons. First, patients consulting in a
DH may present with a less advanced disease, thus
modifying the test’s sensitivity and speciﬁcity. For example,
the KAtex urine test was shown to be signiﬁcantly less
sensitive in patients with a shorter duration of fever and a
smaller spleen size (Rijal et al. 2004). Second, the preval-
ence (prior probability) of VL among clinical suspects can
differ from the one found in a referral hospital and this
would directly inﬂuence the positive and negative predic-
tive value of the tests. Third, limited training of the
laboratory technicians, their high workload and poor
logistic facilities can alter the execution and/or the inter-
pretation of the test. For these reasons, we assessed the
validity, reproducibility and feasibility of three candidate
tests for decentralized use, the rK39 dipstick test, the FGT
and the KAtex, in the setting of a ﬁrst-referral hospital
located in an endemic area of VL in Nepal.
Materials and methods
Study site
The study was conducted at Rangeli DH in Rangeli, a
15 000 inhabitants town of the district of Morang. This
rural hospital serves a district with 800 000 inhabitants
located in the Eastern Region of Nepal and bordering the
Bihar State of India. The Rangeli DH is a 15-bed
government hospital that caters to patients from neigh-
bouring villages who may, or may not, have had a prior
consultation at the health post in their village. The clinical
activities at Rangeli DH are supervised by two medical
doctors. The other medical staff includes one clinical
ofﬁcer, four nurses, one laboratory technician and one
laboratory assistant. The two laboratory workers under-
went a 2-week training before the start of the study at the
Kala-azar Laboratory of the B.P. Koirala Institute of
Health Sciences (BPKIHS). Both were trained in perform-
ing and interpretation of the rK39 dipstick and the KAtex
tests and reviewed the procedures of the FGT and the
microscopic search for Leishmania donovani bodies in
bone marrow aspirates. The BPKIHS is a 648-bed teaching
hospital with strong expertise in VL diagnostics and
research located in Dharan, at 150 km by road from
Rangeli DH. The BPKIHS laboratory served as a reference
laboratory in this study.
Patients
All patients with a history of 2 weeks or more of fever and
a clinically assessed enlarged spleen were deﬁned as suspect
VL cases and were eligible for the study. Patient recruit-
ment aimed at enrolling at least 50 VL cases and 50 non-
VL cases to achieve sufﬁcient precision for the sensitivity
and speciﬁcity estimates of the tests. Therefore the total
sample size was ﬁxed at 150 patients, assuming a certain
degree of imbalance between VL and non-VL cases.
Patients were enrolled consecutively until the required
sample size was achieved. They were included in the study
after informed consent given by the patient or his/her
guardian in case of minors. The research protocol was
approved by the Ethical Committee of the BPKIHS in July
2001.
Diagnostic work up
All patients included in the study were admitted in the in-
patient ward of the Rangeli DH for the initial diagnostic
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work up (Figure 1) and treatment. Blood was drawn on the
day of admission (day 0) for a complete blood count and a
thick and thin smear for malaria parasite. Two ﬁlter papers
were impregnated with whole blood, allowed to dry and
transported to the Kala-azar Laboratory of BPKIHS within
48 h. After elution of the blood from the ﬁlter papers, the
DAT was performed at the BPKIHS and the result was
faxed back to the physician of Rangeli DH. The remaining
blood sampled on day 0 was centrifuged at Rangeli DH
and the serum was collected to perform the FGT and the
rK39 antigen based dipstick. Urine was collected from all
patients and stored in the refrigerator between 4 and 8 C
for a maximum of 48 h. A bone marrow aspirate was
performed on day 0 for all patients and six slides were
prepared and ﬁxed. Slide staining and a microscopic search
for the amastigote form of L. donovani were carried out
independently at the Rangeli DH Laboratory and at the
Kala-azar Laboratory of the BPKIHS. Quantiﬁcation of
parasites was graded from 1+ to 6+. Slides with discrepant
reading results between the two laboratories were reviewed
at the Kala-azar Laboratory of the BPKIHS and the
outcome of this additional reading was recorded as ﬁnal
result. Testing for HIV was not performed because of the
lack of proper counselling available at Rangeli DH and the
expected low prevalence of HIV among the rural popula-
tion living in the area.
Patient with ≥ 2 weeks fever 
+ clinical splenomegaly + in-
formed consent signed
Clinical data collection 
Blood sampling 
Urine sampling 
Anti-malarials started 
Patient
included
Rangeli DH laboratory : 
- Formol Gel test 
- Katex  
- rK 39 dipstick 
- bone marrow aspirate reading 
Impregnated filter papers, bone 
marrow aspirate slides, serum 
and urine samples transported 
to the BPKIHS laboratory 
 Bone marrow aspirate 
positive  negative 
 DAT
≥ 1:3200 
 DAT
< 1:3200 
Treat for VL Investigate for alternative diagnosis 
Figure 1 Operational ﬂow-chart for the diagnosis of VL at the Rangeli DH, Nepal, during the study period (September 2001–December
2002).
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Test procedures
For the FGT, 20 ll of 40% formaldehyde (Glaxo India
Ltd., Bombay, India) was added to 200 ll of the patient’s
serum in a glass tube. After 20 min, the geliﬁcation
reaction was visually assessed as positive or negative.
The rK39 antigen-based dipstick (Insure One-Step
Rapid Test for VL, InBios International, Seattle, USA) was
performed according to the manufacturer’s instructions. In
brief: 20 ll of the patient’s serum was added to the test’s
strip. The strip was placed in a test tube and two drops of
the chase buffer solution were added. The test was read
after 5 min and, if negative, after 10 min. Even a weak line
was considered as positive.
The Latex agglutination test (KAtex, Kalon Biological
Ltd., Aldershot, UK) was performed according to the
manufacturer’s instructions. As pre-treatment, 1 ml of urine
was transferred into the sample tube and placed in a rack
immersed in a boiling water bath for 5 min. The sample and
the reagents were brought to room temperature before
testing. About 50 ll of the treated urine sample were added
onto a reaction zone on the glass slide and a drop of test latex
was added to it. The liquids were stirred to a completely
homogenous mixture and rotated continuously for 2 min.
Any agglutination discerned when compared with the
negative control was considered as positive.
Formol gel test, rK39 dipstick and KAtex were all
performed on day 0 in Rangeli DH laboratory. Results were
kept blinded to the physician in charge of the patient. The
remaining serum and urine were stored in the refrigerator
and sent in a cool box up to three-time per week to the Kala-
azar Laboratory of the BPKIHSwhere all testswere repeated
by a laboratory technician with extensive experience in VL
diagnosis within 24 h after reception. The same test proce-
dures were used in both laboratories.
The time interval between the sampling of blood/bone
marrow and the test results, as well as the time required to
perform the tests, were measured in a subset of nine
patients at the Rangeli DH laboratory by an independent
observer. The feasibility of the diagnostic tests was also
qualitatively assessed with the laboratory workers of the
Rangeli DH. The cost per test unit was determined by the
price in use at Rangeli DH for the FGT and the bone
marrow aspiration and reading. The cost of the rK39
dipstick was recorded from the retail price of the manu-
facturer. The commercial cost of the KAtex has not been
determined yet.
Treatment and follow up
Malaria is most frequently due to Plasmodium vivax in this
region and blood-circulating parasites are usually scanty,
leading to possible false negative blood smear examination.
Therefore, all patients included in the study received a full
course of anti-malarials on admission day, independently
of diagnostic tests results. Early speciﬁc treatment also
allowed for an easier assessment of response to anti-
malarials during the short period of hospitalization. All
patients with a positive bone marrow aspirate or a negative
bone marrow aspirate but a positive DAT result (end-
dilution titre ‡1:3200) were treated with intramuscular
sodium stibogluconate (SAG from Albert David Ltd.,
Calcutta, India) 20 mg/kg/day for 30 days. The initial
injections were performed at Rangeli DH until clinical
improvement and the remaining injections were completed
in the village health post. Patients with a previous history
of treatment for VL were considered as relapse cases and
were treated with intravenous amphotericin B 0.5 mg/kg/
day for 14 days. Patients with a negative initial bone
marrow aspirate and negative DAT were further investi-
gated at Rangeli DH (or referred to the BPKIHS) and
treated for an alternative diagnosis.
All VL and non-VL patients were scheduled for follow-
up visits at 1, 3 and 6 months after hospital discharge.
Bone marrow aspiration was repeated at 1 (test of initial
cure) and 6 month (test of deﬁnite cure) follow-up visit for
all patients with a positive initial bone marrow aspirate
and at any visit in case of clinical suspicion of VL.
Case deﬁnitions
As the sensitivity of bone marrow aspirate is only around
80%, we based our reference standard on a combination of
parasitological, serological (DAT) and clinical evidence. A
conﬁrmed case of VL was deﬁned as a patient with (1) a
positive bone marrow aspirate during initial evaluation or
(2) a positive bone marrow aspirate during any follow-up
visit of an initial aspirate-negative case or (3) a negative
bone marrow aspirate but a positive DAT (titre ‡1:3200)
at day 0 and an absence of response to anti-malarial
treatment but a successful response to anti-leishmanial
therapy (deﬁnite cure documented at month 6 of follow
up). A conﬁrmed case of non-VL was deﬁned as a patient
with a negative bone marrow aspirate at initial and follow-
up evaluation with (1) a negative DAT (titre <1:3200) or
(2) a positive DAT but a deﬁnite cure with anti-malarial or
other non-VL speciﬁc therapy. All other patients were
classiﬁed as cases with uncertain disease status and were
excluded from the analysis.
Data analysis
Personal and medical characteristics, diagnostic tests’
results, follow-up data and patients’ outcome were entered
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in case-report forms by the study ﬁeld supervisor. Data from
the case-report formswere entered in anExcel data sheet and
later checked by two investigators. The data were analysed
with SPSS 11.0 forWindows version (SPSS Inc., Chicago, IL,
USA). Numerical variables were summarized by mean and
SD if normally distributed and if they were not, by median
and quartiles. Categorical variables were compared using
cross-tabulations and chi-square tests whereas numerical
variables (means) were compared with Student’s t-test, at a
critical a-level of 0.05. All P values were two-sided.
Sensitivity, speciﬁcity, positive and negative predictive
values and their exact 95% binomial conﬁdence interval
were calculated for the FGT, the rK39 dipstick test and the
KAtex from the groups of conﬁrmed VL and non-VL
patients. Reproducibility between the performance of the
FGT, rK39 dipstick, KAtex and bonemarrow aspirate at the
Rangeli DH and BPKIHS was assessed by Cohen’s kappa
and interpreted following the grading system described by
Landis and Koch (1977). The time to get the test result was
measured from the sampling of blood or bonemarrow to the
availability of the test result. The time of actual work for
the nurse or physician (blood or bonemarrow sampling) and
the laboratory workers (test procedures) was measured,
including working times of 2 min for blood centrifugation,
2 min for the FGTprocedure and10 min for stainingof bone
marrow aspirates.
Results
Between September 2001 and December 2002, 155
patients were admitted to Rangeli DH with a clinical
suspicion of VL. Of these, 154 patients were recruited in
the study and one patient defaulted. Four patients did not
complete the diagnostic work up and were excluded from
the analysis. Of the 150 remaining patients, the proportion
of patients examined during follow-up 1, 3 and 6 months
after hospital discharge was 64%, 55% and 72%,
respectively. After completion of the diagnostic work-up,
treatment and follow-up, 85 patients (57%) were con-
ﬁrmed with VL whereas 57 patients (38%) had VL
excluded and were classiﬁed as non-VL patients. Of the 85
patients with VL, the diagnosis was conﬁrmed by a positive
bone marrow aspiration in 75 patients during initial
evaluation and in four patients during follow-up while six
patients had a DAT ‡1:3200 and were deﬁnitely cured
6 months after completion of sodium stibogluconate
treatment. The ﬁnal diagnosis of the 57 non-VL patients
was malaria (38), enteric fever (10), tuberculosis (4), liver
disease (2), haematologic disorder (1) and others (2). Fifty-
two (91%) non-VL patients had a negative initial DAT and
did not develop VL during follow up. Five (9%) non-VL
patients had a positive DAT but did not receive anti-
leishmanials and were deﬁnitely cured at 6 months after
treatment for malaria (3), enteric fever (1) and tuberculosis
(1). Eight patients (5%) had an uncertain diagnosis and
could not be classiﬁed as VL or non-VL: all had a DAT
‡1:3200 but did not receive SAG treatment and/or were
lost to follow up. These eight patients were excluded from
further analysis.
The general, clinical and biological characteristics of the
85 VL patients and the 57 non-VL patients are presented
and compared in Table 1. Weight loss, emaciation and
darkened skin were signiﬁcantly more frequent in patients
with VL (P < 0.05). VL patients also presented with a
signiﬁcantly longer duration of fever, a larger spleen and
lower Hb, WBC and platelet counts (P < 0.05).
Test validity
The three tests were performed at the Rangeli DH
Laboratory in all 142 patients. Results of the FGT and the
rK39 antigen based dipstick were all included in the
validation analysis. One month after the start of the study,
we found that the reagent initially supplied with the KAtex
(Lot No. K11-035/1) had a defect (absence of reaction with
the positive control at both Rangeli DH and BPKIHS). The
reagent was swiftly replaced by the manufacturer. Only
the results of the KAtex from the 124 patients tested with
the new lot of reagent (Lot No. K11-064/1) were included
in the validation analysis.
The FGT had a 52% sensitivity [95% conﬁdence interval
(CI): 41–62], a 97% speciﬁcity (95% CI: 88–99), a 96%
PPV (95% CI: 86–99) and a 57% NPV (95% CI: 47–67).
The rK39 antigen based dipstick test had a 89% sensitivity
(95% CI: 81–94), a 90% speciﬁcity (95% CI: 79–95), a
93% PPV (95% CI: 85–97) and a 85% NPV (95% CI:
74–92). The KAtex urine test had a 57% sensitivity (95%
CI: 44–67), a 98% speciﬁcity (95% CI: 88–100), a 98%
PPV (95% CI: 89–100) and a 56% NPV (95% CI: 45–67).
The performance of the FGT and the rK39 dipstick test,
when used in combinations, are also shown in Table 2.
The sensitivity and the speciﬁcity of the tests were not
signiﬁcantly modiﬁed when the analysis was restricted to
the 130 patients with no previous history of VL (data
not shown). Interestingly, out of the six non-VL patients
with a history of previous VL, all had a negative FGT
and KAtex but two patients had a falsely positive rK39
dipstick. These two patients also had a positive DAT
with high titres (‡1:102400).
Test reproducibility
The FGT, rK39 dipstick and KAtex urine tests were
repeated using the same test batches at the Kala-azar
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Laboratory of the BPKIHS in 135, 142 and 116 patients,
respectively. The strength of agreement was almost perfect
for the K39 dipstick test (j ¼ 0.87), substantial for the
FGT (j ¼ 0.68) and moderate for the KAtex (j ¼ 0.43).
Despite the fact that microscopic reading of bone
marrow aspirates was performed on different sets of slides
(but sampled at the same time) at Rangeli DH and
BPKIHS, we assessed the strength of agreement and we
found it to be substantial (j ¼ 0.71). Twenty (14%) out of
142 sets of slides examined showed discordant results, of
which 17 (85%) were found in slides graded as 1+ by one
of the readers.
Test feasibility
The cost per test unit, time of actual work and time to get
the results are presented in Table 3. The median time of
actual work was below 10 min for the FGT and the rK39
dipstick, 20 min for the KAtex urine test and 50 min for
the bone marrow aspirate whereas the median time to get
the results was 20 min for the rK39 dipstick, 25 min for
the KAtex, 40 min for the FGT and 80 min for the bone
marrow aspirate.
Discussion
We found the rK39 antigen-based dipstick (Insure one-step
rapid test for VL) to be signiﬁcantly more sensitive and
more reproducible than the FGT and the urine antigen
detection test (KAtex). Moreover, the rK39 dipstick
required little actual work and gave quick results. The FGT
and the KAtex were insufﬁciently sensitive but showed a
non-signiﬁcant trend towards a higher speciﬁcity than the
rK39 dipstick.
An accurate validation of diagnostic tests for VL had
been previously achieved in several studies conducted in
optimally controlled conditions at the BPKIHS, a referral
teaching hospital located in Eastern Nepal (Chappuis et al.
2003; Boelaert et al. 2004; Rijal et al. 2004). Our study
was conducted in the real conditions of a DH located in the
Table 1 Comparison of the general, clin-
ical and biological characteristics of the 85
VL patients and the 57 non-VL patients at
the Rangeli DH, NepalCharacteristics
VL patients
(total: 85) n (%)
or mean (SD)
Non-VL patients
(total: 57) n (%)
or mean (SD) P value
Gender
Female 37 (43) 20 (35) 0.31
Male 48 (57) 37 (65)
Age 22.0 (13.4) 25.5 (15.2) 0.15
Profession
Farmer 24 (28) 19 (33) 0.34
Student or pre-school 33 (39) 18 (32)
Housewife 18 (21) 16 (28)
Others 10 (12) 4 (7)
Previous treatment for VL 6 (7) 6 (11) 0.47
Symptoms (self-reported)
Chills 31 (37) 26 (46) 0.28
Skin darkening 27 (32) 3 (5) <0.001
Anorexia 21 (25) 9 (16) 0.20
Cough 13 (15) 6 (11) 0.41
Weight loss 13 (15) 2 (4) 0.025
Abdominal pain 3 (4) 0 (0) 0.15
Bleeding 0 (0) 0 (0) –
Duration of fever (weeks) 6.3 (4.8) 3.6 (2.6) <0.001
Signs
Emaciation 28 (33) 4 (7) 0.001
Hepatomegaly 79 (93) 49 (86) 0.17
Enlarged lymph nodes 3 (4) 2 (4) 0.99
Spleen size from costal margin (cm) 6.4 (3) 4.5 (2.8) <0.001
Haematology
Haemoglobin (g/dl) 9.2 (1.3) 9.7 (1.2) 0.01
White blood cell count (per mm3) 4270 (1193) 6880 (2180) <0.001
Platelet count (per mm3) 126753 (34746) 159404 (31913) <0.001
VL, visceral leishmaniasis.
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same endemic area, and we evaluated the effectiveness
rather than the efﬁcacy of those diagnostic tests. No extra-
staff was hired for the study and the laboratory technicians
received a limited previous training on the diagnostic test
procedures. This might have impaired the accuracy of the
test validation but we believe that our results showed a
more realistic picture of the performance of the tests when
used in daily ﬁeld practice. Our reference standard for the
validation was based on a combination of parasitological,
serological and clinical evidence, as systematic splenic
aspiration of all suspects was not possible in this context.
Nonetheless this should not jeopardize the validity of our
sensitivity and speciﬁcity estimates. Documented response
to treatment in chronic febrile splenomegaly patients with
a positive DAT should be considered as sufﬁcient evidence
of VL (Zijlstra et al. 1991), because antimonials have a
very narrow therapeutic spectrum.
Despite these limitations, the results of the tests valid-
ation were in accordance with previous studies (Boelaert
et al. 2004; Rijal et al. 2004), which equally showed a low
sensitivity of FGT and KAtex. This low sensitivity is most
likely inﬂuenced by patient’s delay in presenting at the
rural hospital. Indeed, we found no clear differences in the
clinical and laboratory parameters when comparing to
cohorts of VL patients previously studied at the tertiary
care centre BPKIHS (data not shown), reﬂecting a similar
degree of disease progression. However, the sensitivity of
KAtex appears better in VL patients co-infected with HIV
because of their higher parasite load (Riera et al. 2004).
The high speciﬁcity of KAtex also conﬁrmed previous
reports and highlights the very interesting concept of the
test (detection of a speciﬁc antigen). Further developments
to improve the sensitivity of speciﬁc antigen detection in
the urine are underway. The high speciﬁcity of the FGT
was more surprising considering the low intrinsic specif-
icity of the test principle (detection of an increased level of
polyclonal immunoglobulins), but conﬁrmed an earlier
report from Nepal (Boelaert et al. 2004). This should be
conﬁrmed in other VL endemic areas such as East Africa
where polyclonal hypergammaglobulinemia might be more
commonly found with other diseases like Plasmodium
falciparum infections (Abele et al. 1965).
The rK39 dipstick (Insure one-step rapid test for VL)
performed well in our study with sensitivity and speciﬁcity
of respectively 89% and 90%. The same dipstick was
previously validated in Nepal and India, showing sensi-
tivity and speciﬁcity ranges of 90–100% and 93–100%,
respectively (Bern et al. 2000; Sundar et al. 2002a,b;
Boelaert et al. 2004). A lower speciﬁcity (71%) was found
with an earlier generation of the Insure dipstick in Nepal
(Chappuis et al. 2003). Other brands of rK39 antigen-
based dipsticks have been evaluated elsewhere but are
either no longer produced (Sundar et al. 1998; Zijlstra
et al. 2001; Veeken et al. 2003), or in need of further
evaluation (Brandonisio et al. 2002; Iqbal et al. 2002).
RK39 antigen-based dipsticks have so far performed
poorly in Sudan (Zijlstra et al. 2001; Veeken et al. 2003).
A newly manufactured rK39 dipstick (Opti-LEISH from
Diamed AG, Switzerland) showed promising results in
India (Sundar et al. 2003), Uganda (personal observation)
and, interestingly, in Sudan (Ritmeijer K, Melaku J, Mo¨ller
M, Kipngetich S, O’Keefe C & Davidson RN, in press).
Table 2 Sensitivity, speciﬁcity, positive
and negative predictive values of the FGT,
the K39 antigen-based dipstick test and the
KAtex urine test at the Rangeli DH, Nepal
Diagnostic test
Sensitivity %
(95% CI)
Speciﬁcity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
Individual tests
FGT 52 (41–62) 97 (88–99) 96 (86–99) 57 (47–67)
K39 dipstick test 89 (81–94) 90 (79–95) 93 (85–97) 85 (74–92)
Katex urine test 57 (46–67) 98 (88–100) 98 (89–100) 56 (45–67)
Tests in combination
FGT+and/or K39 dipstick+ 93 (85–97) 88 (77–94) 92 (84–96) 89 (79–95)
FGT+ and K39 dipstick+ 47 (37–58) 98 (91–100) 98 (87–100) 55 (46–65)
FGT, formol gel test; PPV, positive predictive value; NPV, negative predictive value; CI,
conﬁdence interval.
Table 3 Cost per unit, time of actual work and time to obtain
results of the diagnostic tests performed at the Rangeli DH, Nepal
Diagnostic
test
Cost
per
unit
(US $)
Time of
actual
work
(min)*
Time to
obtain
results
(min)*
rK39 dipstick test 1 9 (6.5; 9) 20 (15; 25)
FGT 0.25 6 (6; 7) 40 (34; 57.5)
Katex urine test Undetermined 20 (15; 22.5) 25 (20; 27.5)
Bone marrow
aspirate
1.5 50 (45; 55) 80 (71.2; 97.5)
FGT, formol gel test.
* Median (quartile 1; quartile 3).
 Price communicated by the manufacturer.
 Price billed to the patients at Rangeli DH.
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We found that two out of six non-VL patients with a
history of previous treatment for VL had a false positive
dipstick result. The rK39 antigen-based dipsticks are not
suited for the diagnosis of relapses due to the long
persistence of antibodies after initial treatment (Zijlstra
et al. 2001), as observed with other serological tests for VL
such as the DAT (Hailu 1990). For patients with a previous
history of VL, parasitological diagnosis remains the
approach of choice but antigen detection in the urine could
be an interesting alternative, provided that the sensitivity of
the test improves.
We found an almost perfect agreement of the rK39
dipstick between the Rangeli DH and the BPKIHS labor-
atories. Inter-reader concordance was already found to be
100% in a previous study (Schallig et al. 2002). This
excellent reproducibility most likely reﬂects the simplicity
of the procedure and the easy interpretation of most
dipstick results. In contrast, we found only a moderate
reproducibility of the KAtex urine test between the two
laboratories (j ¼ 0.43), lower than previously reported
(j ¼ 0.69) by Rijal et al. (2004). This is likely to be due to
the difﬁculty in interpreting weakly positive agglutinations
and to some practical problems occurring during the test
procedure such as having the urine sample spoiled by the
boiling water during the heating process. Nevertheless, we
cannot exclude that the strength of concordance was
underestimated by some degree of deterioration of the
antigen during storage and transport of urine samples.
Discordant results of bone marrow aspirate examinations
between the two laboratories were not rare and mostly
occurred in patients with low parasite densities, emphasi-
zing the high level of expertise required to perform this test
with accuracy.
The time to get the results of the FGT, rK39 dipstick and
the KAtex urine test is equal or less than 40 min. The three
tests thus deserve to be labelled as ‘rapid tests’. They
compare favourably with the minimal time of 18 h to get
the result of the DAT when performed on site. Their direct
cost is low (0.25 US $ for the FGT) to moderate (1 US $ for
the dipstick). The time of actual work to perform the
KAtex urine test exceeds the time needed to perform the
rK39 dipstick and the FGT. This should be taken into
account for the calculation of the real cost of these
diagnostic tests, bearing in mind that the cost of test-
treatment strategies depends mainly on the cost of
hospitalization and treatment (Boelaert et al. 1999d).
Our ﬁndings support the recent yearly distribution of
several thousands Insure dipsticks to the DHs of VL
endemic areas by the Nepalese Ministry of Health. As
recently shown in the neighboring Bihar State of India
(Sundar et al. 2002b), the rK39 antigen-based dipstick
appears as the best ﬁrst-line single diagnostic test for the
diagnosis of VL in this part of the world. It fulﬁls most of
the ‘ASSURED’ criteria that describe the ideal character-
istics of a diagnostic test for resource-limited settings
(Mabey et al. 2004). The DAT is a well-validated and
robust test, especially when freeze-dried antigen is used
(Abdallah et al. 2004), but it is too sophisticated to be
widely used at ﬁrst line health services in the endemic areas
of Nepal and India. Sending blood-impregnated ﬁlter
papers to a reference laboratory performing the DAT, as
done during our study and routinely in some endemic areas
(i.e. Somalia), is neither practical nor sustainable. Integra-
ting the FGT in the diagnostic tree as a ﬁrst-step procedure
and restraining the use of the rK39 dipsticks to negative
FGT results appears as a promising approach in this
endemic region. This approach would slightly improve
diagnostic accuracy (cf. Table 2) and would decrease the
cost by decreasing the consumption of dipsticks (a 32%
decrease in our study). A careful cost-effectiveness analysis
remains to be performed before a ﬁnal diagnostic tree can
be proposed to national policy makers. Similar evaluations
should be done in other VL endemic areas such as East
Africa or South America.
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Validite´, reproductibilite´ et faisabilite´ sur le terrain des tests de diagnostic de la leishmaniose visce´rale en milieu rural au Ne´pal
objectifs Evaluer sur le terrain la pre´cision, la reproductibilite´ et la faisabilite´ du test au Gel de Formol (FGT), du test de l’agglutination urine-latex
(KAtex) et du test sur bandelette a` l’antige`ne rK39, pour le diagnostic de la leishmaniose visce´rale (LV) en milieu rural du Ne´pal.
Me´thode Les patients avec une suspicion clinique de la LV ont e´te´ recrute´s a` l’hoˆpital du district de Rangeli, un hoˆpital gouvernemental de 15 lits, situe´
dans le sud-est du Ne´pal. Les tests FGT, KAtex et au rK39 ont e´te´ applique´s sur place et re´pe´te´s ulte´rieurement dans le laboratoire de diagnostic de
re´fe´rence du Kala-azar pour e´valuer leur reproductibilite´. Le diagnostic de la LV a e´te´ conﬁrme´ soit par examen positif d’aspiration de moelle osseuse ou
par un re´sultat positif du test d’agglutination direct (titre DAT ‡1:3200), chez les patients qui, plus tard ont re´pondu au traitement anti-leishmaniose.
re´sultats Sur 155 patients initialement recrute´s, 142 (85 avec la LV et 57 avec un autre diagnostic) ont e´te´ inclus dans l’e´tude. La sensibilite´ pour le
test au rK39 (89%, IC 95%: 81–94) e´tait signiﬁcativement plus e´leve´e que celle du KAtex (57%, IC95%: 46–67) et celle du FGT (52%, IC95%: 41–62).
Tous les trois tests avaient une spe´ciﬁcite´ d’au moins 90%. La concordance e´tait plus e´leve´e pour le test au rK39 (j ¼ 0.87) que pour le FGT (j ¼ 0.68)
et le KAtex (j ¼ 0.43). Tous les tests ne´cessitaient £20 min de travail effectif et £40 min au total pour l’obtention des re´sultats.
conclusion Les bandelettes au rK39 e´taient d’utilisation facile avec des re´sultats plus pre´cis et plus reproductibles que les autres tests de diagnostic de
la LV dans un hoˆpital de district dans le Ne´pal rural. Ce test devrait eˆtre inte´gre´ dans cette re´gion dans l’algorithme du diagnostic sur le terrain de la LV
et les me´canismes pour assurer sa disponibilite´ devraient eˆtre trouve´s.
Mots cle´s kala-azar, leishmaniose visce´rale, diagnostic, se´rologie, de´tection d’antige`nes, Ne´pal
Validez en el campo, reproducibilidad y factibilidad de test diagno´sticos para leishmaniasis visceral en Nepal rural
objetivos Evaluar la exactitud en el campo, la reproducibilidad y la factibilidad del test de gel de formol (FGT), el test de latex en orina (KAtex) y la
tira diagno´stica basada en el antı´geno rK39 para el diagno´stico de leishmaniasis visceral (LV) en el Nepal rural.
me´todo Pacientes con sospecha clı´nica de LV fueron reclutados en el hospital distrital de Rangeli, un hospital gubernamental de 15 camas, localizado
en el sur occidente de Nepal. Pruebas con FGT, KAtex y las tiras diagno´sticas rK39 se realizaron in situ y posteriormente repetidas en un laboratorio de
referencia para el diagno´stico de kala-azar con el ﬁn de evaluar su reproducibilidad. El diagno´stico de LV se conﬁrmo´, bien por aspirado de me´dula o´sea
positivo o por test de aglutinacio´n directa (titulo DAT ‡1:3200) en pacientes que luego respondieron a terapia anti-leishmania.
resultados De los 155 pacientes inicialmente reclutados, se incluyeron 142 (85 con LV y 57 con otros diagno´sticos). La sensibilidad de la tira
diagno´stica rK39 (89%; 95% CI: 81–94) fue signiﬁcativamente ma´s alta que la del KAtex (57%; 95%CI: 46–67) y la del FGT (52%; 95%CI: 41–62). El
acuerdo fue ma´s alto para la tira diagno´stica rK39 (j ¼ 0.87) que para el FGT (0.68) o el KAtex (0.43). Todos los test necesitaron £20 min de trabajo
real y £40 min para obtener resultados.
conclusio´n La tira diagno´stica rK39 fue ma´s fa´cil, ma´s exacta y reproducible que los otros test ra´pidos utilizados en un hospital distrital del a´rea rural
de Nepal para el diagno´stico de la LV. Se deberı´a integrar dentro del algoritmo diagno´stico de esta regio´n, ası´ como encontrar los mecanismos para
asegurar su disponibilidad.
Palabras clave kala-azar, leishmaniasis visceral, diagno´stico, serologı´a, deteccio´n antige´nica, Nepal
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6. General conclusions 
The thesis summarizes the clinical and epidemiological research on VL we 
conducted at the B.P. Koirala Institute of Health Sciences, Dharan, Nepal over a 
period of 6 years. This university hospital located in the terai, lowlands, has 
established itself as a specialized VL centre, attracting VL patients from a wide area. 
The centre has also taken a lead to conduct need based research to generate 
evidence for the better management and control of kala-azar.  
6.1 The burden of visceral leishmaniasis in Nepal 
We have documented, from observations over the preceding 5 years, that the VL 
endemic in Nepal shows no signs of decline in spite of an ongoing governmental 
control program for more than 10 years. In addition to VL being well established in 
the already known endemic areas we provide evidence that signals a possible further 
extension that should be urgently examined. We have also described how 
economically catastrophic the disease can be to the affected households. 
The goal of the national health policy, to reduce VL incidence to less than 1 in 
100,000 person-years by the year 2018 would look futile in the present perspective 
unless remedial steps are taken. The reasons for failure to bring the disease under 
control could be linked to multiple factors. In addition to the weaknesses in the 
implementation of the present control measures, other factors such as patient 
behavior, changing ecology and the regional political context need to be taken into 
consideration. 
The current strategy of the VL control program has mainly focused on vector control 
using indoor residual insecticide spraying (IRS) along with early case detection and 
appropriate treatment. Intensive campaigns, using “blanket spraying” of all houses 
in the region, decreased the incidence of VL in India and Bangladesh to undetectable 
levels in the 1960’s (Bora 1999). However, these results have not been replicable 
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during routine activities, where reliable surveillance data and information on 
effectiveness of insecticides is crucial. 
In Nepal, IRS activity is limited to high VL transmission foci identified from routine 
surveillance data. However, complete and adequate surveillance data for VL in the 
subcontinent has been lacking mainly due to underreporting and under-diagnosis. 
Desjeux (1991) found a 1:5 ratio of declared to undeclared VL cases in community 
surveys in India. In Nepal only those patients attending the public health facility are 
recorded in the MOH surveillance network, the cases attending the private sectors 
and other institutions do not get included (Bista 1998). The fact that we observed 
several cases in our tertiary care centre from non-endemic regions hitherto was not 
reflected in the concurrent surveillance data of the MOH. This indicates the 
limitations of the present surveillance system for VL, which does not extend beyond 
the known endemic districts. 
Information on the effectiveness of the insecticides used becomes particularly 
important in view of some reports from Bihar, India, of resistance of the sandfly to 
DDT (Mukhopadhyay et al. 1990; Singh et al. 2001).  
An alternative to residual household spraying with insecticides for the control of 
sandfly could be the use of insecticide treated bednets (ITN). Over the last two 
decades ITN have been shown to be one of the most effective methods of reducing 
man-vector contact and intra- and peridomiciliary transmission of malaria (Lengeler 
1998). In a landmark study from The Gambia, use of ITN reduced childhood 
mortality by 60% (Alonso et al. 1991). However, the benefits conferred by ITN depend 
greatly on the biting habits of the vector along with human behavior. In the hilly and 
forested area of central southern Vietnam, where the main vector is exophagic and 
exophilic, ITN had limited impact in the prevention of malaria among the forest 
workers (Erhart et al. 2004).  
The insecticides used in ITN (synthetic pyrethenoids) combine the properties of low 
to moderate mammalian toxicity, low volatility and high insecticidal activity. The 
ITNs in addition to acting as ‘baited traps’ also have important repellent and 
deterrent effects and also overcome some of the disadvantages of IRS. They require 
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less insecticide and as the households exert control over its application there is less 
dependence on a top-down planned control programme. The periodic re-
impregnation of insecticides in ITN has now been partially overcome by the long-
lasting-insecticide-treated-nets (LLIN) in which the insecticide is combined with the 
material during the manufacturing process.  
The endophagic behavior of Phlebotomus argentipes, the sandfly vector in the Indian 
subcontinent, along with its night biting habits provides a rationale that ITN would 
potentially be protective in this region. There is experimental evidence of ITNs 
reducing the sandfly biting rate by 64 to 100% (Murray et al. 2005) and their effect 
on VL is presently being evaluated in the Indian subcontinent. Although it may not 
be justified to advocate its use yet in the routine VL control programmes at present, 
LLIN has the potential to be an extremely valuable tool for sandfly control.  
The lack of regular supply of anti-VL drugs has been a major obstacle for access to 
drugs within the region. In Bangladesh, SSG shortages both in the government 
supply system and in the private sector were common during the last few years 
(Ahluwalia et al. 2003). The VL control programme in Nepal is a priority -1 category 
programme of the MOH, and they have been able to supply and distribute free anti-
VL drugs quite regularly to the kala-azar endemic districts. But it has not been 
effective in making them available at the primary level health care facilities. We 
observed that majority of the patients with past history of VL received their 
treatment at or above a district level hospital. For most VL patients coming from 
remote rural areas and surviving on daily wages, the loss of earnings along with the 
added cost of transport and hospitalization makes access to these hospitals very 
difficult. Moreover, with little knowledge of the disease (Koirala et al. 1998) they 
prefer to visit the traditional faith healers or local unqualified private practitioners. 
We showed that this not only delays specific VL treatment but also lead to 
catastrophic expenses. In addition to the difficulties of access to the drugs, there is 
at present no proper system for monitoring the completeness of the therapy.  
The contiguity of the VL endemic regions in the state of Bihar, India and Nepal along 
with socio-cultural similarity has facilitated large scale migration of populations, 
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which is an important risk factor for spread of the disease within the region (Desjeux 
2001). Moreover, the ongoing violent conflict and increasing poverty has further 
accelerated migration including to the urban areas. We have observed increasing 
number of cases from the urban areas, mostly confined to newly established and 
unorganized settlements.  
An important sequel following kala-azar, which may be possibly related to 
inadequate treatment, is post kala-azar dermal leishmaniasis (PKDL). Though 
patients with this condition have been recognized as an important reservoir for VL, it 
remains a neglected part of the control program. PKDL is a well recognized entity in 
Nepal (Garg et al. 2001) but there is no provision for the diagnosis or treatment 
within the present control program. 
It would look irrational to single out one disease from the “burden” of many tropical 
diseases as they are often interrelated in their impact on the population’s health. 
However, the implications of VL on those affected communities can be devastating. 
The model with the cycle of illness leading to poverty which then subsequently 
blocks economic development in addition to predisposing the affected households to 
further disease can be clearly demonstrated with this disease. 
Though there has been a strong political commitment from the MOH, the lack of 
adequate resources has been a major deterrent to implement or upgrade the existing 
control program. The recently launched “Elimination of kala-azar from endemic 
countries from South-East Asia region” (TDR 2005) brings an opportunity to 
overcome these present constraints and facilitate in upgrading the existing control 
program. It also presents a platform to strengthen regional collaborations for VL 
control within the subcontinent. 
6.2 Novel tests for early diagnosis of VL 
The challenge for VL diagnosis has been to find a test that can be easily applied at 
the level of a peripheral health facility. This led to development of serological tests, 
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including DAT and rK39 strip test, over the last 2 decades but these failed to be 
adopted due to lack of consensus on their performance. The results varied 
depending on the phase of development, region and the manufacturer.  
An ideal test should be sensitive, specific, reproducible, feasible and cheap. We 
showed both the DAT and the rK39 strip test have sufficiently high sensitivity and 
specificity and can be recommended as a diagnostic test in the south-east Asia 
region. We could overcome the bias associated with the use of an imperfect gold 
standard, which may have been one of the factors for the discrepancies in the 
assessment of these tests earlier on, by applying LCA, a mathematical modeling 
technique. In addition to the higher cost of DAT compared with the rK 39 strip test, 
its main limitations has been the unavailability of a commercial kit (Guerin et al. 
2002) and the relative sophistication which precludes its use in the peripheral 
health care centres. This is not the case with the rK39 strip test. Subsequently, we 
also showed the rK39 strip test had good sensitivity, specificity and reproducibility 
even when evaluated at a peripheral level hospital, the site where we expect most VL 
patients to attend. The evidence from our research was instrumental in 
recommending the rK39 strip test as a diagnostic test in the control programme in 
Nepal in 2002.  
An antigen based test like KAtex could become a major break through for VL 
diagnosis as it overcomes the limitations of the serological tests. However, we found 
that it has for the moment a low sensitivity although, interestingly, a positive 
correlation with parasite load was seen. The excellent sensitivity of KAtex seen in 
VL-HIV co-infected patients (Riera et al. 2004) may be related to a higher Leishmania
parasitemia in these patients. With improved sensitivity and reproducibility this test 
could be very useful as it would obviate the need for repeating the parasitological 
examination to assess cure after completion of therapy. 
The potential impact of the availability of an accurate diagnostic test that can be 
easily applied at a peripheral level hospital cannot be overemphasized. The benefits 
extend from decreasing the morbidity and mortality related to delay in diagnosis 
(Collin et al. 2004) to reducing the cost related to the disease. We observed how the 
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majority of the costs related to VL treatment occurred even before the disease was 
diagnosed. Moreover, with humans being the only known reservoir in anthroponotic 
VL, early diagnosis facilitating effective treatment is considered a significant 
measure to control disease transmission (Guerin et al. 2002).
6.3. Efficacy of the current VL treatment in Nepal 
We documented the cure rates with SSG, the first line therapy, in Nepal. They were 
significantly lower in cases coming from areas close to the Bihar high resistance 
focus when compared to the other areas. Similarly, the mortality with treatment was 
also much higher in cases from this region. 
The failure of therapy could be related to use of inadequate or incomplete treatment 
schedules, development of acquired resistance of the parasite to SSG or decreased 
immune status of the patient. In our study the adequacy of the therapy was ensured 
and the incidence of Leishmania/HIV co-infection was negligible, so emergence of 
acquired resistance is suspected, which can only be confirmed by performing drug 
monitoring tests.  
In the adjoining state of Bihar, a steady decrease of SSG cure rates, even with the 
maximum recommended doses, has been reported since the early 1990’s (Sundar 
2001) and this has been linked to development of resistance of the Leishmania
parasite to SSG (Lira et al. 1999) which is reported to be widespread in Bihar 
(Thakur et al. 2004).  
Evidence of increasing failure rates of SSG in some areas in Nepal may suggest that 
the situation in Nepal may follow the same path of drug failure as that seen in the 
state of Bihar, India unless immediate remedial steps are taken. The major factors 
which may have directly or indirectly contributed to SSG treatment failure in Bihar 
include lack of sustained and effective control programmes, inadequate and/or 
incomplete therapy and emergence of resistance strains of Leishmania parasite. 
The control measures implemented with the start of the epidemics in Bihar (1977 
and 1991-92) were not only discontinued after only 3 years (Thakur 2005) but it was 
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also observed that 57% of the houses had not in fact been sprayed with DDT 
between 1992 to 1994 (Thakur 2000). The unabated intense transmission leading to 
the presence of a large biomass of parasites has contributed to the steady increase 
in primary resistance to SSG observed in Bihar (Bryceson 2001) . The areas showing 
lower cure rates in Nepal, in addition to being closer to the Bihar high resistance 
zone, also have more intense transmission as they have experienced the epidemic for 
a longer duration compared to the other areas.  
 The shortcomings in the implementation of the control program in Bihar also 
include delivery of drugs to patients as documented in a study, which reported that 
only a quarter of the patients received adequate SSG treatment, most of the patients 
had been treated by unqualified practitioners and almost all the patients used their 
own resources to buy the drug (Sundar et al.1994). The patients who failed therapy 
in this study were found to receive sub-therapeutic or incomplete doses, which is 
considered an important factor for the development of secondary resistance to SSG 
(Bryceson 2001). It would thus appear that having an effective control programme is 
crucial not only for reducing treatment failure but also for prevention of 
development of drug resistance. 
The availability of generic brands of SSG has had a significant effect on bringing 
down the cost of treatment without compromising the safety or efficacy of therapy 
when implemented with drugs from bonafide manufacturers. We showed the need 
for establishing rigorous quality control measures of generic drugs to prevent 
serious toxicity and deaths related to substandard and toxic products. 
The present evidence of low cure rates of SSG implicates the need for reviewing the 
drug policy for VL treatment in Nepal. The presently available options to replace SSG 
include amphotericin B or miltefosine, both of which have shown excellent cure 
rates in recent studies conducted in the Indian subcontinent (Jha et al. 1999; Rijal 
S et al. 2005; Thakur et al. 1999). In addition to its toxicity, the need for prolonged 
hospitalization for amphotericin B could be a major limitation in the face of limited 
hospital beds. The oral drug, miltefosine, overcomes this disadvantage but needs to 
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be used with caution in women of childbearing age because of its teratogenic 
potential. Strengthening of the drug distribution and monitoring would be 
paramount before this drug could be safely brought into the existing control 
programme. 
In summary we have documented that the VL epidemic in Nepal continues 
unabated, provided evidence for the validity and feasibility of using a rapid test, 
rK39 strip test, at peripheral level hospital and showed that the present drug 
regimen is no longer effective. Our research work has also brought into focus some 
important issues which would need to be pursued further. Epidemiological and 
entomological studies need to be conducted urgently to confirm the presence of new 
foci and to measure the intensity of transmission. There is also an immediate need 
to monitor Leishmania/HIV co-infections. Establishment of regular monitoring of 
drug resistance as described by Croft (Croft 2001) would be vital to guide a rational 
drug policy.  
What are the  implications of our observations from Nepal for the other 
anthroponotic VL areas in the Indian subcontinent and east Africa? In similar socio-
economic environments, the devastating economic consequences of the VL disease 
will be similar; as was already observed in Bangladesh (Ahluwalia et al. 2003). It is 
also expected that the performance of serological tests (rK39 strip test and DAT) in 
these regions would be as good as observed in Nepal with regard to sensitivity, but 
the specificity may be somewhat lower if there is an increased prevalence of VL 
antibody in the general community in regions which have experienced prolonged 
and intense transmission of the disease e.g. Bihar, India. In this scenario, though 
the negative predictive value may remain good, the positive predictive value of these 
antibody detection based tests being lower would necessitate the use of more 
specific tests as an antigen detection test or else the parasitological confirmation in 
a second step. In fact, the diagnostic policy in Bihar, India presently combines a 
serological test along with a specific biological criteria e. g. lecopenia. As efficacy of 
SSG varies in different regions and sometimes even within the same country 
(Sundar et al. 2000) extrapolation of our results is not appropriate to guide drug 
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policy elsewhere. It is absolutely necessary for the national control programmes to 
set up effective monitoring of efficacy of the VL drugs. 
In addition to the emergence of drug resistance, increase in Leishmania /HIV co-
infections would pose serious threats for the control of VL in future. This co-
infection reinforces the effects on the immune system making it difficult to make a 
serological diagnosis and also to achieve cure. The spread of the AIDS pandemic 
from the urban to rural areas along with simultaneous spread of VL from rural to 
urban regions augments the risk for this co-infection.  
Though there have been some exiting advances in recent years for controlling this 
neglected disease with the availability of serological tests and new drugs like 
miltefosine much more needs to be done. More affordable field tools (including 
antigen detection tests) for rapid diagnosis customized for specific geographical 
regions and tests for predicting prognosis and early detection of relapses are 
required. Development of molecular probes for detection of drug resistant strains 
would be a useful tool in the light of emergence of drug resistance strains. Moreover, 
as in malaria, adopting combination therapy for VL seems the most logical way to 
preserve the current and future drugs from becoming resistant. 
Finally, we have emphasized the need for strengthening the existing health system 
including the surveillance network as the successful delivery of any control strategy 
is ultimately dependent on the performance of the health system.  
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